<DOCUMENT>
<TYPE>10-K/A
<SEQUENCE>1
<FILENAME>a05-1861_210ka.htm
<DESCRIPTION>10-K/A
<TEXT>
<html>

<head>





</head>

<body lang="EN-US">

<div style="font-family:Times New Roman;">

<div style="border:none;border-top:double windowtext 9.0pt;padding:0in 0in 0in 0in;">

<p align="center" style="border:none;margin:0in 0in .0001pt;padding:0in;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>

</div>

<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><b><font size="5" face="Times New Roman" style="font-size:18.0pt;font-weight:bold;">UNITED STATES</font></b></p>

<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><b><font size="5" face="Times New Roman" style="font-size:18.0pt;font-weight:bold;">SECURITIES
AND EXCHANGE COMMISSION</font></b></p>

<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">Washington, D.C. 20549</font></b></p>

<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>

<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><b><font size="5" face="Times New Roman" style="font-size:18.0pt;font-weight:bold;">FORM
10-K/A</font></b></p>

<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">(Amendment No. 1)</font></b></p>

<div align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">

<hr size="1" width="25%" noshade color="black" align="center">

</font></div>

<p style="margin:0in 0in .0001pt 27.35pt;text-indent:-27.35pt;"><b><font size="3" face="Times New Roman" style="font-size:12.0pt;font-weight:bold;">(Mark
One)</font></b></p>

<p style="font-size:12.0pt;margin:0in 0in .0001pt 63.35pt;text-indent:-63.35pt;"><b><font size="3" face="Wingdings" style="font-size:12.0pt;font-weight:bold;">&#253;</font>ANNUAL REPORT
PURSUANT TO SECTION&nbsp;13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934</b></p>

<p style="margin:0in 0in .0001pt 63.35pt;text-indent:-63.35pt;"><b><font size="3" face="Times New Roman" style="font-size:12.0pt;font-weight:bold;">&nbsp;</font></b></p>

<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">For the
fiscal year ended December 31, 2004</font></b></p>

<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">&nbsp;</font></b></p>

<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">OR</font></b></p>

<p style="margin:0in 0in .0001pt;"><b><font size="3" face="Times New Roman" style="font-size:12.0pt;font-weight:bold;">&nbsp;</font></b></p>

<p style="font-size:12.0pt;margin:0in 0in .0001pt 63.35pt;text-indent:-63.35pt;"><b><font size="3" face="Wingdings" style="font-size:12.0pt;font-weight:bold;">o</font>TRANSITION
REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934</b></p>

<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>

<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">Commission File Number 000-21873</font></b></p>

<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>

<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><b><font size="5" face="Times New Roman" style="font-size:18.0pt;font-weight:bold;">BIOSITE
INCORPORATED</font></b></p>

<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">(Exact name of registrant as specified in its charter)</font></p>

<div align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">

<hr size="1" width="25%" noshade color="black" align="center">

</font></div>

<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>

<div align="center">

<table border="0" cellspacing="0" cellpadding="0" width="100%" style="border-collapse:collapse;width:100.0%;">
 <tr>
  <td width="63%" valign="top" style="padding:0in .7pt 0in .7pt;width:63.08%;">
  <p align="center" style="margin:0in 0in .0001pt;text-align:center;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">Delaware</font></b></p>
  </td>
  <td width="4%" valign="bottom" style="padding:0in .7pt 0in .7pt;width:4.34%;">
  <p style="margin:0in 0in .0001pt;"><b><font size="2" face="Times New Roman" style="font-size:1.0pt;font-weight:bold;">&nbsp;</font></b></p>
  </td>
  <td width="32%" valign="top" style="padding:0in .7pt 0in .7pt;width:32.6%;">
  <p align="center" style="margin:0in 0in .0001pt;text-align:center;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">33-0288606</font></b></p>
  </td>
 </tr>
 <tr>
  <td width="63%" valign="top" style="padding:0in .7pt 0in .7pt;width:63.08%;">
  <p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">(State
  or other jurisdiction of</font></p>
  </td>
  <td width="4%" valign="bottom" style="padding:0in .7pt 0in .7pt;width:4.34%;">
  <p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>
  </td>
  <td width="32%" valign="top" style="padding:0in .7pt 0in .7pt;width:32.6%;">
  <p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">(I.R.S.
  Employer</font></p>
  </td>
 </tr>
 <tr>
  <td width="63%" valign="top" style="padding:0in .7pt 0in .7pt;width:63.08%;">
  <p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">incorporation
  or organization)</font></p>
  </td>
  <td width="4%" valign="bottom" style="padding:0in .7pt 0in .7pt;width:4.34%;">
  <p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>
  </td>
  <td width="32%" valign="top" style="padding:0in .7pt 0in .7pt;width:32.6%;">
  <p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Identification
  No.)</font></p>
  </td>
 </tr>
 <tr>
  <td width="63%" valign="top" style="padding:0in .7pt 0in .7pt;width:63.08%;">
  <p align="center" style="margin:0in 0in .0001pt;text-align:center;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">11030 Roselle Street</font></b></p>
  </td>
  <td width="4%" valign="bottom" style="padding:0in .7pt 0in .7pt;width:4.34%;">
  <p style="margin:0in 0in .0001pt;"><b><font size="2" face="Times New Roman" style="font-size:1.0pt;font-weight:bold;">&nbsp;</font></b></p>
  </td>
  <td width="32%" valign="top" style="padding:0in .7pt 0in .7pt;width:32.6%;">
  <p align="center" style="margin:0in 0in .0001pt;text-align:center;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">92121</font></b></p>
  </td>
 </tr>
 <tr>
  <td width="63%" valign="top" style="padding:0in .7pt 0in .7pt;width:63.08%;">
  <p align="center" style="margin:0in 0in .0001pt;text-align:center;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">San Diego, California</font></b></p>
  </td>
  <td width="4%" valign="bottom" style="padding:0in .7pt 0in .7pt;width:4.34%;">
  <p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>
  </td>
  <td width="32%" valign="top" style="padding:0in .7pt 0in .7pt;width:32.6%;">
  <p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">(Zip
  Code)</font></p>
  </td>
 </tr>
 <tr>
  <td width="63%" valign="top" style="padding:0in .7pt 0in .7pt;width:63.08%;">
  <p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">(Address
  of principal executive offices)</font></p>
  </td>
  <td width="4%" valign="bottom" style="padding:0in .7pt 0in .7pt;width:4.34%;">
  <p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>
  </td>
  <td width="32%" valign="top" style="padding:0in .7pt 0in .7pt;width:32.6%;">
  <p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>
  </td>
 </tr>
</table>

</div>

<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>

<div align="center">

<table border="0" cellspacing="0" cellpadding="0" width="100%" style="border-collapse:collapse;width:100.0%;">
 <tr>
  <td width="100%" valign="top" style="padding:0in .7pt 0in .7pt;width:100.0%;">
  <p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Registrant&#146;s
  telephone number, including area code:<b><font style="font-weight:bold;"> (858) 455-4808</font></b></font></p>
  </td>
 </tr>
</table>

</div>

<div align="center" style="margin:4.0pt 0in;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">

<hr size="1" width="25%" noshade color="black" align="center">

</font></div>

<div align="center">

<table border="0" cellspacing="0" cellpadding="0" width="100%" style="border-collapse:collapse;width:100.0%;">
 <tr>
  <td width="100%" valign="top" style="padding:0in .7pt 0in .7pt;width:100.0%;">
  <p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Securities
  registered pursuant to Section&nbsp;12(b) of the Act:</font></p>
  </td>
 </tr>
 <tr>
  <td width="100%" valign="top" style="padding:0in .7pt 0in .7pt;width:100.0%;">
  <p align="center" style="margin:0in 0in .0001pt;text-align:center;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">NONE</font></b></p>
  </td>
 </tr>
 <tr>
  <td width="100%" valign="top" style="padding:0in .7pt 0in .7pt;width:100.0%;">
  <p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Securities
  registered pursuant to Section&nbsp;12(g) of the Act:</font></p>
  </td>
 </tr>
 <tr>
  <td width="100%" valign="top" style="padding:0in .7pt 0in .7pt;width:100.0%;">
  <p align="center" style="margin:0in 0in .0001pt;text-align:center;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">Common Stock, $.01 par value</font></b></p>
  </td>
 </tr>
 <tr>
  <td width="100%" valign="top" style="padding:0in .7pt 0in .7pt;width:100.0%;">
  <p align="center" style="margin:0in 0in .0001pt;text-align:center;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">Preferred Stock Purchase Rights</font></b></p>
  </td>
 </tr>
 <tr>
  <td width="100%" valign="top" style="padding:0in .7pt 0in .7pt;width:100.0%;">
  <p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">(Title
  of Class)</font></p>
  </td>
 </tr>
</table>

</div>

<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>

<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; Indicate by check mark
whether the registrant (1)&nbsp;has filed all reports required to be filed by
Section&nbsp;13 or 15(d) of the Securities Exchange Act of 1934 during the
preceding 12&nbsp;months (or for such shorter period that the registrant was
required to file such reports) and (2)&nbsp;has been subject to such filing
requirements for the past 90&nbsp;days.&#160;
Yes </font><font size="2" face="Wingdings" style="font-size:10.0pt;">&#253;</font><font size="2" style="font-size:10.0pt;">&#160;&#160;&#160;&#160; No </font><font size="2" face="Wingdings" style="font-size:10.0pt;">o</font></p>

<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>

<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; Indicate by check mark
if disclosure of delinquent filers pursuant to Item 405 of Regulation S-K is
not contained herein, and will not be contained, to the best of the registrant&#146;s
knowledge, in definitive proxy or information statements incorporated by
reference in Part III of this Form 10-K or any amendment to this Form 10-K.
</font><font size="2" face="Wingdings" style="font-size:10.0pt;">o</font></p>

<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>

<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; Indicate by check mark
whether the registrant is an accelerated filer (as defined in Rule 12b-2 of the
Securities Exchange Act of 1934.&#160; Yes </font><font size="2" face="Wingdings" style="font-size:10.0pt;">&#253;</font><font size="2" style="font-size:10.0pt;">&#160;&#160;&#160;&#160; No </font><font size="2" face="Wingdings" style="font-size:10.0pt;">o</font></p>

<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>

<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; The aggregate market
value of the shares of Common Stock held by non-affiliates of the Company,
based upon the closing price of the Common Stock on June 30, 2004 as reported
on the Nasdaq National Market, was approximately $570,000,000.&#160; Shares of Common Stock held by each executive
officer and director and by each person who owned 10% or more of the
outstanding Common Stock have been excluded in that such persons may be deemed
to be affiliates.&#160; This determination of
affiliate status is not necessarily a conclusive determination for other
purposes.&#160; The determination of who was a
10% stockholder and the number of shares held by such person is based on
Schedule 13G filings with the Securities and Exchange Commission, or SEC, as of
June 30, 2004.</font></p>

<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>

<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; As of February 21,
2005, there were 16,790,662 shares of the Registrant&#146;s Common Stock
outstanding.</font></p>

<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>

<p align="center" style="margin:0in 0in .0001pt;page-break-after:avoid;text-align:center;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">DOCUMENTS
INCORPORATED BY REFERENCE</font></b></p>

<p style="margin:0in 0in .0001pt;page-break-after:avoid;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>

<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; Certain information
from Registrant&#146;s Proxy Statement to be filed with the SEC in connection with
the solicitation of proxies for the Registrant&#146;s 2005 Annual Meeting of
Stockholders is incorporated by reference in Part III of this Form 10-K.</font></p>

<div style="border:none;border-bottom:double windowtext 9.0pt;padding:0in 0in 0in 0in;">

<p align="center" style="border:none;margin:0in 0in .0001pt;padding:0in;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>

</div>

<div style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">

<hr size="2" width="100%" noshade color="gray" align="left">

</font></div>

</div>
<!-- SEQ.=1,FOLIO='',FILE='C:\JMS\jboldua\05-1861-2\task332382\1861-2-ba.htm',USER='jboldua',CD='Mar  4 04:20 2005' -->


<br clear="all" style="page-break-before:always;">


<div>

<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>

<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">EXPLANATORY NOTE</font></b></p>

<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>

<p style="margin:0in 0in .0001pt;text-indent:13.5pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">The Company is filing
this Amendment No. 1 to its Form 10-K for the year ended December 31, 2004
solely for the purpose of correcting typographical errors in the first
paragraph of the Overview portion on page one of the Business section of Part
1.</font></p>

<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>

<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">i</font></p>

<div style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">

<hr size="2" width="100%" noshade color="gray" align="left">

</font></div>

</div>
<!-- SEQ.=1,FOLIO='i',FILE='C:\JMS\jboldua\05-1861-2\task332382\1861-2-ba.htm',USER='jboldua',CD='Mar  4 04:20 2005' -->


<br clear="all" style="page-break-before:always;">


<div style="font-family:Times New Roman;">

<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>

<h1 style="font-weight:bold;margin:0in 0in .0001pt;text-align:center;text-transform:uppercase;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;text-transform:none;">PART I</font></b></h1>

<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>

<h2 align="left" style="font-weight:bold;margin:0in 0in .0001pt;text-align:left;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;">Item 1.&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; Business</font></b></h2>

<p style="margin:0in 0in .0001pt;page-break-after:avoid;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>

<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Forward-looking Statements</font></p>

<h2 align="left" style="font-weight:bold;margin:0in 0in .0001pt;text-align:left;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></b></h2>

<p style="margin:0in 0in .0001pt;text-indent:13.5pt;"><i><font size="2" face="Times New Roman" style="font-size:10.0pt;font-style:italic;">The matters discussed in this Annual Report on Form 10-K
contain forward-looking statements that involve risks and uncertainties,
including: the impact of competition, including products competitive with our
Triage</font></i><i><sup><font size="2" style="font-size:10.0pt;font-style:italic;">&#174;</font></sup></i><i><font size="2" style="font-size:10.0pt;font-style:italic;"> BNP
Tests, from companies with greater capital and resources; our ability to
effectively promote our products, whether directly or through distributors,
including our ability to effectively promote our products in the physician
office market; our ability to successfully expand our business through direct
sales in certain European countries; the outcome of ongoing litigation between
us and Roche Diagnostics Corporation and others; potential contract disputes or
patent conflicts; the extent to which our products and products under development
are successfully developed and gain market acceptance; our ability to obtain
regulatory approvals and complete other clinical and pre-market activities
needed to launch new products and gain market acceptance of any new products;
manufacturing inefficiencies, backlog, delays or capacity constraints; the
timing of significant orders or the impact of seasonality; regulatory changes,
uncertainties or delays; product recalls; dependence on third-party
manufacturers and suppliers; changing market conditions and the other risks and
uncertainties described under &#147;Risk Factors&#148; and throughout this Annual Report
on Form&nbsp;10-K.&#160; Actual results
may differ materially from those projected.&#160;
These forward-looking statements represent our judgment as of the date
of the filing of this Annual Report on Form 10-K.&#160; We disclaim any intent or obligation to
update these forward-looking statements.</font></i></p>

<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>

<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Overview</font></p>

<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>

<p align="left" style="letter-spacing:-.1pt;margin:0in 0in .0001pt;text-align:left;text-indent:13.5pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Founded
in 1988, Biosite<i><sup><font style="font-style:italic;">&#174;</font></sup></i>
Incorporated is a leading bio-medical company commercializing proteomics
discoveries for the advancement of medical diagnosis.&#160; We believe that our novel, rapid medical
diagnostic products, largely evolved from an intensive study of protein
biomarkers of disease, can contribute to improvements in medical care by aiding
physicians in the diagnosis of critical diseases and health conditions.&#160; We have been profitable for the past 23
consecutive quarters.&#160; Our compounded
annual growth rates for net product sales and net income over the past five
years are 41% and 107%, respectively.</font></p>

<p align="left" style="letter-spacing:-.1pt;margin:0in 0in .0001pt;text-align:left;text-indent:13.5pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>

<p align="left" style="letter-spacing:-.1pt;margin:0in 0in .0001pt;text-align:left;text-indent:13.5pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">We
believe that utilizing biotechnology to provide physicians with rapid, reliable
diagnostic information is vital to improving patient outcomes and easing the
tremendous cost pressures that threaten to undermine healthcare
excellence.&#160; In selecting market
opportunities, we primarily target highly prevalent diseases that are poorly
diagnosed by existing technologies. Currently, we offer diagnostic products for
drug screening, heart attack, congestive heart failure, or CHF, acute coronary
syndromes, or ACS, evaluation of shortness of breath and certain bacterial and
parasitic infections.</font></p>

<p align="left" style="letter-spacing:-.1pt;margin:0in 0in .0001pt;text-align:left;text-indent:13.5pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>

<p align="left" style="letter-spacing:-.1pt;margin:0in 0in .0001pt;text-align:left;text-indent:9.0pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Our strategy for sustained
growth is built around our unique discovery, development and commercialization
platform, which is intended to ultimately produce a portfolio of proprietary,
high value diagnostic products.</font></p>

<p align="left" style="letter-spacing:-.1pt;margin:0in 0in .0001pt 13.5pt;text-align:left;text-indent:0in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>

<p align="left" style="letter-spacing:-.1pt;margin:0in 0in .0001pt 31.5pt;text-align:left;text-indent:-.25in;"><font size="3" face="Times New Roman" style="font-size:12.0pt;">&#149;</font><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font><font size="2" style="font-size:10.0pt;">To implement this concept,
our technology platform includes phage display antibody discovery and
production, microfluidic devices for specimen and reagent handling, and
fluorescence-energy-transfer measurement systems.</font></p>

<p align="left" style="letter-spacing:-.1pt;margin:0in 0in .0001pt 31.5pt;text-align:left;text-indent:-.25in;"><font size="3" face="Times New Roman" style="font-size:12.0pt;">&#149;</font><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font><font size="2" style="font-size:10.0pt;">To augment our internal
capabilities, we work with a growing network of proteomics and pharmaceutical
companies and clinical institutions that collaborate with us in the discovery
of new disease markers and in the assessment of their medical utility.</font></p>

<p align="left" style="letter-spacing:-.1pt;margin:0in 0in .0001pt 31.5pt;text-align:left;text-indent:-.25in;"><font size="3" face="Times New Roman" style="font-size:12.0pt;">&#149;</font><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font><font size="2" style="font-size:10.0pt;">To commercialize
discoveries, our regulatory and marketing strategies are different from
traditional diagnostics companies. In some cases, the novelty of our tests may
require that we obtain premarket approval from the FDA, support extensive
clinical studies, and provide medical education directed at the caregivers who
use our products.</font></p>

<p align="center" style="letter-spacing:-.1pt;margin:0in 0in .0001pt;text-align:center;text-indent:0in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>

<p align="center" style="letter-spacing:-.1pt;margin:0in 0in .0001pt;text-align:center;text-indent:0in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">1</font></p>

<div align="left" style="letter-spacing:-.1pt;margin:0in 0in .0001pt;text-align:left;text-indent:0in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">

<hr size="2" width="100%" noshade color="gray" align="left">

</font></div>

</div>
<!-- SEQ.=1,FOLIO='1',FILE='C:\JMS\jboldua\05-1861-2\task332382\1861-2-ba.htm',USER='jboldua',CD='Mar  4 04:20 2005' -->


<br clear="all" style="page-break-before:always;">


<div style="font-family:Times New Roman;">

<p align="center" style="letter-spacing:-.1pt;margin:0in 0in .0001pt;text-align:center;text-indent:0in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>

<p align="left" style="letter-spacing:-.1pt;margin:0in 0in .0001pt;text-align:left;text-indent:13.5pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">We
believe this innovative approach provides the potential for a competitive
advantage over traditional diagnostic companies, not only because of the unique
nature of our science, but also because it provides us with the basis for key
patent applications.&#160; Since the medical
and economic value of providing better, faster answers to pressing diagnostic
questions is substantial, we believe the profit potential of our products
currently in development, if successfully developed and commercialized, could
parallel those of other important, proprietary medical devices.</font></p>

<p align="left" style="letter-spacing:-.1pt;margin:0in 0in .0001pt;text-align:left;text-indent:13.5pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>

<p align="left" style="letter-spacing:-.1pt;margin:0in 0in .0001pt;text-align:left;text-indent:13.5pt;"><i><font size="2" face="Times New Roman" style="font-size:10.0pt;font-style:italic;">Discovery</font></i></p>

<p align="left" style="letter-spacing:-.1pt;margin:0in 0in .0001pt;text-align:left;text-indent:13.5pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>

<p align="left" style="letter-spacing:-.1pt;margin:0in 0in .0001pt;text-align:left;text-indent:13.5pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">The
recent upsurge in the understanding and utility of human biomarkers or
analytes, including proteins, peptides, enzymes, hormones and other blood-borne
molecules that are the biologically active components of normal and diseased
physiology, has been the catalyst for our discovery effort.&#160;&#160; In most diseases, tissue damage and
biological response mechanisms change the blood levels of analytes enabling
them to be used as diagnostic &#147;disease markers.&#148;&#160; Most disease markers currently in clinical
use signal disease when their concentrations rise above a defined normal
cut-off point.&#160; For example, above-normal
concentrations of the following markers result in a positive disease diagnosis:</font></p>

<p align="left" style="letter-spacing:-.1pt;margin:0in 0in .0001pt;text-align:left;text-indent:13.5pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>

<div align="center">

<table border="0" cellspacing="0" cellpadding="0" width="84%" style="border-collapse:collapse;width:84.0%;">
 <tr>
  <td width="48%" valign="top" style="border:none;border-bottom:solid windowtext 1.0pt;padding:0in .7pt 0in .7pt;width:48.12%;">
  <p style="margin:0in 0in .0001pt;"><b><font size="1" face="Times New Roman" style="font-size:8.0pt;font-weight:bold;">Marker</font></b></p>
  </td>
  <td width="5%" valign="bottom" style="padding:0in .7pt 0in .7pt;width:5.98%;">
  <p style="margin:0in 0in .0001pt;"><b><font size="1" face="Times New Roman" style="font-size:1.0pt;font-weight:bold;">&nbsp;</font></b></p>
  </td>
  <td width="45%" valign="top" style="border:none;border-bottom:solid windowtext 1.0pt;padding:0in .7pt 0in .7pt;width:45.9%;">
  <p style="margin:0in 0in .0001pt;"><b><font size="1" face="Times New Roman" style="font-size:8.0pt;font-weight:bold;">Disease</font></b></p>
  </td>
 </tr>
 <tr>
  <td width="48%" valign="top" bgcolor="#CCEEFF" style="background:#CCEEFF;border:none;padding:0in .7pt 0in .7pt;width:48.12%;">
  <p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Glucose</font></p>
  </td>
  <td width="5%" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in .7pt 0in .7pt;width:5.98%;">
  <p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>
  </td>
  <td width="45%" valign="top" bgcolor="#CCEEFF" style="background:#CCEEFF;border:none;padding:0in .7pt 0in .7pt;width:45.9%;">
  <p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">diabetes</font></p>
  </td>
 </tr>
 <tr>
  <td width="48%" valign="top" style="padding:0in .7pt 0in .7pt;width:48.12%;">
  <p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Prostate specific antigen</font></p>
  </td>
  <td width="5%" valign="bottom" style="padding:0in .7pt 0in .7pt;width:5.98%;">
  <p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>
  </td>
  <td width="45%" valign="top" style="padding:0in .7pt 0in .7pt;width:45.9%;">
  <p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">prostate cancer</font></p>
  </td>
 </tr>
 <tr>
  <td width="48%" valign="top" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in .7pt 0in .7pt;width:48.12%;">
  <p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Hepatitis surface antigen</font></p>
  </td>
  <td width="5%" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in .7pt 0in .7pt;width:5.98%;">
  <p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>
  </td>
  <td width="45%" valign="top" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in .7pt 0in .7pt;width:45.9%;">
  <p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">hepatitis B</font></p>
  </td>
 </tr>
 <tr>
  <td width="48%" valign="top" style="padding:0in .7pt 0in .7pt;width:48.12%;">
  <p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">B-type natriuretic
  peptide, or BNP</font></p>
  </td>
  <td width="5%" valign="bottom" style="padding:0in .7pt 0in .7pt;width:5.98%;">
  <p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>
  </td>
  <td width="45%" valign="top" style="padding:0in .7pt 0in .7pt;width:45.9%;">
  <p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Congestive heart failure,
  or CHF</font></p>
  </td>
 </tr>
</table>

</div>

<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>

<p align="left" style="letter-spacing:-.1pt;margin:0in 0in .0001pt;text-align:left;text-indent:13.7pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;letter-spacing:0pt;">Given the low returns to date, marker discovery has
historically been viewed as an expensive, time consuming and risky undertaking
for commercial enterprises.&#160; As a result,
large diagnostic companies generally look to academic researchers for new
marker validation or rely on clinically proven markers in developing testing
menus.</font></p>

<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>

<p align="left" style="letter-spacing:-.1pt;margin:0in 0in .0001pt;text-align:left;text-indent:13.5pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">We
have developed our own internal program, Biosite Discovery, focused on
screening potential protein disease markers in order to identify novel proteins
or combinations of proteins that function as disease markers and have high
diagnostic utility.&#160; We believe our
discovery platform is significantly different from discovery methods employed
by other companies.&#160; Key to Biosite
Discovery is our proprietary Omniclonal<sup>&#174;</sup> phage display antibody development technology, which
enables the rapid and cost-efficient development of immunoassays that can be
used to evaluate up to several hundred potential disease markers each year.</font></p>

<p align="left" style="letter-spacing:-.1pt;margin:0in 0in .0001pt;text-align:left;text-indent:13.5pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>

<p align="left" style="letter-spacing:-.1pt;margin:0in 0in .0001pt;text-align:left;text-indent:13.5pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Our
Biosite Discovery program encompasses a three-step process:</font></p>

<p align="left" style="letter-spacing:-.1pt;margin:0in 0in .0001pt;text-align:left;text-indent:13.5pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>

<p align="left" style="letter-spacing:-.1pt;margin:0in 0in .0001pt 49.5pt;text-align:left;text-indent:-22.5pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">1.</font><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font><font size="2" style="font-size:10.0pt;">Through a variety of
collaborations, we collect patient blood samples related to disease states in
which we are interested.&#160; These samples
include disease-specific samples, samples from patients with conditions that
mimic the targeted disease, as well as samples from a normal, disease-free
population.&#160; We seek to establish
comprehensive sample banks, accumulating thousands of samples.&#160; Sample collection can be time intensive and
subject to fluctuations in timing, therefore, our ability to establish
relationships and collaborations with reliable sources of samples is essential.</font></p>

<p align="left" style="letter-spacing:-.1pt;margin:0in 0in .0001pt;text-align:left;text-indent:13.5pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>

<p align="left" style="letter-spacing:-.1pt;margin:0in 0in .0001pt 49.5pt;text-align:left;text-indent:-22.5pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">2.</font><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font><font size="2" style="font-size:10.0pt;">Once samples are available,
we use them for testing as we conduct &#147;marker mining&#148; to find markers with high
diagnostic utility for a targeted disease.&#160;
To do this, we use immunoassays, which require tightly binding, or
high-affinity, antibodies, to test potential markers against our samples
bank.&#160; Our ability to efficiently develop
large quantities of high-affinity antibodies for these research immunoassays
allows us to screen large numbers of markers in our efforts to identify those
most suitable for a diagnostic product.</font></p>

<p align="left" style="letter-spacing:-.1pt;margin:0in 0in .0001pt;text-align:left;text-indent:13.5pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>

<p align="left" style="letter-spacing:-.1pt;margin:0in 0in .0001pt 49.5pt;text-align:left;text-indent:-22.5pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">3.</font><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font><font size="2" style="font-size:10.0pt;">When data for potential
markers is available, we use a proprietary software system to define the
priority of the markers in terms of their importance in diagnosing the targeted
disease.&#160; This enables us to determine
the optimal markers for a diagnostic product.&#160;
Once this decision is made, the product proceeds to development.</font></p>

<p align="center" style="letter-spacing:-.1pt;margin:0in 0in .0001pt;text-align:center;text-indent:0in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>

<p align="center" style="letter-spacing:-.1pt;margin:0in 0in .0001pt;text-align:center;text-indent:0in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">2</font></p>

<div align="left" style="letter-spacing:-.1pt;margin:0in 0in .0001pt;text-align:left;text-indent:0in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">

<hr size="2" width="100%" noshade color="gray" align="left">

</font></div>

</div>
<!-- SEQ.=1,FOLIO='2',FILE='C:\JMS\jboldua\05-1861-2\task332382\1861-2-ba.htm',USER='jboldua',CD='Mar  4 04:20 2005' -->


<br clear="all" style="page-break-before:always;">


<div style="font-family:Times New Roman;">

<p align="left" style="letter-spacing:-.1pt;margin:0in 0in .0001pt;text-align:left;text-indent:13.7pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>

<p align="left" style="letter-spacing:-.1pt;margin:0in 0in .0001pt;text-align:left;text-indent:13.7pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">We believe that our Biosite Discovery model is significantly different
from discovery methods employed by other companies.&#160; Some of our differentiating qualities
include:</font></p>

<p align="left" style="letter-spacing:-.1pt;margin:0in 0in .0001pt;text-align:left;text-indent:0in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>

<p align="left" style="letter-spacing:-.1pt;margin:0in 0in .0001pt;text-align:left;text-indent:13.5pt;"><i><font size="2" face="Times New Roman" style="font-size:10.0pt;font-style:italic;">Rapid Antibody Development</font></i><font size="2" style="font-size:10.0pt;">:&#160; We believe we enjoy a unique position in the
area of phage display antibody development.&#160;
In the 1970&#146;s, the discovery of hybridoma technology, a process for
creating monoclonal antibodies, made it possible to precisely measure blood
proteins at very low concentrations.&#160;
Initially, we incorporated this technology into our research programs;
however, the time consuming and resource intensive nature of this hybridoma
technology limited the scope of research that could be performed.</font></p>

<p align="left" style="letter-spacing:-.1pt;margin:0in 0in .0001pt;text-align:left;text-indent:13.5pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>

<p align="left" style="letter-spacing:-.1pt;margin:0in 0in .0001pt;text-align:left;text-indent:13.5pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">In
the 1990&#146;s, we began in-licensing and refining technology for a new approach to
antibody discovery and production called phage display, which creates
genetically engineered, antibody-producing microorganisms.&#160; Through further advancement of this process,
we were able to create Omniclonal antibody libraries, which contain thousands
of gene-encoded antibodies to specific protein targets.&#160; Generally, development of antibodies may take
nine months or more.&#160; Using our
proprietary Omniclonal phage display antibody development technology, we can
quickly create human or murine libraries in weeks. Following evaluation for
clinical relevance, the useful antibodies can be economically produced.</font></p>

<p align="left" style="letter-spacing:-.1pt;margin:0in 0in .0001pt;text-align:left;text-indent:13.5pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>

<p align="left" style="letter-spacing:-.1pt;margin:0in 0in .0001pt;text-align:left;text-indent:13.5pt;"><i><font size="2" face="Times New Roman" style="font-size:10.0pt;font-style:italic;">High Throughput Capacity</font></i><font size="2" style="font-size:10.0pt;">:&#160; Because we utilize a highly efficient
antibody technology and have automated the most significant liquid handling
steps, we believe we currently have a high throughput capacity to develop high
affinity antibodies.&#160; With this high
throughput capacity, we are able to generate antibodies to a substantial number
of targets in a cost-efficient manner.&#160; This
permits us to take on significant discovery endeavors, such as our stroke
program, to identify, evaluate and develop novel diagnostics.</font></p>

<p align="left" style="letter-spacing:-.1pt;margin:0in 0in .0001pt;text-align:left;text-indent:13.5pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>

<p align="left" style="letter-spacing:-.1pt;margin:0in 0in .0001pt;text-align:left;text-indent:13.5pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&#160;<i><font style="font-style:italic;">Target
Validation Approach</font></i>:&#160; We focus
on serious health problems that are in need of improved diagnosis, prognosis
and monitoring.&#160; We collaborate with
commercial companies and clinical institutions to collect large numbers of
protein targets and clinically documented samples that can be studied for
association with selected diseases.</font></p>

<p align="left" style="letter-spacing:-.1pt;margin:0in 0in .0001pt;text-align:left;text-indent:13.5pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>

<p style="margin:0in 0in .0001pt;text-indent:.25in;"><i><font size="2" face="Times New Roman" style="font-size:10.0pt;font-style:italic;letter-spacing:-.1pt;">Proven Rapid Commercialization Capability</font></i><font size="2" style="font-size:10.0pt;">:&#160; We have a track record of successfully moving
novel diagnostics, including the Triage<i><sup><font style="font-style:italic;">&#174;</font></sup></i>
BNP Test, through the development pipeline.&#160;
We commercialized the first portable fluorescence-based quantitative
immunoassay platform and we developed the first rapid, quantitative
point-of-care immunoassays to receive U.S. Food and Drug Administration, or
FDA, clearance for the measurement of cardiac markers as an aid in the
diagnosis of acute myocardial infarction, of BNP as an aid in the diagnosis of
CHF, and of overdosed and abused drug analytes as an aid in the identification
of drug overdose.</font></p>

<p align="left" style="letter-spacing:-.1pt;margin:0in 0in .0001pt;text-align:left;text-indent:13.5pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>

<p align="left" style="letter-spacing:-.1pt;margin:0in 0in .0001pt;text-align:left;text-indent:13.5pt;"><i><font size="2" face="Times New Roman" style="font-size:10.0pt;font-style:italic;">Self-funded Program</font></i><font size="2" style="font-size:10.0pt;">: We leverage development
efficiencies to contain costs, and subsidize our discovery efforts with
revenues generated from collaborations.</font></p>

<p align="left" style="letter-spacing:-.1pt;margin:0in 0in .0001pt;text-align:left;text-indent:13.5pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>

<p align="left" style="letter-spacing:-.1pt;margin:0in 0in .0001pt;text-align:left;text-indent:13.5pt;"><i><font size="2" face="Times New Roman" style="font-size:10.0pt;font-style:italic;">Development</font></i></p>

<p align="left" style="letter-spacing:-.1pt;margin:0in 0in .0001pt;text-align:left;text-indent:13.5pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>

<p style="margin:0in 0in .0001pt;text-autospace:none;text-indent:.25in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Our on-going product
development goal is to provide physicians with timely and relevant information
upon which to base their diagnoses, prognoses and therapeutic strategies.&#160; The integration of several core scientific
and engineering disciplines is the foundation for our research and development
efforts.&#160; These include antibody
development, analyte cloning and synthesis, development of highly sensitive
fluorescence energy transfer dyes, microcapillary protein array technology and
sample handling.&#160; More recently, however,
we have enhanced our expertise in the development of test panels capable of
multi-marker measurements.</font></p>

<p style="margin:0in 0in .0001pt;text-autospace:none;text-indent:.25in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>

<p style="margin:0in 0in .0001pt;text-autospace:none;text-indent:.25in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Because many acute diseases
and conditions, such as chest pain, stroke, sepsis and abdominal pain, have
complicated causes, we are focusing a considerable portion of our development
efforts on multi-marker test panels.&#160;
Through Biosite Discovery, we believe we can select the optimal markers
for a targeted condition.&#160; Our research
has shown that discrete measurements of markers on a multi-marker panel, while
sufficient, may not always provide the most useful result.&#160; Therefore, we have developed a proprietary
process for reducing multiple protein concentrations to a single MultiMarker
Index&#153; value that we believe can be more easily interpreted than multiple
marker measurements and is more accurate in the clinical setting for diagnosis
and prognosis.</font></p>

<p align="center" style="margin:0in 0in .0001pt;text-align:center;text-autospace:none;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>

<p align="center" style="margin:0in 0in .0001pt;text-align:center;text-autospace:none;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">3</font></p>

<div style="margin:0in 0in .0001pt;text-autospace:none;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">

<hr size="2" width="100%" noshade color="gray" align="left">

</font></div>

</div>
<!-- SEQ.=1,FOLIO='3',FILE='C:\JMS\jboldua\05-1861-2\task332382\1861-2-ba.htm',USER='jboldua',CD='Mar  4 04:20 2005' -->


<br clear="all" style="page-break-before:always;">


<div style="font-family:Times New Roman;">

<p align="center" style="margin:0in 0in .0001pt;text-align:center;text-autospace:none;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>

<p style="margin:0in 0in .0001pt;text-autospace:none;text-indent:.25in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">We anticipate that the
MultiMarker Index value will be initially used in two potential products, the
Triage Profiler CP Panel and the Triage Stroke Panel, pending regulatory
approvals.&#160; </font><font size="2" style="font-size:10.0pt;">Clinical study data collected from more than 2,000
acute coronary syndromes and non-cardiac chest pain patients demonstrated that
the Triage Profiler CP</font><font size="2" style="font-size:10.0pt;">&#153;</font><font size="2" style="font-size:10.0pt;"> Panel MultiMarker Index value significantly improved the overall
diagnostic accuracy for the early diagnosis of acute coronary syndromes and
heart attack.</font></p>

<p style="margin:0in 0in .0001pt;text-autospace:none;text-indent:.25in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>

<p style="margin:0in 0in .0001pt;text-autospace:none;text-indent:.25in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">An important component of
our product development strategy is our approach to validating the clinical
usefulness of the MultiMarker Index value.&#160;
Historically, most new products in the diagnostics arena measured
biomarkers or analytes, such as glucose, cholesterol and prostate specific
antigen, for which clinical validity was already established.&#160; Consequently, the pre-market validation
process for these tests usually focused on showing that the new product
measurements correlated with diagnostic products already on the market.&#160; Manufacturers could perform this validation
in their own laboratories.&#160; Many
potential Biosite products lack pre-existing diagnostic models and we will be
required to demonstrate that these tests provide valid diagnostic
outcomes.&#160; To this end, we believe that
we have developed the organizational and institutional relationships necessary
to sponsor large clinical trials with the goal of obtaining data to support the
diagnostic indications that we wish to claim for our products.&#160; We may also fund follow-on clinical studies
once a product is launched to further validate diagnostic utility or new
applications for the test.&#160; While our
clinical trial process adds considerable time and expense to our development
timelines, we believe it provides us with important competitive advantages and,
most importantly, can help improve patient care.</font></p>

<p style="margin:0in 0in .0001pt;text-autospace:none;text-indent:.25in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>

<p style="margin:0in 0in .0001pt;text-autospace:none;text-indent:.25in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">We believe that our novel
approach to discovering and developing new multi-marker diagnostic products for
unmet applications will provide us with the best opportunity to establish and
maintain broad patent protection, which may in turn support a favorable market
position for our products.&#160; Many of the
technologies that enable our products are already covered by issued patents or
are the subject of patent filings.&#160; We
have filed foundational patents covering our MultiMarker Index approach to
diagnosis and prognosis, which claim both the generic algorithm used to derive
a MultiMarker Index value, as well as certain combinations of proteins for
specific diseases and conditions, such as stroke, sepsis, chest pain, shortness
of breath, myocardial infarction, acute coronary syndromes and abdominal pain.</font></p>

<p style="margin:0in 0in .0001pt;text-autospace:none;text-indent:.25in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>

<p style="margin:0in 0in .0001pt;text-autospace:none;text-indent:.25in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>

<p style="margin:0in 0in .0001pt;text-autospace:none;text-indent:.25in;"><i><font size="2" face="Times New Roman" style="font-size:10.0pt;font-style:italic;">Commercialization</font></i></p>

<p align="left" style="letter-spacing:-.1pt;margin:0in 0in .0001pt;text-align:left;text-indent:13.5pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>

<p align="left" style="letter-spacing:-.1pt;margin:0in 0in .0001pt;text-align:left;text-indent:13.5pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Our efforts culminate
with the Total Triage Solution, a custom diagnostic system designed to fit our
customers&#146; unique needs.&#160; With the Total
Triage Solution, we seek to provide our healthcare customers with access to
better, faster and more efficient and accurate diagnostic and prognostic
technology backed by a comprehensive education and support network.&#160; Our products are principally sold to acute
care hospitals, which number approximately 5,400 in the United States.&#160; To market our products, we utilize a direct
sales team that focuses its efforts primarily on larger centers with more than
200 beds and smaller hospitals that are high volume users of our products.&#160; We also use a network of distributors both in
the United States and internationally.</font></p>

<p align="left" style="letter-spacing:-.1pt;margin:0in 0in .0001pt;text-align:left;text-indent:13.5pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>

<p style="margin:0in 0in .0001pt;text-autospace:none;text-indent:.25in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">To commercialize MultiMarker
Index products, we have developed a testing platform that can quickly and
easily quantify multiple proteins using a small amount of whole-blood.&#160; The product can be used at the point-of-care,
as well as in a laboratory.&#160; We have key
intellectual property rights to many elements of our platform.</font></p>

<p style="margin:0in 0in .0001pt;text-autospace:none;text-indent:.25in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>

<p align="left" style="letter-spacing:-.1pt;margin:0in 0in .0001pt;text-align:left;text-indent:13.5pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">The Fisher HealthCare
Division of the Fisher Scientific Company, or Fisher, distributes our products
primarily in hospitals in the United States and supports our direct sales
force, particularly in smaller hospitals.&#160;
We have a distribution agreement with Fisher that extends through
December 31, 2005.&#160; Sales to Fisher
represented 86% and 90% of our product sales in 2004 and 2003, respectively.&#160; We utilize distributor relationships with
Physician Sales &amp; Services, or PSS, and Henry Schein, Inc., or Henry
Schein, to market our products to physician office laboratories in the United
States.</font></p>

<p align="left" style="letter-spacing:-.1pt;margin:0in 0in .0001pt;text-align:left;text-indent:13.5pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>

<p align="left" style="letter-spacing:-.1pt;margin:0in 0in .0001pt;text-align:left;text-indent:13.5pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">In
international markets, we have established direct selling efforts in several
countries and utilize a network of country-specific and regional distributors
in other areas.&#160; During 2003 and 2004, we
initiated direct sales and distribution operations in France, Germany, Belgium,
Luxembourg, the United Kingdom and Italy.&#160;
In the future, we may transition to direct sales and distribution of our
products in additional countries.&#160; Sales
to international customers in 2004, 2003, and 2002 totaled $26.0 million, $14.5
million, and $11.4 million, respectively.</font></p>

<p align="center" style="letter-spacing:-.1pt;margin:0in 0in .0001pt;text-align:center;text-indent:0in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>

<p align="center" style="letter-spacing:-.1pt;margin:0in 0in .0001pt;text-align:center;text-indent:0in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">4</font></p>

<div align="left" style="letter-spacing:-.1pt;margin:0in 0in .0001pt;text-align:left;text-indent:0in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">

<hr size="2" width="100%" noshade color="gray" align="left">

</font></div>

</div>
<!-- SEQ.=1,FOLIO='4',FILE='C:\JMS\jboldua\05-1861-2\task332382\1861-2-ba.htm',USER='jboldua',CD='Mar  4 04:20 2005' -->


<br clear="all" style="page-break-before:always;">


<div>

<p align="center" style="letter-spacing:-.1pt;margin:0in 0in .0001pt;text-align:center;text-indent:0in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>

<p align="left" style="letter-spacing:-.1pt;margin:0in 0in .0001pt;text-align:left;text-indent:13.5pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Because
our products are designed to change the practice of medicine, rather than
merely reduce the cost of testing, we invest substantially in education for
healthcare clinicians using our diagnostic products.&#160; While diagnostic companies traditionally
market their products solely to clinical laboratories, we generate demand for
our products among laboratory clinicians, physicians and hospital
administrators, by demonstrating the medical and economic advantages of our
diagnostic products.&#160; Supporting our
worldwide sales team is a field-based network that includes clinically
experienced individuals providing pre- and post- sale education and training
and customer and technical support resources to assist with ongoing utilization
of our products.&#160; As of December 31,
2004, our worldwide sales team and our supporting field-based network consisted
of 101 and 35 representatives, respectively.</font></p>

<p align="left" style="letter-spacing:-.1pt;margin:0in 0in .0001pt;text-align:left;text-indent:13.5pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>

<p align="left" style="letter-spacing:-.1pt;margin:0in 0in .0001pt;text-align:left;text-indent:13.5pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Our
product sales for 2004 were $240.6 million, representing a 42% increase over
2003.&#160; This growth resulted largely from
increased sales of our Triage BNP Test products, which are primarily used to
aid in the diagnosis of CHF.&#160; Our
meter-based Triage BNP Test, launched domestically in January 2001, was the
first blood test available to aid in the detection of CHF and benefited from a
semi-exclusive position in the market until the entry of direct competition in
June 2003.&#160; In December 2003, we received
clearance from the FDA to market our Triage BNP Test for Beckman Coulter<i><sup><font style="font-style:italic;">&#174;</font></sup></i> Immunoassay Systems and began
selling the product in the United States in January 2004.&#160; As a result, a customer can perform BNP
testing using either our rapid, portable Triage MeterPlus system or any of
Beckman Coulter Inc.&#146;s automated immunoassay systems.</font></p>

<p align="left" style="letter-spacing:-.1pt;margin:0in 0in .0001pt;text-align:left;text-indent:13.5pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>

<p align="left" style="letter-spacing:-.1pt;margin:0in 0in .0001pt;text-align:left;text-indent:13.5pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Today,
our Triage BNP Test products are among several FDA-cleared products for use as
an aid in the diagnosis of CHF.&#160; These
include products from Bayer Healthcare, Dade Behring, Roche Diagnostics and
Abbott Laboratories, which offer products based on large, centralized automated
testing platforms.&#160; We have experienced,
and continue to experience, competition from these companies and anticipate
competition from others in the future. Our competitors may succeed in
developing or marketing products that are more effective or more commercially
attractive than the Triage BNP Tests.&#160;
Moreover, we may not have the financial resources, technical expertise
or marketing, distribution or support capabilities to compete successfully with
these and other competitors in the future.</font></p>

<p align="left" style="letter-spacing:-.1pt;margin:0in 0in .0001pt;text-align:left;text-indent:13.5pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>

<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Industry Background</font></p>

<p align="left" style="letter-spacing:-.1pt;margin:0in 0in .0001pt;text-align:left;text-indent:13.5pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>

<p align="left" style="letter-spacing:-.1pt;margin:0in 0in .0001pt;text-align:left;"><b><i><font size="2" face="Times New Roman" style="font-size:10.0pt;font-style:italic;font-weight:bold;">Testing Platforms</font></i></b></p>

<p align="left" style="letter-spacing:-.1pt;margin:0in 0in .0001pt;text-align:left;text-indent:13.5pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>

<p align="left" style="letter-spacing:-.1pt;margin:0in 0in .0001pt;text-align:left;text-indent:13.5pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Generally,
automated analyzers have been the preferred diagnostic testing platform in
mainstream hospitals.&#160; Competition within
the diagnostics industry, has traditionally centered around improvements in
cost-effectiveness, throughput and the ability to precisely measure disease
markers.&#160; Testing platform development
within the industry usually involves relatively low technical risk, and
platforms are typically marketed to clinical laboratories that run tests,
rather than to the physicians who order diagnostics.&#160; There are a variety of automated analyzers
for clinical laboratories to choose from and menus are typically not
proprietary, therefore, competition is intense and the industry suffers from
low margins compared with other medical devices.&#160; Industry leaders tend to be those companies
with low cost positions and the marketing mass to succeed with commodity
product lines.</font></p>

<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>

<p align="left" style="letter-spacing:-.1pt;margin:0in 0in .0001pt;text-align:left;text-indent:13.5pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Within
hospitals, diagnosis is typically accomplished through a battery of testing
methods including immunoassays.&#160;
Historically, the majority of immunoassay testing has been accomplished
through a centralized process using large automated analyzers housed in the
central laboratory.&#160; These centralized
immunoassay analyzers utilize automated liquid handling mechanisms and
pipetting systems for reagent addition.&#160;
Modern centralized immunoassay analyzers are capable of storing and
selecting multiple reagents for a variety of analytes, including drugs,
hormones and cancer antigens. They also provide accurate and highly sensitive
test results and help to simplify the performance of immunoassays.&#160; While automated immunoassay analyzers may
meet hospitals&#146; routine testing needs, the use of centralized automation may
lead to lengthy turnaround times to accommodate transport of the sample to the
testing laboratory, time-consuming sample preparation and delivery of results
to the physician.&#160; Additionally,
centralized immunoassay analyzers require high volumes of sample throughput to
justify the investment in equipment, training, staffing and other costs
required to operate and support the systems.</font></p>

<p align="left" style="letter-spacing:-.1pt;margin:0in 0in .0001pt;text-align:left;text-indent:13.5pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>

<p align="left" style="letter-spacing:-.1pt;margin:0in 0in .0001pt;text-align:left;text-indent:13.5pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">In
recent years, rapid testing methods that can be performed in minutes with
minimal training have emerged to complement centralized automated testing.&#160; Simple, rapid immunoassays are capable of
detecting a single analyte marker with a color change that can be visually
interpreted.&#160; Formats such as dipsticks,
test tubes and membrane test </font></p>

<p align="center" style="letter-spacing:-.1pt;margin:0in 0in .0001pt;text-align:center;text-indent:0in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>

<p align="center" style="letter-spacing:-.1pt;margin:0in 0in .0001pt;text-align:center;text-indent:0in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">5</font></p>

<div align="left" style="letter-spacing:-.1pt;margin:0in 0in .0001pt;text-align:left;text-indent:0in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">

<hr size="2" width="100%" noshade color="gray" align="left">

</font></div>

</div>
<!-- SEQ.=1,FOLIO='5',FILE='C:\JMS\jboldua\05-1861-2\task332382\1861-2-ba.htm',USER='jboldua',CD='Mar  4 04:20 2005' -->


<br clear="all" style="page-break-before:always;">


<div>

<p align="center" style="letter-spacing:-.1pt;margin:0in 0in .0001pt;text-align:center;text-indent:0in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>

<p align="left" style="letter-spacing:-.1pt;margin:0in 0in .0001pt;text-align:left;text-indent:0in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">cartridges have been used to provide fast, non-instrument read results
for conditions where a single analyte marker is present in high concentrations
and where a simple yes/no non-numeric answer is clinically relevant.&#160; Rapid color change test formats are widely
available for drugs of abuse, pregnancy, strep throat and ovulation
prediction.&#160; Many of these tests utilize
compact, portable testing platforms that enable testing to occur at the
point-of-care.</font></p>

<p align="left" style="letter-spacing:-.1pt;margin:0in 0in .0001pt;text-align:left;text-indent:13.5pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>

<p align="left" style="letter-spacing:-.1pt;margin:0in 0in .0001pt;text-align:left;text-indent:13.5pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">We
believe that significant market potential exists for rapid diagnostics with
novel applications that are capable of precise quantitative measurement of
single or multiple analytes.&#160; Studies,
including one published in the February 2004 issue of the <i><font style="font-style:italic;">New England
Journal of Medicine</font></i>, have shown that rapid testing, including
point-of-care testing, may help to reduce overall healthcare delivery costs and
improve patient outcomes by providing diagnosis in a reduced period of time,
thereby minimizing the time to medical intervention.&#160; Patients undergoing emergency procedures can
benefit from more timely and accurate testing results, both of which improve
decision-making, which could limit unnecessary use of costly inpatient care.
Faster diagnosis can also permit earlier and more appropriate patient
management, potentially shortening the duration of illness.&#160; Furthermore, the development of new
diagnostics for diseases that currently lack accurate diagnostic products could
improve treatment and provide better outcomes.</font></p>

<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>

<p align="left" style="letter-spacing:-.1pt;margin:0in 0in .0001pt;text-align:left;text-indent:13.5pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">We
believe that rapid, point-of-care testing is optimal to significantly improve
patient care and reduce healthcare costs, especially for acute conditions.&#160; However, we also recognize that diagnostic
needs and objectives vary from hospital to hospital.&#160; Therefore, in addition to providing our rapid
Triage BNP Test on our existing Triage MeterPlus platform, we offer a version
of the product for use on a centralized automated testing platform.&#160; We have an agreement with Beckman Coulter
under which it manufactures the Triage BNP Test for Beckman Coulter Immunoassay
Systems for us, and we exclusively sell and market the product.&#160; The product received 510(k) Premarket
Notification, or 510(k), clearance from the FDA in December 2003.&#160; We began selling the product in Europe in
December 2003 and in the United States in January 2004.&#160; In the future, we may also choose to offer
other products for use on centralized automated testing platforms.</font></p>

<h4 style="font-size:10.0pt;font-weight:bold;margin:0in 0in .0001pt;page-break-after:avoid;text-decoration:underline;"><font face="Times New Roman"><font style="text-decoration:none;">&nbsp;</font></font></h4>

<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>

<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Technology</font></p>

<p align="left" style="letter-spacing:-.1pt;margin:0in 0in .0001pt;text-align:left;text-indent:13.5pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>

<p align="left" style="letter-spacing:-.1pt;margin:0in 0in .0001pt;text-align:left;text-indent:13.5pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Historically,
we have made significant investments in research and development, exceeding
traditional diagnostic industry standards.&#160;
These investments have yielded several proprietary advances in the
biological and physical sciences that serve as the basis for our diagnostic
marker discovery platform and make practical the development and manufacture of
rapid, accurate and cost-effective diagnostics.&#160;
Our products integrate our expertise in several core scientific and
engineering disciplines, including antibody development and engineering,
analyte cloning and synthesis, signaling chemistry and microcapillary fluidics,
each of which is described below.&#160; By
combining research capabilities in each of these areas, we create novel single
and multi-analyte diagnostics that overcome the limitations of traditional
diagnostic technologies and seek to address the significant unmet need for
effective, real-time diagnostic information.</font></p>

<p align="left" style="letter-spacing:-.1pt;margin:0in 0in .0001pt;text-align:left;text-indent:13.5pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>

<p style="margin:0in 0in .0001pt;"><i><font size="2" face="Times New Roman" style="font-size:10.0pt;font-style:italic;">Antibody Development</font></i></p>

<p align="left" style="letter-spacing:-.1pt;margin:0in 0in .0001pt;text-align:left;text-indent:13.5pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>

<p align="left" style="letter-spacing:-.1pt;margin:0in 0in .0001pt;text-align:left;text-indent:13.5pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Traditionally,
antibodies have been recognized as valuable tools for the characterization of
protein targets because they can be used to localize the protein in tissues, to
quantify the protein in body fluids and to modulate the biological activity of
the protein by, for example, binding to the protein and blocking its natural
function. Antibodies have traditionally been derived from immunization of
animals and either the harvest of antiserum containing antibodies or the
development of monoclonal antibodies using hybridoma technology.&#160; Antisera were generally of limited utility
and monoclonal antibody technology is labor intensive and not cost-effective
for the validation of large numbers of protein targets.&#160; In 1990, the phage display of antibodies was
invented and over the past decade it has enabled the development of antibodies
with much greater efficiency than the previous methods.</font></p>

<p align="left" style="letter-spacing:-.1pt;margin:0in 0in .0001pt;text-align:left;text-indent:13.5pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>

<p align="left" style="letter-spacing:-.1pt;margin:0in 0in .0001pt;text-align:left;text-indent:13.5pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">We
believe that our internal antibody development capabilities allow rapid
identification and development of antibodies with optimal specificity, affinity
and stability characteristics.&#160; We
initially utilized hybridoma technology for the selection and production of our
novel antibodies.&#160; However, hybridoma
technology has distinct disadvantages, including the length of time required to
develop antibody candidates, higher costs associated with the use of this
technology and the need to restart the antibody development process when
unwanted characteristics such as cross reactivities are discovered.</font></p>

<p align="center" style="letter-spacing:-.1pt;margin:0in 0in .0001pt;text-align:center;text-indent:0in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>

<p align="center" style="letter-spacing:-.1pt;margin:0in 0in .0001pt;text-align:center;text-indent:0in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">6</font></p>

<div align="left" style="letter-spacing:-.1pt;margin:0in 0in .0001pt;text-align:left;text-indent:0in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">

<hr size="2" width="100%" noshade color="gray" align="left">

</font></div>

</div>
<!-- SEQ.=1,FOLIO='6',FILE='C:\JMS\jboldua\05-1861-2\task332382\1861-2-ba.htm',USER='jboldua',CD='Mar  4 04:20 2005' -->


<br clear="all" style="page-break-before:always;">


<div style="font-family:Times New Roman;">

<p align="center" style="letter-spacing:-.1pt;margin:0in 0in .0001pt;text-align:center;text-indent:0in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>

<p align="left" style="letter-spacing:-.1pt;margin:0in 0in .0001pt;text-align:left;text-indent:13.5pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Instead,
we developed a proprietary process utilizing the phage display of antibodies,
which we believe enables faster and more efficient selection and production of
antibodies than is possible using hybridoma technology.&#160; The technology enables the high throughput
generation of custom Omniclonal antibody libraries containing genes encoding
antibodies specific to the target analyte.&#160;
Omniclonal antibodies produced from such libraries can contain thousands
of different antibodies that bind to a target analyte with high affinity, which
refers to an antibody&#146;s ability to bind tightly to targets and is a highly
desired attribute.&#160; Monoclonal antibody
candidates can be rapidly selected from an Omniclonal antibody library and
produced in quantities sufficient for product development.&#160; During the course of product development,
unexpected antibody cross reactivities often require additional selection of
antibodies to improve the assay specificity.&#160;
Unlike hybridoma technology, Omniclonal antibody libraries can rapidly
provide additional antibody candidates in these circumstances.</font></p>

<p align="left" style="letter-spacing:-.1pt;margin:0in 0in .0001pt;text-align:left;text-indent:0in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>

<p style="margin:0in 0in .0001pt;"><i><font size="2" face="Times New Roman" style="font-size:10.0pt;font-style:italic;">Analyte Cloning and Synthesis</font></i></p>

<p align="left" style="letter-spacing:-.1pt;margin:0in 0in .0001pt;text-align:left;text-indent:13.5pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>

<p align="left" style="letter-spacing:-.1pt;margin:0in 0in .0001pt;text-align:left;text-indent:13.5pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Our
molecular biology capabilities include the cloning and identification of
specific proteins useful in the development of immunoassays.&#160; We developed proprietary expression vectors
that enable the production and purification of these proteins for the
development of antibodies and for use as calibrators and controls in our
immunoassay products.&#160; In addition, our
considerable expertise in synthetic organic chemistry allows the synthesis of
targets and useful derivatives.&#160; We
develop products where the targeted analyte is small (i.e., haptens, such as
drugs) or large (i.e., proteins, such as cardiac enzymes).&#160; We believe that the ability to develop,
stabilize and manufacture the target analyte or its analogues is key to the
development of highly accurate immunoassays.</font></p>

<p align="left" style="letter-spacing:-.1pt;margin:0in 0in .0001pt;text-align:left;text-indent:13.5pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>

<p style="margin:0in 0in .0001pt;"><i><font size="2" face="Times New Roman" style="font-size:10.0pt;font-style:italic;">Highly Sensitive Fluorescence Energy Transfer Dyes</font></i></p>

<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>

<p align="left" style="letter-spacing:-.1pt;margin:0in 0in .0001pt;text-align:left;text-indent:13.5pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Immunoassays
require the attachment of a detectable label to an antibody or target
analyte.&#160; We developed a variety of
labels for use in our products. For our qualitative products, a visual label
that produces color is attached to antibodies or analytes through either
non-covalent or covalent chemical methods to provide yes/no results. For our
Triage MeterPlus platform products, we developed novel fluorescent dyes that
are attached to antibodies or analytes using both noncovalent and covalent
chemical means. Although fluorescence is a potentially powerful label for use
in immunoassays, its potential has been limited by the lack of available dyes
that are stable and have no sample interference, and by the requirement of a
complex instrument for detection.&#160; We have
invented our own proprietary&nbsp;dyes that satisfy four criteria:</font></p>

<p align="left" style="letter-spacing:-.1pt;margin:0in 0in .0001pt;text-align:left;text-indent:13.5pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>

<p align="left" style="letter-spacing:-.1pt;margin:0in 0in .0001pt 24.0pt;text-align:left;text-indent:-10.5pt;"><font size="3" face="Times New Roman" style="font-size:12.0pt;">&#149;</font><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font><font size="2" style="font-size:10.0pt;">they are usable with complex
biological samples such as serum, plasma, and whole-blood;</font></p>

<p align="left" style="letter-spacing:-.1pt;margin:0in 0in .0001pt 24.0pt;text-align:left;text-indent:-10.5pt;"><font size="3" face="Times New Roman" style="font-size:12.0pt;">&#149;</font><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font><font size="2" style="font-size:10.0pt;">they are stable for the
dating period of the product;</font></p>

<p align="left" style="letter-spacing:-.1pt;margin:0in 0in .0001pt 24.0pt;text-align:left;text-indent:-10.5pt;"><font size="3" face="Times New Roman" style="font-size:12.0pt;">&#149;</font><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font><font size="2" style="font-size:10.0pt;">they utilize fluorescence
energy transfer, which results in a substantial phase shift away from
background fluorescence in samples; and</font></p>

<p align="left" style="letter-spacing:-.1pt;margin:0in 0in .0001pt 24.0pt;text-align:left;text-indent:-10.5pt;"><font size="3" face="Times New Roman" style="font-size:12.0pt;">&#149;</font><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font><font size="2" style="font-size:10.0pt;">they are excited at near
infrared wavelengths chosen to be compatible with inexpensive solid state
components.</font></p>

<p align="left" style="letter-spacing:-.1pt;margin:0in 0in .0001pt;text-align:left;text-indent:13.5pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>

<p style="margin:0in 0in .0001pt;"><i><font size="2" face="Times New Roman" style="font-size:10.0pt;font-style:italic;">Microcapillary/Protein Array Technology</font></i></p>

<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>

<p align="left" style="letter-spacing:-.1pt;margin:0in 0in .0001pt;text-align:left;text-indent:13.5pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">We
developed proprietary technology to design, develop and manufacture protein
arrays containing microcapillaries to control the flow of fluids in immunoassay
processes.&#160; The qualitative device format
uses microcapillaries to draw fluids through a membrane that contains
immobilized antibody zones for the detection of specific substances.&#160;&#160; The quantitative device format moves fluids
through the microcapillaries in a controlled manner.&#160; When a sample is added to the quantitative
assay device, a filter contained within the device separates blood cells from
plasma.&#160; Then the plasma moves by
capillary action into a chamber that contains dried fluorescent immunoassay
reagents.&#160; Inside the chamber, the
analytes that are to be measured bind to the fluorescent immunoassay reagents.&#160; After an incubation time that is determined
by another microcapillary element of the array we call the time gate, the
sample flows through a microcapillary path termed the protein array. The
protein array is comprised of antibodies that are specific to the analytes and
immobilized onto the surface of the device in discrete zones.&#160; The fluorescent reagents, which are bound to
the analyte, bind to the respective zones on the protein array. The excess
sample that was added to the device washes the unbound fluorescent reagents
from the protein array. The binding of fluorescent reagents at the protein
array is detected by our Triage MeterPlus and the fluorescence intensity at the
discrete zone is related to the concentration of the substance or analyte being
tested and measured in the sample.&#160; We
also developed the engineering capability to design unique microcapillary
structures in plastic parts and to fabricate them in commercial scale
quantities using </font></p>

<p align="center" style="letter-spacing:-.1pt;margin:0in 0in .0001pt;text-align:center;text-indent:0in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>

<p align="center" style="letter-spacing:-.1pt;margin:0in 0in .0001pt;text-align:center;text-indent:0in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">7</font></p>

<div align="left" style="letter-spacing:-.1pt;margin:0in 0in .0001pt;text-align:left;text-indent:0in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">

<hr size="2" width="100%" noshade color="gray" align="left">

</font></div>

</div>
<!-- SEQ.=1,FOLIO='7',FILE='C:\JMS\jboldua\05-1861-2\task332382\1861-2-ba.htm',USER='jboldua',CD='Mar  4 04:20 2005' -->


<br clear="all" style="page-break-before:always;">


<div>

<p align="center" style="letter-spacing:-.1pt;margin:0in 0in .0001pt;text-align:center;text-indent:0in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>

<p align="left" style="letter-spacing:-.1pt;margin:0in 0in .0001pt;text-align:left;text-indent:0in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">injection molding processes.</font></p>

<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>

<p style="margin:0in 0in .0001pt;"><i><font size="2" face="Times New Roman" style="font-size:10.0pt;font-style:italic;">Sample Handling</font></i></p>

<p align="left" style="letter-spacing:-.1pt;margin:0in 0in .0001pt;text-align:left;text-indent:13.5pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>

<p align="left" style="letter-spacing:-.1pt;margin:0in 0in .0001pt;text-align:left;text-indent:13.5pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">We
developed proprietary technology relating to sample handling and preparation,
including technology that allows whole-blood to be passively separated into its
plasma component or to be passively lysed to release the target analyte.&#160; We also developed technologies for the
handling of stool samples that concentrate and purify the target analytes or
organisms from solid stool materials.&#160; In
addition, we developed technologies that can be used to assay urine samples.</font></p>

<p align="left" style="letter-spacing:-.1pt;margin:0in 0in .0001pt;text-align:left;text-indent:13.5pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>

<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Commercialized Products</font></p>

<p align="left" style="letter-spacing:-.1pt;margin:0in 0in .0001pt;text-align:left;text-indent:0in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>

<p align="left" style="letter-spacing:-.1pt;margin:0in 0in .0001pt;text-align:left;text-indent:13.5pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Our
products are principally sold to acute care hospitals, which number
approximately 5,400 in the United States.&#160;
To market our products, we utilize a direct sales team that focuses its
efforts on larger centers with more than 200 beds and smaller hospitals that
are high volume users of our products.&#160;
Fisher distributes all of our products in U.S. hospitals and supports
our direct sales force, particularly in smaller hospitals and in some U.S.
physician offices.&#160; PSS and Henry Schein
distribute our product to U.S. physician offices.&#160; A field-based network of clinically
experienced individuals supports the sales effort by providing pre- and post-
sale education and training.&#160; In
international markets, we have established direct selling efforts in six
European countries and utilize a network of country-specific and regional
distributors in other areas.</font></p>

<p align="left" style="letter-spacing:-.1pt;margin:0in 0in .0001pt;text-align:left;text-indent:13.5pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>

<p align="left" style="letter-spacing:-.1pt;margin:0in 0in .0001pt;text-align:left;text-indent:0in;"><i><font size="2" face="Times New Roman" style="font-size:10.0pt;font-style:italic;">Triage
MeterPlus</font></i></p>

<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>

<p align="left" style="letter-spacing:-.1pt;margin:0in 0in .0001pt;text-align:left;text-indent:13.5pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Our
Triage MeterPlus is a rapid testing platform designed to provide quantitative
or qualitative results for immunoassays using urine, whole-blood, serum or
plasma.&#160; The compact, portable Triage
MeterPlus consists of a proprietary fluorescence meter that can be used in
laboratories or at the point-of-care.&#160;
After a sample is applied to a Triage panel assay device, the assay
device is inserted into the meter, which is designed to automatically and
simultaneously detect multiple analytes and display the numerical results on an
electronic read-out.&#160; The meter utilizes
proprietary software that it accesses from its own internal flash memory to
perform its many functions. The meter&#146;s internal flash memory may be updated at
any time using a common, commercially available memory chip that we distribute
to end users.&#160; The contents of a memory
chip are in essence, disposable, because after an end-user downloads the
contents of the memory chip to the meter&#146;s internal flash memory, the memory
chip is removed and may be discarded.&#160;
This allows the meter to operate on a stand-alone basis, freeing the end
user from any need to retain the memory chips or match a memory chip to a
particular lot of assay devices.&#160; Thus,
the meter&#146;s entire design, from its optic and electronic systems to the design
of the assay device, allows any Triage MeterPlus to perform any product that we
offer.&#160; In January 2004, we announced the
commencement of a platform development program intended to miniaturize the
Triage MeterPlus Platform.&#160; The program
is intended to yield a state-of-the-art testing platform with enhanced speed,
accuracy and precision.</font></p>

<p align="left" style="letter-spacing:-.1pt;margin:0in 0in .0001pt;text-align:left;text-indent:.25in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>

<p align="left" style="letter-spacing:-.1pt;margin:0in 0in .0001pt;text-align:left;text-indent:0in;"><i><font size="2" face="Times New Roman" style="font-size:10.0pt;font-style:italic;">Congestive Heart Failure</font></i></p>

<p align="left" style="letter-spacing:-.1pt;margin:0in 0in .0001pt;text-align:left;text-indent:0in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>

<p align="left" style="letter-spacing:-.1pt;margin:0in 0in .0001pt;text-align:left;text-indent:13.5pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">CHF,
also known as congestive heart failure, is a chronic inability of the heart to
maintain an adequate output of blood from one or both of its ventricles,
resulting in congestion or swelling of certain veins or organs, and an inadequate
blood supply to the body.&#160; According to
the American Heart Association, AHA, nearly five million people in the United
States currently live with CHF.&#160; With
approximately 550,000 new cases diagnosed annually in the United States alone,
CHF imposes a growing toll, in terms of disability and mortality.&#160; In 2002, CHF contributed to approximately
265,000 deaths, and hospital discharges for CHF increased 157% between 1979 and
2002.&#160; The direct and indirect costs of
CHF in the United States in 2005 are expected to exceed $27 billion.</font></p>

<p align="left" style="letter-spacing:-.1pt;margin:0in 0in .0001pt;text-align:left;text-indent:13.5pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>

<p align="left" style="letter-spacing:-.1pt;margin:0in 0in .0001pt;text-align:left;text-indent:13.5pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">The
2004 National Hospital Ambulatory Medical Care Survey suggests that each year
over four million individuals visit emergency departments, or EDs, with
complaints of shortness of breath or breathing difficulties, two common
symptoms of CHF.&#160; Because many of these
patients are among the elderly, a patient population subject to multiple
overlapping diseases, physicians must consider several possible diagnoses.&#160; Standard clinical diagnostic guidelines
include the evaluation of patient history and symptoms and typically an
x-ray.&#160; These subjective methods may
detect CHF in patients at the most advanced stages, but are not always
effective in patients who are not severely ill.&#160;
Patients suspected of having CHF might receive an echocardiogram, which
is used to detect left ventricular dysfunction.&#160;
</font></p>

<p align="center" style="letter-spacing:-.1pt;margin:0in 0in .0001pt;text-align:center;text-indent:0in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>

<p align="center" style="letter-spacing:-.1pt;margin:0in 0in .0001pt;text-align:center;text-indent:0in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">8</font></p>

<div align="left" style="letter-spacing:-.1pt;margin:0in 0in .0001pt;text-align:left;text-indent:0in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">

<hr size="2" width="100%" noshade color="gray" align="left">

</font></div>

</div>
<!-- SEQ.=1,FOLIO='8',FILE='C:\JMS\jboldua\05-1861-2\task332382\1861-2-ba.htm',USER='jboldua',CD='Mar  4 04:20 2005' -->


<br clear="all" style="page-break-before:always;">


<div>

<p align="center" style="letter-spacing:-.1pt;margin:0in 0in .0001pt;text-align:center;text-indent:0in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>

<p align="left" style="letter-spacing:-.1pt;margin:0in 0in .0001pt;text-align:left;text-indent:0in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Studies have shown that traditional clinical diagnostic techniques for
CHF can result in delayed treatment, misdiagnosis and ED inefficiency.</font></p>

<p align="left" style="letter-spacing:-.1pt;margin:0in 0in .0001pt;text-align:left;text-indent:.25in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>

<p align="left" style="letter-spacing:-.1pt;margin:0in 0in .0001pt;text-align:left;text-indent:13.5pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">In
1996, we obtained a semi-exclusive license (worldwide, except Japan) to
technology and patents related to BNP from Scios, Inc., which became a
subsidiary of Johnson &amp; Johnson in 2003.&#160;
Clinical studies have demonstrated that BNP is a highly reliable
indicator of CHF and that the protein marker is found in increasingly higher
levels as disease progression occurs.&#160; In
January 2001, we launched our first Triage BNP Test, based on the Triage
MeterPlus platform, to provide physicians with a cost-effective, 15-minute
diagnostic product to easily, rapidly and accurately measure BNP levels to aid
in the diagnosis of CHF.&#160; In December
2003, we received FDA 510(k) clearance to market our Triage BNP Test for
Beckman Coulter Immunoassay Systems.&#160; We
began selling the product in the United States in January 2004.&#160; As a result, a customer can perform BNP
testing using either our rapid, portable Triage MeterPlus system or any of
Beckman Coulter, Inc.&#146;s automated immunoassay systems.</font></p>

<p align="left" style="letter-spacing:-.1pt;margin:0in 0in .0001pt;text-align:left;text-indent:13.5pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>

<p align="left" style="letter-spacing:-.1pt;margin:0in 0in .0001pt;text-align:left;text-indent:13.5pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&#160; Currently, the Triage BNP Test is primarily
used to differentiate CHF from other diseases that share symptoms similar to
those associated with CHF.&#160;&#160; Subsequent
to the November 2000 FDA clearance of the Triage BNP Test as an aid in the
diagnosis of CHF, we received FDA clearances for additional applications of the
Triage BNP Test.&#160; The diagnostic product
was cleared for the risk stratification of patients with ACS, another
cardiovascular condition, and for the assessment of disease severity in patients
with CHF.&#160; We are currently supporting
clinical studies intended to explore other possible applications.&#160; A decision to pursue these or other new
applications would require that we seek additional clearances for the new
applications from the FDA.</font></p>

<p align="left" style="letter-spacing:-.1pt;margin:0in 0in .0001pt;text-align:left;text-indent:13.5pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>

<p align="left" style="letter-spacing:-.1pt;margin:0in 0in .0001pt;text-align:left;text-indent:13.5pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">In
2003, we began to market the Triage BNP Test for use in physician offices.&#160; We have formed a small direct sales force
specifically focusing on the physician office market and have signed agreements
granting PSS, Henry Schein, and Fisher certain distribution rights in this
market segment.&#160; We may also engage other
distributors for this market in the future.&#160;
We are currently targeting the estimated 14,000 physician office
laboratories that are licensed to perform non-waived tests, which is the
existing CLIA categorization for the Triage BNP Test.&#160; These laboratories serve cardiology
practices, as well as those internal medicine and family practice physicians
who see large numbers of CHF patients.&#160;
We have applied to the FDA for a recategorization of our Triage BNP Test
to waived status, a designation that would allow us to target an additional
36,000 U.S. physician office laboratories that might want to use our
product.&#160; We intend to expand our
marketing to these additional physician office laboratories if we receive the
CLIA waiver for our Triage BNP Test.</font></p>

<p align="left" style="letter-spacing:-.1pt;margin:0in 0in .0001pt;text-align:left;text-indent:13.5pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>

<p align="left" style="letter-spacing:-.1pt;margin:0in 0in .0001pt;text-align:left;text-indent:13.5pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">We
believe that significant validation of the Triage BNP Test in physician offices
will be necessary in order to achieve widespread acceptance of this diagnostic
test, particularly among family practice and internal medicine physicians, who
are unlikely to be familiar with BNP.&#160;
Additionally, in order to promote use of the diagnostic product at the
point-of-care, it will be necessary to demonstrate clinical and economic value
for physicians.&#160; While significant
interest is already apparent, we have and intend to continue to sponsor
multiple clinical studies of varying sizes in order to demonstrate the
diagnostic utility of our Triage BNP Test.&#160;
Additionally, we are investing in other educational programs and
resources.</font></p>

<p align="left" style="letter-spacing:-.1pt;margin:0in 0in .0001pt;text-align:left;text-indent:13.5pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>

<p align="left" style="letter-spacing:-.1pt;margin:0in 0in .0001pt;text-align:left;text-indent:13.5pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Today,
our Triage BNP Test products are among several cleared blood tests used as an
aid in the diagnosis of CHF.&#160; These
include products from Bayer Healthcare, Dade Behring, Roche Diagnostics and
Abbott Laboratories, which offer products based on large, centralized automated
testing platforms.&#160; We have experienced,
and continue to experience, competition from these companies and anticipate
competition from others in the future. Our competitors may succeed in
developing or marketing products that are more effective or more commercially
attractive than the Triage BNP Tests.&#160;
Moreover, we may not have the financial resources, technical expertise
or marketing, distribution or support capabilities to compete successfully with
these and other competitors in the future.</font></p>

<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>

<p style="margin:0in 0in .0001pt;"><i><font size="2" face="Times New Roman" style="font-size:10.0pt;font-style:italic;">Cardiovascular Ischemia</font></i></p>

<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>

<p align="left" style="letter-spacing:-.1pt;margin:0in 0in .0001pt;text-align:left;text-indent:13.5pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Chest
pain, a common symptom of cardiovascular ischemia, was the second leading
reason for visits to U.S. EDs in 2002.&#160;
Information from the 2004 National Hospital Ambulatory Medical Care
Survey indicates that in 2002, in the United States there were nearly six
million ED visits by adults suffering from chest pain.&#160;&#160; Among chest pain patients, those with acute
myocardial infarction, or heart attack, are at greatest risk and in need of
rapid diagnosis.</font></p>

<p align="center" style="letter-spacing:-.1pt;margin:0in 0in .0001pt;text-align:center;text-indent:0in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>

<p align="center" style="letter-spacing:-.1pt;margin:0in 0in .0001pt;text-align:center;text-indent:0in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">9</font></p>

<div align="left" style="letter-spacing:-.1pt;margin:0in 0in .0001pt;text-align:left;text-indent:0in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">

<hr size="2" width="100%" noshade color="gray" align="left">

</font></div>

</div>
<!-- SEQ.=1,FOLIO='9',FILE='C:\JMS\jboldua\05-1861-2\task332382\1861-2-ba.htm',USER='jboldua',CD='Mar  4 04:20 2005' -->


<br clear="all" style="page-break-before:always;">


<div>

<p align="center" style="letter-spacing:-.1pt;margin:0in 0in .0001pt;text-align:center;text-indent:0in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>

<p align="left" style="letter-spacing:-.1pt;margin:0in 0in .0001pt;text-align:left;text-indent:13.5pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Misdiagnosis
of chest pain is a significant source of healthcare costs. Of the patients
presenting to EDs with chest pain, almost 67% will be admitted to hospitals,
however, only a small percentage of these individuals will be diagnosed with a
heart attack.&#160; Additionally, it is
estimated in the United States that the unnecessary hospitalization of chest
pain patients costs over $2.5 billion annually.&#160;
The high incidence of chest pain visits to hospital EDs may also
contribute to overcrowding which, in dire situations, can result in hospitals
diverting patients to other hospitals.&#160;
This results in additional healthcare costs and risks.</font></p>

<p align="left" style="letter-spacing:-.1pt;margin:0in 0in .0001pt;text-align:left;text-indent:13.5pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>

<p align="left" style="letter-spacing:-.1pt;margin:0in 0in .0001pt;text-align:left;text-indent:13.5pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Today,
chest pain is typically evaluated using a diagnostic regimen that includes
physical examination, electrocardiogram, which has diagnostic utility in only
25% to 50% of cases, and testing of cardiac markers.&#160; Two cardiac markers, CK-MB and troponin, are
the most broadly accepted markers for use in the diagnosis of heart attack.&#160;&#160; While each has beneficial properties, each
also has disadvantages.&#160; CK-MB begins to
rise soon after an event, but can be elevated in patients with damage to
muscles other than the heart.&#160; Troponin,
while more specific to heart muscle damage, typically is not present in
detectable levels until five or more hours after an event.&#160; Studies have shown that observing the
temporal patterns associated with CK-MB, troponin and other cardiac markers may
lead to better diagnosis of heart attack; however, because most testing of
cardiac markers is done using centralized automated analyzers, obtaining
frequent measurements of cardiac markers is often not practical.</font></p>

<p align="left" style="letter-spacing:-.1pt;margin:0in 0in .0001pt;text-align:left;text-indent:13.5pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>

<p align="left" style="letter-spacing:-.1pt;margin:0in 0in .0001pt;text-align:left;text-indent:13.5pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Our
Triage Cardiac Panel, intended to aid in the diagnosis of acute myocardial
infarction, or heart attack, was broadly launched in 1999.&#160; This approximately 15-minute diagnostic
product simultaneously and quantitatively measures the presence of CK-MB,
troponin I and complexes and myoglobin, a cardiac marker that rises soon after
an event occurs.&#160; We believe use of the
Triage Cardiac Panel in conjunction with a protocol incorporating frequent,
serial measurement of the three cardiac markers can significantly improve
diagnosis of heart attack.&#160; The adoption
of new protocols for evaluating chest pain patients in the ED, however, is not
yet widespread and we believe that education of the medical community will be a
key factor in penetrating the market.&#160;
Associations such as the National Academy of Clinical Biochemistry, or
NACB, have issued guidelines recommending greater use of cardiac markers in
evaluating chest pain in the ED.&#160; The
NACB has recommended the use of at least two markers (an early marker and a
specific marker) and has stated that if results cannot be obtained from a
laboratory within 60 minutes then testing should be performed at the point-of-care.&#160; Guidelines such as these have caused more
hospitals to explore new protocols incorporating rapid, serial testing of all
three markers.&#160; We are investing in
clinical studies and in a significant physician education effort in order to
help the medical community better understand the need for, and benefits
associated with, frequent, serial testing of cardiac markers.</font></p>

<p align="left" style="letter-spacing:-.1pt;margin:0in 0in .0001pt;text-align:left;text-indent:13.5pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>

<p align="left" style="letter-spacing:-.1pt;margin:0in 0in .0001pt;text-align:left;text-indent:13.5pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Due
to the complicated nature of most cardiac diseases, we believe that panels of
multiple markers will be extremely useful as diagnostic tools for cardiac
conditions.&#160; In the second quarter of
2003, we commenced marketing of a second-generation cardiac panel, the Triage
Cardio ProfilER<i><sup><font style="font-style:italic;">&#153;</font></sup>  </i>Panel, which incorporates CK-MB,
myoglobin, troponin I and complexes and BNP.&#160;
The Triage Cardio ProfilER Panel is intended to serve as an enhancement
to our existing Triage Cardiac Panel.&#160;
Studies suggest that low levels of troponin I, a cardiac marker, present
in a patient&#146;s bloodstream could be indicative of ACS.</font></p>

<p align="left" style="letter-spacing:-.1pt;margin:0in 0in .0001pt;text-align:left;text-indent:13.5pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>

<p align="left" style="letter-spacing:-.1pt;margin:0in 0in .0001pt;text-align:left;text-indent:13.5pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">We
are continuing to research potential cardiac markers and combinations of
cardiac markers that may further assist in evaluating and diagnosing chest pain
patients.&#160; One such potential product,
the Triage Profiler CP Panel, is designed as an aid in the early diagnosis of
ACS, including heart attack and the assessment of severity of heart
failure.&#160; The product measures four
biomarkers, CK-MB, myoglobin, troponin I and BNP, like our currently marketed
Triage Cardio ProfilER Panel.&#160; It also
incorporates a proprietary MultiMarker Index process which analyzes information
from all four markers and presents a single composite index result.&#160; Our clinical study data collected from more
than 2,000 ACS and non-cardiac chest pain patients demonstrated that the Triage
Profiler CP MultiMarker Index process significantly improved the overall
diagnostic accuracy for the early diagnosis of ACS and heart attack.</font></p>

<p align="left" style="letter-spacing:-.1pt;margin:0in 0in .0001pt;text-align:left;text-indent:13.5pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>

<p align="left" style="letter-spacing:-.1pt;margin:0in 0in .0001pt;text-align:left;text-indent:13.5pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">In
October 2004, we filed a 510(k) with the FDA seeking clearance for our Triage
Profiler CP Panel.&#160; Given the proprietary
MultiMarker Index algorithm used in the calculation of the composite result,
the FDA has determined that the device is not substantially equivalent to
devices marketed in interstate commerce prior to May 28, 1976 and therefore
classified the device, by statute, to class III (Premarket Approval
Application, or PMA).&#160; We believe that
the FDA&#146;s decision to request that we file a PMA in no way reflects on the
quality of the data we previously submitted, or the perceived diagnostic
utility of the MultiMarker Index algorithm.&#160;
Rather, we believe that the FDA&#146;s decision was based on the fact that
the Triage Profiler CP Panel has new technological characteristics that may not
be generally used </font></p>

<p align="center" style="letter-spacing:-.1pt;margin:0in 0in .0001pt;text-align:center;text-indent:0in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>

<p align="center" style="letter-spacing:-.1pt;margin:0in 0in .0001pt;text-align:center;text-indent:0in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">10</font></p>

<div align="left" style="letter-spacing:-.1pt;margin:0in 0in .0001pt;text-align:left;text-indent:0in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">

<hr size="2" width="100%" noshade color="gray" align="left">

</font></div>

</div>
<!-- SEQ.=1,FOLIO='10',FILE='C:\JMS\jboldua\05-1861-2\task332382\1861-2-ba.htm',USER='jboldua',CD='Mar  4 04:20 2005' -->


<br clear="all" style="page-break-before:always;">


<div>

<p align="center" style="letter-spacing:-.1pt;margin:0in 0in .0001pt;text-align:center;text-indent:0in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>

<p align="left" style="letter-spacing:-.1pt;margin:0in 0in .0001pt;text-align:left;text-indent:0in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">in medical practice today.&#160; We
are working with the FDA to build on the clinical data we previously submitted
and to determine the appropriate regulatory pathway for this potential product.&#160; The PMA and 510(k) processes are discussed in
greater detail in the section below entitled &#147;Government Regulation.&#148;</font></p>

<p align="left" style="letter-spacing:-.1pt;margin:0in 0in .0001pt;text-align:left;text-indent:13.5pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>

<p align="left" style="letter-spacing:-.1pt;margin:0in 0in .0001pt;text-align:left;text-indent:13.5pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Several
diagnostic tests have been developed to quantitatively measure the blood levels
of cardiac markers. These are most commonly available on large, automated
immunoassay analyzers marketed by companies such as Abbott Laboratories, Dade
Behring, Roche Diagnostics, Beckman Coulter, Bayer Diagnostics and others.&#160; These systems cannot directly analyze
whole-blood and results are not always available on a rapid basis.&#160; Since turnaround time is critical to enabling
frequent, serial testing of cardiac markers, current immunoassay systems may
not satisfy physician needs. Nevertheless, these systems are predominant in the
market today.&#160; Smaller automated systems
have recently been developed; however, they are not portable, have low
throughput and often cannot provide results for all three markers in
approximately 15 minutes.</font></p>

<p align="left" style="letter-spacing:-.1pt;margin:0in 0in .0001pt;text-align:left;text-indent:13.5pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>

<p style="margin:0in 0in .0001pt;"><i><font size="2" face="Times New Roman" style="font-size:10.0pt;font-style:italic;">Shortness of Breath</font></i></p>

<p align="left" style="letter-spacing:-.1pt;margin:0in 0in .0001pt;text-align:left;text-indent:13.5pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>

<p align="left" style="letter-spacing:-.1pt;margin:0in 0in .0001pt;text-align:left;text-indent:13.5pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&#160;In June 2004, we received 510(k) clearance
from the FDA to market the Triage Profiler Shortness of Breath<sup>&#153;</sup>
(SOB) Panel. We initiated shipments of the Triage Profiler SOB Panel in August
2004.&#160; This new diagnostic test panel is
intended to accelerate and improve ED evaluation of shortness of breath and
breathing difficulty, which rank among the top reasons for ED visits.&#160; The Triage Profiler SOB Panel simultaneously
measures five disease biomarkers &#151; CK-MB, myoglobin, troponin I, BNP and
D-dimer in about 15 minutes.&#160; The
multi-marker panel is designed to help physicians rapidly distinguish among the
most common causes of shortness of breath: CHF, heart attack or silent heart
attack, and pulmonary embolism, or PE.&#160;
Portable and easy-to-use, this diagnostic product can be used in the ED,
eliminating the need for the hospital to obtain multiple blood samples or
employ one or more laboratory-based analyzers to accomplish multiple tests.</font></p>

<p align="left" style="letter-spacing:-.1pt;margin:0in 0in .0001pt;text-align:left;text-indent:13.5pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>

<p align="left" style="letter-spacing:-.1pt;margin:0in 0in .0001pt;text-align:left;text-indent:13.5pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">In
December 2004, we received 510(k) clearance from the FDA to market the Triage
D-Dimer Test. This diagnostic product is intended to be used as an aid in the
assessment and evaluation of patients suspected of having thromboembolic
events, including PE, a blockage of one or more of the pulmonary arteries by
blood clot.&#160; With at least 650,000 cases
occurring each year in the United States, PE is a common and highly lethal
condition that is among the leading causes of death in all age groups.&#160; It is the first or second most common cause
of unexpected death in most age groups. The highest incidence of recognized PE
occurs in hospitalized patients. Autopsy results show as many as 60 percent of
patients dying in the hospital have had a PE, but the diagnosis has been missed
in about 70 percent of the cases.</font></p>

<p align="left" style="letter-spacing:-.1pt;margin:0in 0in .0001pt;text-align:left;text-indent:13.5pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>

<p align="left" style="letter-spacing:-.1pt;margin:0in 0in .0001pt;text-align:left;text-indent:0in;"><i><font size="2" face="Times New Roman" style="font-size:10.0pt;font-style:italic;">Drug
Overdose</font></i></p>

<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>

<p align="left" style="letter-spacing:-.1pt;margin:0in 0in .0001pt;text-align:left;text-indent:13.5pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Drug
abuse plays a significant role in emergency medicine cases, either as a primary
cause or as a contributing factor.&#160; A
diagnostic dilemma confronts physicians when patients present with symptoms
that could be either drug related or non-drug related.&#160; For instance, a patient brought into an ED in
a coma may be under the influence of narcotics or sedatives, thus requiring a
certain type of treatment or intervention.&#160;
Conversely, the same patient may have had a stroke or suffered some form
of trauma requiring a completely different type of care.&#160; The ability to obtain a differential
diagnosis in a timely manner greatly aids the course of treatment.</font></p>

<p align="left" style="letter-spacing:-.1pt;margin:0in 0in .0001pt;text-align:left;text-indent:13.5pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>

<p align="left" style="letter-spacing:-.1pt;margin:0in 0in .0001pt;text-align:left;text-indent:13.5pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">We
introduced the first Triage Drugs of Abuse Panel in 1992 and launched the
second-generation Triage TOX Drug Screen in January 2002.&#160; The Triage Drugs of Abuse Panels and Triage
TOX Drug Screen are rapid, qualitative urine screens that analyze a single test
sample for different illicit and prescription drugs or drug classes, and
provide results in approximately 10 to 15 minutes.&#160; The Triage Drugs of Abuse Panels are
configured to test for various combinations of drugs and provide a visual
result in about ten minutes.&#160; The Triage
TOX Drug Screen is a single test panel that is used for the determination of
the major metabolites of up to eight drug classes and produces a
positive/negative result in about 15 minutes.&#160;
<font style="background:white;">In November 2004, we submitted a 510(k)
for the Triage TOX Drug Screen with the addition of a new analyte,
acetaminophen. We anticipate this product will be used to rule out
acetaminophen overdose.&#160; In the United
States, acetaminophen overdose is estimated to represent 5%, or 275,000, of the
5.2 million total toxic exposures annually, and nearly 10% of all toxic
pharmaceutical exposures annually (275,000 out of 2.9 million).</font></font></p>

<p align="center" style="letter-spacing:-.1pt;margin:0in 0in .0001pt;text-align:center;text-indent:0in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>

<p align="center" style="letter-spacing:-.1pt;margin:0in 0in .0001pt;text-align:center;text-indent:0in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">11</font></p>

<div align="left" style="letter-spacing:-.1pt;margin:0in 0in .0001pt;text-align:left;text-indent:0in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">

<hr size="2" width="100%" noshade color="gray" align="left">

</font></div>

</div>
<!-- SEQ.=1,FOLIO='11',FILE='C:\JMS\jboldua\05-1861-2\task332382\1861-2-ba.htm',USER='jboldua',CD='Mar  4 04:20 2005' -->


<br clear="all" style="page-break-before:always;">


<div style="font-family:Times New Roman;">

<p align="center" style="letter-spacing:-.1pt;margin:0in 0in .0001pt;text-align:center;text-indent:0in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>

<p align="left" style="letter-spacing:-.1pt;margin:0in 0in .0001pt;text-align:left;text-indent:13.5pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Illicit
drugs detectable by the Triage Drugs of Abuse Panels and Triage TOX Drug Screen
include:</font></p>

<p align="left" style="letter-spacing:-.1pt;margin:0in 0in .0001pt;text-align:left;text-indent:13.5pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>

<p align="left" style="letter-spacing:-.1pt;margin:0in 0in .0001pt;text-align:left;text-indent:13.5pt;"><font size="3" face="Times New Roman" style="font-size:12.0pt;">&#149;</font><font size="2" style="font-size:10.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160; amphetamines/methamphetamines (ecstasy,
speed, crystal);</font></p>

<p align="left" style="letter-spacing:-.1pt;margin:0in 0in .0001pt;text-align:left;text-indent:13.5pt;"><font size="3" face="Times New Roman" style="font-size:12.0pt;">&#149;</font><font size="2" style="font-size:10.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160; cocaine (crack);</font></p>

<p align="left" style="letter-spacing:-.1pt;margin:0in 0in .0001pt;text-align:left;text-indent:13.5pt;"><font size="3" face="Times New Roman" style="font-size:12.0pt;">&#149;</font><font size="2" style="font-size:10.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160; opiates (heroin);</font></p>

<p align="left" style="letter-spacing:-.1pt;margin:0in 0in .0001pt;text-align:left;text-indent:13.5pt;"><font size="3" face="Times New Roman" style="font-size:12.0pt;">&#149;</font><font size="2" style="font-size:10.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160; phencyclidine (angel dust); and</font></p>

<p align="left" style="letter-spacing:-.1pt;margin:0in 0in .0001pt;text-align:left;text-indent:13.5pt;"><font size="3" face="Times New Roman" style="font-size:12.0pt;">&#149;</font><font size="2" style="font-size:10.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160; cannabinoids/THC (pot, marijuana).</font></p>

<p align="left" style="letter-spacing:-.1pt;margin:0in 0in .0001pt;text-align:left;text-indent:13.5pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>

<p align="left" style="letter-spacing:-.1pt;margin:0in 0in .0001pt;text-align:left;text-indent:13.5pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Prescription
drugs tested by the Triage Drugs of Abuse Panel include:</font></p>

<p align="left" style="letter-spacing:-.1pt;margin:0in 0in .0001pt;text-align:left;text-indent:13.5pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>

<p align="left" style="letter-spacing:-.1pt;margin:0in 0in .0001pt;text-align:left;text-indent:13.5pt;"><font size="3" face="Times New Roman" style="font-size:12.0pt;">&#149;</font><font size="2" style="font-size:10.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160; barbiturates (Phenobarbital);</font></p>

<p align="left" style="letter-spacing:-.1pt;margin:0in 0in .0001pt;text-align:left;text-indent:13.5pt;"><font size="3" face="Times New Roman" style="font-size:12.0pt;">&#149;</font><font size="2" style="font-size:10.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160; benzodiazepines (Valium, Librium,
Halcion);</font></p>

<p align="left" style="letter-spacing:-.1pt;margin:0in 0in .0001pt;text-align:left;text-indent:13.5pt;"><font size="3" face="Times New Roman" style="font-size:12.0pt;">&#149;</font><font size="2" style="font-size:10.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160; tricyclic antidepressants (Elavil,
Tofranil);</font></p>

<p align="left" style="letter-spacing:-.1pt;margin:0in 0in .0001pt;text-align:left;text-indent:13.5pt;"><font size="3" face="Times New Roman" style="font-size:12.0pt;">&#149;</font><font size="2" style="font-size:10.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160; propoxyphene (Darvon); and</font></p>

<p align="left" style="letter-spacing:-.1pt;margin:0in 0in .0001pt;text-align:left;text-indent:13.5pt;"><font size="3" face="Times New Roman" style="font-size:12.0pt;">&#149;</font><font size="2" style="font-size:10.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160; methadone.</font></p>

<p align="left" style="letter-spacing:-.1pt;margin:0in 0in .0001pt;text-align:left;text-indent:13.5pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>

<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Products Under Development</font></p>

<p align="left" style="letter-spacing:-.1pt;margin:0in 0in .0001pt;text-align:left;text-indent:0in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>

<p align="left" style="letter-spacing:-.1pt;margin:0in 0in .0001pt;text-align:left;text-indent:13.5pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Our
strategy for potential future products, including our current products under
development, is to focus our attention on large market opportunities where we
can potentially achieve market leadership and/or a proprietary patent position
related to disease biomarkers with novel therapeutic and/or diagnostic
applications.&#160; Our development efforts
focus on new marker mining as well as on the investigation of new applications
for existing markers and/or combinations of existing markers.&#160; To support our efforts, we utilize a variety
of means to gain access to potential markers such as internal research,
licensing and collaborations.&#160; We are
currently researching many potential disease marker candidates.&#160; Additionally, we have established clinical
collaborations with many leading medical institutions that provide samples for
use in our research efforts.&#160; Among the
products with novel diagnostic applications that we are attempting to develop
are diagnostic products for cerebral ischemia or stroke, cardiovascular
disease, sepsis and abdominal pain.</font></p>

<p align="left" style="letter-spacing:-.1pt;margin:0in 0in .0001pt;page-break-after:avoid;text-align:left;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>

<p style="margin:0in 0in .0001pt;page-break-after:avoid;"><i><font size="2" face="Times New Roman" style="font-size:10.0pt;font-style:italic;">Stroke</font></i></p>

<p style="margin:0in 0in .0001pt;page-break-after:avoid;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>

<p align="left" style="letter-spacing:-.1pt;margin:0in 0in .0001pt;text-align:left;text-indent:13.5pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Among
the nation&#146;s costliest diseases, stroke affects the vessels supplying blood to
the brain, which requires a constant flow of blood in order to function
properly.&#160; A stroke occurs when the blood
supply to the brain is disrupted due to a blood clot blocking a blood vessel
(ischemic stroke), or when a blood vessel breaks, interrupting blood flow to an
area of the brain (hemorrhagic stroke).&#160;
The AHA estimates that approximately 88% of stroke patients have
ischemic strokes and 12% have hemorrhagic strokes.</font></p>

<p align="left" style="letter-spacing:-.1pt;margin:0in 0in .0001pt;text-align:left;text-indent:13.5pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>

<p align="left" style="letter-spacing:-.1pt;margin:0in 0in .0001pt;text-align:left;text-indent:13.5pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">According
to the AHA, approximately 700,000 people suffer a new or recurrent stroke each
year.&#160; The disease is currently a leading
cause of serious, long-term disability in the United States.&#160; In 2002, there were 942,000 hospital
discharges for stroke in the United States, and from 1988 to 1997 total
hospitalizations for stroke increased nearly 39%.&#160; The AHA estimates that in 2005, the direct
and indirect costs associated with stroke in the United States will exceed $56
billion.</font></p>

<p align="left" style="letter-spacing:-.1pt;margin:0in 0in .0001pt;text-align:left;text-indent:13.5pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>

<p align="left" style="letter-spacing:-.1pt;margin:0in 0in .0001pt;text-align:left;text-indent:13.5pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">We
believe that each year, in the United States, there may be eight million visits
to EDs by people displaying symptoms that could be associated with cerebral
ischemia or stroke.&#160; Typically, stroke is
diagnosed through clinical evaluation and through use of a computed tomography,
or CT, scan, a diagnostic imaging technique.&#160;
However, CT scans are typically not highly sensitive in the early hours
after onset of an ischemic stroke.&#160; Given
the narrow window of opportunity for aggressive therapeutic intervention
following a stroke, we believe that the availability of additional and faster
methods of detection could significantly improve clinical outcomes.</font></p>

<p align="left" style="letter-spacing:-.1pt;margin:0in 0in .0001pt;text-align:left;text-indent:13.5pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>

<p align="left" style="letter-spacing:-.1pt;margin:0in 0in .0001pt;text-align:left;text-indent:13.5pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">In
our efforts to develop a diagnostic product for stroke, we studied more than 70
biomarkers that appeared to be related to stroke.&#160; Using our marker mining process, we narrowed
those 70 markers to a panel of markers that is highly correlated with stroke.&#160; We intend to commercialize a single panel of
markers on a Triage assay device for use on the Triage MeterPlus.&#160; Like the Triage Profiler CP Panel, our stroke
panel will incorporate a proprietary MultiMarker </font></p>

<p align="center" style="letter-spacing:-.1pt;margin:0in 0in .0001pt;text-align:center;text-indent:0in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>

<p align="center" style="letter-spacing:-.1pt;margin:0in 0in .0001pt;text-align:center;text-indent:0in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">12</font></p>

<div align="left" style="letter-spacing:-.1pt;margin:0in 0in .0001pt;text-align:left;text-indent:0in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">

<hr size="2" width="100%" noshade color="gray" align="left">

</font></div>

</div>
<!-- SEQ.=1,FOLIO='12',FILE='C:\JMS\jboldua\05-1861-2\task332382\1861-2-ba.htm',USER='jboldua',CD='Mar  4 04:20 2005' -->


<br clear="all" style="page-break-before:always;">


<div>

<p align="center" style="letter-spacing:-.1pt;margin:0in 0in .0001pt;text-align:center;text-indent:0in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>

<p align="left" style="letter-spacing:-.1pt;margin:0in 0in .0001pt;text-align:left;text-indent:0in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Index process, which analyzes information from all markers on the panel
and presents a single representative value, the MultiMarker Index value.&#160; Our research suggests that discrete
measurements of our stroke markers, in and of themselves, are not adequate to
determine the presence of cerebral ischemia or stroke.&#160; We intend to provide substantial education
regarding the advantages of the MultiMarker Index algorithm concept.</font></p>

<p align="left" style="letter-spacing:-.1pt;margin:0in 0in .0001pt;text-align:left;text-indent:13.5pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>

<p align="left" style="letter-spacing:-.1pt;margin:0in 0in .0001pt;text-align:left;text-indent:13.5pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Data
from a retrospective study, comprising more than 1,000 patients, suggest that
our diagnostic product for stroke can significantly improve a physician&#146;s
ability to diagnose stroke, adding valuable information to a complex,
time-constrained diagnostic process.&#160;
Furthermore, in a sub-study of 59 patients, our diagnostic product for
stroke was more accurate than a CT scan in detecting ischemic stroke in the
early hours after onset.</font></p>

<p align="left" style="letter-spacing:-.1pt;margin:0in 0in .0001pt;text-align:left;text-indent:13.5pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>

<p align="left" style="letter-spacing:-.1pt;margin:0in 0in .0001pt;text-align:left;text-indent:13.5pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">In
December, 2004, we filed a PMA with the FDA seeking approval to market our
diagnostic product for stroke.&#160; We are
continuing to collect patient samples and to gain access to, and research,
additional stroke markers that could potentially be added to future generations
of our diagnostic product for stroke.</font></p>

<p style="margin:0in 0in .0001pt;page-break-after:avoid;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>

<p style="margin:0in 0in .0001pt;page-break-after:avoid;"><i><font size="2" face="Times New Roman" style="font-size:10.0pt;font-style:italic;">Cardiovascular Diseases</font></i></p>

<p align="left" style="letter-spacing:-.1pt;margin:0in 0in .0001pt;text-align:left;text-indent:13.5pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>

<p align="left" style="letter-spacing:-.1pt;margin:0in 0in .0001pt;text-align:left;text-indent:13.5pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Cardiovascular
disease is a primary focus area of our research and development efforts and
product development is underway in a number of different areas.&#160; In addition to developing diagnostic products
that can be used to detect a specific disease, we are also concentrating our
efforts on the development of multi-marker panels that can be used with patients
exhibiting symptoms that could be associated with a variety of diseases.&#160; These panels are intended to help physicians
quickly and accurately distinguish between causes of symptoms using only a
single test panel.&#160; Together with various
commercial and clinical collaborators, we are continuing to analyze other
protein targets believed to be associated with ACS and other cardiovascular
diseases.</font></p>

<p align="left" style="letter-spacing:-.1pt;margin:0in 0in .0001pt;text-align:left;text-indent:13.5pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>

<p align="left" style="letter-spacing:-.1pt;margin:0in 0in .0001pt;text-align:left;text-indent:0in;"><i><font size="2" face="Times New Roman" style="font-size:10.0pt;font-style:italic;">Sepsis</font></i></p>

<p align="left" style="letter-spacing:-.1pt;margin:0in 0in .0001pt;text-align:left;text-indent:13.5pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>

<p align="left" style="letter-spacing:-.1pt;margin:0in 0in .0001pt;text-align:left;text-indent:13.5pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Sepsis
is a complex syndrome that can take on a variety of different forms.&#160; In general, it is an inflammatory reaction
initiated by microorganisms, including bacteria, viruses and fungi, which can
cause widespread damage to the blood vessels leading to circulatory shock,
organ failure, gangrene of extremities and death.&#160; In the United States, each year approximately
750,000 patients develop sepsis and the aging population is accelerating the
prevalence of the disease.&#160; Overall
mortality of patients developing sepsis ranges from 20-50%.&#160; Total annual costs for sepsis exceed $16
billion in the United States with the average hospital cost per adult case
estimated to be between $22,000 and $50,000.</font></p>

<p align="left" style="letter-spacing:-.1pt;margin:0in 0in .0001pt;text-align:left;text-indent:13.5pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>

<p align="left" style="letter-spacing:-.1pt;margin:0in 0in .0001pt;text-align:left;text-indent:13.5pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">The
complications associated with sepsis can advance quickly.&#160; Diagnosis is complicated by a lack of
effective diagnostic tools to detect the disease in its early stages.&#160; We are currently studying markers that may be
useful in the diagnosis or risk prognosis of septic patients.&#160; We have commenced collection of approximately
7,000 patient samples to be used in studying potential biomarkers for sepsis.&#160; Our objective is to initiate a clinical study
for a sepsis diagnostic product in the second half of 2005.</font></p>

<p align="left" style="letter-spacing:-.1pt;margin:0in 0in .0001pt;text-align:left;text-indent:13.5pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>

<p align="left" style="letter-spacing:-.1pt;margin:0in 0in .0001pt;text-align:left;text-indent:0in;"><i><font size="2" face="Times New Roman" style="font-size:10.0pt;font-style:italic;">Abdominal Pain</font></i></p>

<p align="left" style="letter-spacing:-.1pt;margin:0in 0in .0001pt;text-align:left;text-indent:13.5pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>

<p align="left" style="letter-spacing:-.1pt;margin:0in 0in .0001pt;text-align:left;text-indent:13.5pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Abdominal
pain complaints represent the number one reason for visits to U.S. EDs.&#160; The diagnosis of this symptom is complicated
by factors such as severity, duration and location of pain and the possibility
of multiple etiologies.&#160; A complex and
often expensive &#147;rule out&#148; diagnostic pathway used by physicians may include
various laboratory tests, imaging studies and surgical interventions.&#160; We are exploring opportunities to use
biomarker panels to diagnose some of the most serious conditions that cause
abdominal pain and we expect to initially analyze approximately 40 protein
biomarkers in 5,000 patient samples that we are in the process of collecting
from our network of clinical collaborators.</font></p>

<p align="center" style="letter-spacing:-.1pt;margin:0in 0in .0001pt;text-align:center;text-indent:0in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>

<p align="center" style="letter-spacing:-.1pt;margin:0in 0in .0001pt;text-align:center;text-indent:0in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">13</font></p>

<div align="left" style="letter-spacing:-.1pt;margin:0in 0in .0001pt;text-align:left;text-indent:0in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">

<hr size="2" width="100%" noshade color="gray" align="left">

</font></div>

</div>
<!-- SEQ.=1,FOLIO='13',FILE='C:\JMS\jboldua\05-1861-2\task332382\1861-2-ba.htm',USER='jboldua',CD='Mar  4 04:20 2005' -->


<br clear="all" style="page-break-before:always;">


<div style="font-family:Times New Roman;">

<p align="center" style="letter-spacing:-.1pt;margin:0in 0in .0001pt;text-align:center;text-indent:0in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>

<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Competition</font></p>

<p style="margin:0in 0in .0001pt;page-break-after:avoid;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>

<p style="margin:0in 0in .0001pt;text-indent:13.5pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">The
market in which we compete is intensely competitive.&#160; Our competitors include:</font></p>

<p style="margin:0in 0in .0001pt;text-indent:13.5pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>

<p style="margin:0in 0in .0001pt;text-indent:13.5pt;"><font size="3" face="Times New Roman" style="font-size:12.0pt;">&#149;</font><font size="2" style="font-size:10.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160; manufacturers of laboratory-based tests
and analyzers;</font></p>

<p style="margin:0in 0in .0001pt;text-indent:13.5pt;"><font size="3" face="Times New Roman" style="font-size:12.0pt;">&#149;</font><font size="2" style="font-size:10.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160; clinical reference laboratories; and</font></p>

<p style="margin:0in 0in .0001pt;text-indent:13.5pt;"><font size="3" face="Times New Roman" style="font-size:12.0pt;">&#149;</font><font size="2" style="font-size:10.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160; other rapid diagnostic product
manufacturers.</font></p>

<p style="margin:0in 0in .0001pt;text-indent:13.5pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>

<p style="margin:0in 0in .0001pt;text-indent:13.5pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Currently,
the majority of diagnostic immunoassays utilized by physicians and other
healthcare providers are performed by independent clinical reference
laboratories and hospital-based laboratories using automated analyzers.&#160; We expect that companies offering analyzers
will compete vigorously to maintain their dominance of the testing market.
Although we now offer our Triage BNP Test for use on Beckman Coulter
Immunoassay Systems, our remaining products are not currently designed for
automated batch testing.&#160; In order to
achieve the broadest market acceptance for our products, we will be required to
demonstrate that our products provide cost-effective and time saving alternatives
to certain tests performed on automated analyzers.&#160; This will require physicians to change their
established means of having such tests performed.&#160; Our rapid products may not be able to compete
with the testing services provided by traditional laboratory services.</font></p>

<p style="margin:0in 0in .0001pt;text-indent:13.5pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>

<p style="margin:0in 0in .0001pt;text-indent:13.5pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">In
addition, companies with a significant presence in the diagnostic market, such
as:</font></p>

<p style="margin:0in 0in .0001pt;text-indent:13.5pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>

<p style="margin:0in 0in .0001pt;text-indent:13.5pt;"><font size="3" face="Times New Roman" style="font-size:12.0pt;">&#149;</font><font size="2" style="font-size:10.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160; Abbott Laboratories;</font></p>

<p style="margin:0in 0in .0001pt;text-indent:13.5pt;"><font size="3" face="Times New Roman" style="font-size:12.0pt;">&#149;</font><font size="2" style="font-size:10.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160; Bayer Diagnostics;</font></p>

<p style="margin:0in 0in .0001pt;text-indent:13.5pt;"><font size="3" face="Times New Roman" style="font-size:12.0pt;">&#149;</font><font size="2" style="font-size:10.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160; Beckman Coulter;</font></p>

<p style="margin:0in 0in .0001pt;text-indent:13.5pt;"><font size="3" face="Times New Roman" style="font-size:12.0pt;">&#149;</font><font size="2" style="font-size:10.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160; Dade Behring;</font></p>

<p style="margin:0in 0in .0001pt;text-indent:13.5pt;"><font size="3" face="Times New Roman" style="font-size:12.0pt;">&#149;</font><font size="2" style="font-size:10.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160; Diagnostic Products Corp;</font></p>

<p style="margin:0in 0in .0001pt;text-indent:13.5pt;"><font size="3" face="Times New Roman" style="font-size:12.0pt;">&#149;</font><font size="2" style="font-size:10.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160; Johnson &amp; Johnson; and</font></p>

<p style="margin:0in 0in .0001pt;text-indent:13.5pt;"><font size="3" face="Times New Roman" style="font-size:12.0pt;">&#149;</font><font size="2" style="font-size:10.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160; Roche Diagnostics</font></p>

<p style="margin:0in 0in .0001pt;text-indent:13.5pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>

<p align="left" style="letter-spacing:-.1pt;margin:0in 0in .0001pt;text-align:left;text-indent:0in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">have developed or are developing diagnostics and/or testing systems
that do or will compete with our products.&#160;
For example, our two formats of the Triage BNP Test are currently among
several FDA-cleared blood tests for use as an aid in the diagnosis of CHF.&#160; Roche Diagnostics and Dade Behring, which
offer tests that measure NT-proBNP, a marker associated with CHF, received FDA
clearance for their tests in November 2002 and September 2004,
respectively.&#160; Abbott Laboratories and
Bayer Diagnostics, which have certain diagnostic rights to BNP, also recently
entered the market for BNP testing.&#160; </font><font size="2" style="font-size:10.0pt;letter-spacing:0pt;">Additionally, in 2003, Abbott Laboratories acquired i-STAT Corp., which
manufactures and sells a point-of-care testing platform that competes with our
Triage MeterPlus platform.&#160; </font><font size="2" style="font-size:10.0pt;">These
competitors may succeed in developing or marketing products that are more
effective or commercially attractive than the Triage BNP Test.&#160; The launch of these competitive products may
also adversely impact the market pricing for BNP testing.&#160; </font><font size="2" style="font-size:10.0pt;letter-spacing:0pt;">These
competitors have substantially greater financial, technical, research and other
resources and larger, more established marketing, sales, distribution and
service organizations than us.&#160; Moreover,
these competitors offer broader product lines and have greater name recognition
than us, and offer discounts as a competitive tactic.</font></p>

<p align="left" style="letter-spacing:-.1pt;margin:0in 0in .0001pt;text-align:left;text-indent:13.5pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>

<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Employees</font></p>

<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>

<p align="left" style="letter-spacing:-.1pt;margin:0in 0in .0001pt;text-align:left;text-indent:.25in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">As of December 31, 2004, we employed 905 regular full-time or part-time
individuals. Of these, 43 held Ph.D.s and 73 held other advanced degrees.&#160; None of our employees are covered by a
collective bargaining agreement.&#160; We
believe that we maintain good relations with our employees.</font></p>

<p align="left" style="letter-spacing:-.1pt;margin:0in 0in .0001pt;text-align:left;text-indent:.25in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>

<p align="left" style="font-style:italic;margin:0in 0in .0001pt;page-break-after:avoid;text-align:left;"><i><font size="2" face="Times New Roman" style="font-size:10.0pt;">Research and Development</font></i></p>

<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>

<p align="left" style="letter-spacing:-.1pt;margin:0in 0in .0001pt;text-align:left;text-indent:13.5pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">We
have increased our investments in research and development in each of the last
three years.&#160; As of December&nbsp;31,
2004, we employed 200 employees in research and development, including 33
Ph.D.s.&#160; Our research and development
organization is dedicated to the study of novel disease biomarkers or
combinations of disease biomarkers, the development of new technologies that
can be applied to future products and the development of new products
compatible with our existing platform technologies.&#160; We also have research staff dedicated to the
development and production of antibodies through a variety of techniques. Recombinant
techniques are used to express proteins for use </font></p>

<p align="center" style="letter-spacing:-.1pt;margin:0in 0in .0001pt;text-align:center;text-indent:0in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>

<p align="center" style="letter-spacing:-.1pt;margin:0in 0in .0001pt;text-align:center;text-indent:0in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">14</font></p>

<div align="left" style="letter-spacing:-.1pt;margin:0in 0in .0001pt;text-align:left;text-indent:0in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">

<hr size="2" width="100%" noshade color="gray" align="left">

</font></div>

</div>
<!-- SEQ.=1,FOLIO='14',FILE='C:\JMS\jboldua\05-1861-2\task332382\1861-2-ba.htm',USER='jboldua',CD='Mar  4 04:20 2005' -->


<br clear="all" style="page-break-before:always;">


<div>

<p align="center" style="letter-spacing:-.1pt;margin:0in 0in .0001pt;text-align:center;text-indent:0in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>

<p align="left" style="letter-spacing:-.1pt;margin:0in 0in .0001pt;text-align:left;text-indent:0in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">as diagnostic markers. Our staff of chemists and biochemists synthesize
drug targets and compounds for diagnostic use and seek to perfect techniques
for coupling these compounds to biological reagents such as antibodies or
labels when necessary.&#160; We developed a
proprietary process utilizing phage display antibody technology that enables
the selection and production of antibodies more rapidly and efficiently than is
possible using hybridoma technology.&#160; Our
engineering staff is involved in the design and development of new diagnostic
device technologies as well as the processes for their fabrication and
interaction with biological and chemical reagents. Our product development
group completes final optimization of assays and our clinical and regulatory
affairs group oversees all in-house clinical studies and coordinates external
clinical studies of our products and prepares applications for worldwide
product licensure applications.</font></p>

<p align="left" style="letter-spacing:-.1pt;margin:0in 0in .0001pt;text-align:left;text-indent:0in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>

<p align="left" style="font-style:italic;margin:0in 0in .0001pt;page-break-after:avoid;text-align:left;"><i><font size="2" face="Times New Roman" style="font-size:10.0pt;">Manufacturing</font></i></p>

<p style="margin:0in 0in .0001pt;page-break-after:avoid;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>

<p align="left" style="letter-spacing:-.1pt;margin:0in 0in .0001pt;text-align:left;text-indent:13.5pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">As
of December 31, 2004, we had 390 employees, and approximately 275 temporary
employees, in manufacturing involved in reagent production, device assembly,
engineering, quality assurance/quality control and materials management.</font></p>

<p align="left" style="letter-spacing:-.1pt;margin:0in 0in .0001pt;text-align:left;text-indent:13.5pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>

<p align="left" style="letter-spacing:-.1pt;margin:0in 0in .0001pt;text-align:left;text-indent:13.5pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Except
for the Triage BNP Test for the Beckman Coulter Immunoassay Systems and the
Triage MeterPlus, all of our products are manufactured at our facility in San
Diego, California.&#160; We have contracted
with Beckman Coulter, Inc., which has a manufacturing plant located in Minnesota,
to manufacture the Triage BNP Test for Beckman Coulter Immunoassay
Systems.&#160; The Triage MeterPlus is
manufactured by LRE Technology Partner GmbH, or LRE, which is located in
Germany.&#160; We developed most of the
antibodies used in the manufacture of our products, and we own or license the
relevant cell lines, in most cases.&#160; In
addition, we maintain our own in-house antibody production capability.&#160; All other raw materials required to
manufacture our products are obtained from outside suppliers.</font></p>

<p align="left" style="letter-spacing:-.1pt;margin:0in 0in .0001pt;text-align:left;text-indent:13.5pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>

<p align="left" style="letter-spacing:-.1pt;margin:0in 0in .0001pt;text-align:left;text-indent:13.5pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">We
invest in the design and development of manufacturing systems and technologies
that can produce a high quality product using controlled, cost-effective
manufacturing processes and equipment.&#160;
We have developed and continue to develop and improve novel and sophisticated
processes and equipment for the manufacture of our Triage MeterPlus platform
products.&#160; Significant additional
resources, implementation of additional automated and semi-automated
manufacturing equipment or changes to our manufacturing processes were, and may
continue to be, required for the scaling-up of each new product prior to
commercialization, or in order to adjust to changes in customer demand once
commercialization begins, and this work may not be completed successfully or
efficiently.</font></p>

<p align="left" style="letter-spacing:-.1pt;margin:0in 0in .0001pt;text-align:left;text-indent:13.5pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>

<p align="left" style="letter-spacing:-.1pt;margin:0in 0in .0001pt;text-align:left;text-indent:13.5pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Our
San Diego manufacturing facility is a registered medical device establishment
with the U.S. federal FDA and a licensed medical device manufacturer with the
California State Department of Health &amp; Services.&#160; We have also been licensed and certified to
manufacture products using controlled substances by the U.S. Drug Enforcement
Agency.&#160; We received ISO 9001
re-certification in August 2004.</font></p>

<p align="left" style="letter-spacing:-.1pt;margin:0in 0in .0001pt;text-align:left;text-indent:13.5pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>

<p align="left" style="letter-spacing:-.1pt;margin:0in 0in .0001pt;text-align:left;text-indent:13.5pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">In
2005, we will begin moving our manufacturing activities to our new corporate
complex when the facilities are ready for use and have been tested and
validated.&#160; We expect to move our
manufacturing operation to the new facilities in stages over a three to six
month period as we attempt to reduce disruption to our manufacturing processes.</font></p>

<p align="left" style="letter-spacing:-.1pt;margin:0in 0in .0001pt;text-align:left;text-indent:13.5pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>

<h6 align="left" style="font-weight:bold;margin:0in 0in .0001pt;page-break-after:avoid;text-align:left;"><b><i><font size="2" face="Times New Roman" style="font-size:10.0pt;font-style:italic;font-weight:normal;">Sales and Marketing</font></i></b></h6>

<p style="margin:0in 0in .0001pt;page-break-after:avoid;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>

<p align="left" style="letter-spacing:-.1pt;margin:0in 0in .0001pt;text-align:left;text-indent:13.5pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">As
of December 31, 2004, we had 200 employees, worldwide, in various sales and
marketing functions.&#160; In the United
States, we employ a direct sales force and utilize Fisher, PSS and Henry Schein
to distribute our products to our primary markets, hospitals and physician
offices.&#160; We also employ a field-based
network of clinically experienced individuals that support the sales force by
providing pre- and post- sale education and training.&#160; In international markets, we have established
direct selling efforts in France, Germany, Belgium, Luxembourg, the United
Kingdom and Italy, and we utilize a network of country-specific and regional
distributors in other areas.</font></p>

<p align="left" style="letter-spacing:-.1pt;margin:0in 0in .0001pt;text-align:left;text-indent:0in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>

<p align="left" style="letter-spacing:-.1pt;margin:0in 0in .0001pt;text-align:left;text-indent:13.5pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">We
anticipate that we may, if appropriate, enter into additional distribution
agreements with respect to our current products, products currently under
development and products that we may develop in the future.&#160; We may not be able to enter into these or
other distribution agreements on acceptable terms, if at all.&#160; If we elect to distribute products directly,
our direct sales, marketing and distribution efforts may not be
successful.&#160; A failure to enter into
acceptable distribution agreements or a failure by us to successfully market
our products would have a material and adverse effect on us.</font></p>

<p align="center" style="margin:0in 0in .0001pt;page-break-after:avoid;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>

<p align="center" style="margin:0in 0in .0001pt;page-break-after:avoid;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">15</font></p>

<div style="margin:0in 0in .0001pt;page-break-after:avoid;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">

<hr size="2" width="100%" noshade color="gray" align="left">

</font></div>

</div>
<!-- SEQ.=1,FOLIO='15',FILE='C:\JMS\jboldua\05-1861-2\task332382\1861-2-ba.htm',USER='jboldua',CD='Mar  4 04:20 2005' -->


<br clear="all" style="page-break-before:always;">


<div style="font-family:Times New Roman;">

<p align="center" style="margin:0in 0in .0001pt;page-break-after:avoid;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>

<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Strategic and Distribution Arrangements</font></p>

<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>

<p align="left" style="letter-spacing:-.1pt;margin:0in 0in .0001pt;text-align:left;text-indent:13.5pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Our
strategy for the research, development, commercialization and distribution of
some of our products entails entering into various arrangements with clinical
and commercial collaborators, licensors, licensees, manufacturers and others,
and is dependent upon the success of these parties in performing their
responsibilities.&#160; These parties might
not perform their obligations as expected or we might not derive any revenue
from these arrangements. Under our existing arrangements, we are not obligated
to make any material capital expenditures.&#160;
If we successfully develop products under some of our existing
arrangements, we may be required to pay royalties on sales of products that
incorporate licensed technology.</font></p>

<p align="left" style="letter-spacing:-.1pt;margin:0in 0in .0001pt;text-align:left;text-indent:13.5pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>

<p style="margin:0in 0in .0001pt;"><i><font size="2" face="Times New Roman" style="font-size:10.0pt;font-style:italic;">Fisher HealthCare Division
of Fisher Scientific Company</font></i></p>

<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>

<p align="left" style="letter-spacing:-.1pt;margin:0in 0in .0001pt;text-align:left;text-indent:13.5pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">We
have a distribution agreement under which Fisher distributes our products
primarily to hospitals within the United States.&#160; Our distribution agreement
with Fisher expires on December 31, 2005 and automatically renews for an
additional one year term unless a notice of non-renewal is delivered by either
company.&#160; Fisher purchases our products
on a monthly basis through firm purchase orders.&#160; Sales to Fisher represented 86%, 90% and 87%
of our product sales in 2004, 2003 and 2002, respectively.</font></p>

<p align="left" style="letter-spacing:-.1pt;margin:0in 0in .0001pt;text-align:left;text-indent:13.5pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>

<p style="margin:0in 0in .0001pt;"><i><font size="2" face="Times New Roman" style="font-size:10.0pt;font-style:italic;">LRE Technology Partner
GmbH</font></i></p>

<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>

<p align="left" style="letter-spacing:-.1pt;margin:0in 0in .0001pt;text-align:left;text-indent:13.5pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">We
have an agreement with LRE for the manufacturing and supply of the Triage
MeterPlus, which is used with our rapid Triage BNP Test, as well as with the
Triage Cardiac Panel, Triage Cardio Profiler Panel, </font><font size="2" style="font-size:10.0pt;letter-spacing:0pt;">Triage
D-Dimer test, </font><font size="2" style="font-size:10.0pt;">Triage Profiler SOB Panel and the Triage TOX Drug
Screen.&#160; All of our products in
development are also intended to be used with the Triage MeterPlus.&#160; Under the terms of the LRE agreement, LRE
manufactures the Triage MeterPlus according to specifications provided by us.
LRE is our exclusive supplier of the Triage MeterPlus during the term of the
LRE agreement.&#160; We purchase the Triage
MeterPlus from LRE in Euros through firm purchase orders on a per meter price
basis.</font></p>

<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>

<p style="margin:0in 0in .0001pt;"><i><font size="2" face="Times New Roman" style="font-size:10.0pt;font-style:italic;">Beckman Coulter, Inc.</font></i></p>

<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>

<p align="left" style="letter-spacing:-.1pt;margin:0in 0in .0001pt;text-align:left;text-indent:13.5pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">We
have an agreement with Beckman Coulter under which it manufactures the Triage
BNP Test for Beckman Coulter Immunoassay Systems for us, and we exclusively
sell and market the product.&#160; Designed to
provide results standardized to match our Triage BNP Test for the Triage
MeterPlus, the new BNP test is available for use on Beckman Coulter Immunoassay
Systems.&#160; We began selling the product in
Europe in December 2003 and in the United States in January 2004.</font></p>

<p align="left" style="letter-spacing:-.1pt;margin:0in 0in .0001pt;text-align:left;text-indent:13.5pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>

<p style="margin:0in 0in .0001pt;"><i><font size="2" face="Times New Roman" style="font-size:10.0pt;font-style:italic;">Biosite Discovery</font></i></p>

<p align="left" style="letter-spacing:-.1pt;margin:0in 0in .0001pt;text-align:left;text-indent:0in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>

<p align="left" style="letter-spacing:-.1pt;margin:0in 0in .0001pt;text-align:left;text-indent:.25in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Biosite Discovery is a collaborative research and in-licensing program
dedicated to the identification and evaluation of new protein targets for acute
diseases.&#160; Through Biosite Discovery, we
conduct analyses on both known proteins that may be markers of disease and
proteins accessed from commercial and clinical collaborators in order to
determine diagnostic utility.&#160; Since
1999, we have initiated over 25 license and collaboration agreements relating
to our discovery program including arrangements with Amgen Inc., Amylin
Pharmaceuticals, Inc., CardioPep Pharma GmbH, Cleveland Clinic Foundation and
PrognostiX Inc., DMI Biosciences, Inc., Eli Lilly and Company, Incyte
Corporation, Medarex, Inc., MedImmune, Inc., Molecular Staging, Inc.,
Neurocrine Biosciences and Novartis Pharma AG.&#160;
In parallel, we have initiated over 70 clinical collaboration agreements
with leading universities, hospitals and health systems.&#160; Also under Biosite Discovery, we have
executed several license or cross-license agreements with companies such as
BioInvent International, MorphoSys AG, Dyax Corp. and others.</font></p>

<p align="center" style="letter-spacing:-.1pt;margin:0in 0in .0001pt;text-align:center;text-indent:0in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>

<p align="center" style="letter-spacing:-.1pt;margin:0in 0in .0001pt;text-align:center;text-indent:0in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">16</font></p>

<div align="left" style="letter-spacing:-.1pt;margin:0in 0in .0001pt;text-align:left;text-indent:0in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">

<hr size="2" width="100%" noshade color="gray" align="left">

</font></div>

</div>
<!-- SEQ.=1,FOLIO='16',FILE='C:\JMS\jboldua\05-1861-2\task332382\1861-2-ba.htm',USER='jboldua',CD='Mar  4 04:20 2005' -->


<br clear="all" style="page-break-before:always;">


<div>

<p align="center" style="letter-spacing:-.1pt;margin:0in 0in .0001pt;text-align:center;text-indent:0in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>

<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Proprietary Technology and Patents</font></p>

<p align="left" style="letter-spacing:-.1pt;margin:0in 0in .0001pt;text-align:left;text-indent:13.5pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>

<p align="left" style="letter-spacing:-.1pt;margin:0in 0in .0001pt;text-align:left;text-indent:.25in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Our intellectual property portfolio includes patents, patent applications,
trade secrets, know-how and trademarks. Our success will depend in part on our
ability to obtain additional patents, maintain trade secrets and operate
without infringing the proprietary rights of others, both in the United States
and in other countries.</font></p>

<p align="left" style="letter-spacing:-.1pt;margin:0in 0in .0001pt;text-align:left;text-indent:.25in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>

<p align="left" style="letter-spacing:-.1pt;margin:0in 0in .0001pt;text-align:left;text-indent:.25in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">We periodically file patent applications to protect the technology,
inventions and improvements that may be important to the development of our
business.&#160; We rely on trade secrets,
know-how, continuing technological innovations and licensing opportunities to
develop and maintain our competitive position.&#160;
We file patent applications on our own behalf as assignee and, when
appropriate, have filed and expect to continue to file, applications jointly
with our collaborators.&#160; These patent
applications cover, among other things, devices, compositions of matter,
methods of treatment, methods of discovery, use of novel compounds, and novel
modes of action that are important in our research and development
activities.&#160; We have been issued
approximately 75 U.S. patents, and have been granted approximately 74 patents
in other countries.&#160; These patents have
expiration dates (not including any patent term extensions) ranging from 2009
to 2020.&#160; We have also licensed a
significant number of other patents and patent applications from third
parties.&#160; We continue actively to seek
patent protection in the United States and in foreign countries, and we intend
to file additional patent applications relating to our technology and to
specific products, as we consider appropriate.</font></p>

<p align="left" style="letter-spacing:-.1pt;margin:0in 0in .0001pt;text-align:left;text-indent:.25in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>

<p align="left" style="letter-spacing:-.1pt;margin:0in 0in .0001pt;text-align:left;text-indent:.25in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">To protect our rights to know-how and technology, we also ask our
employees, technical consultants and advisors, and collaborators to enter into
confidentiality agreements that prohibit the unauthorized use of, and restrict
the disclosure of, confidential information and require disclosure and
assignment to us of their ideas, developments, discoveries and inventions.&#160; In connection with our research and
development activities, we also sponsor research at various outside
institutions.&#160; Generally, under these
agreements, we fund the work of investigators in exchange for the results of
the specified work and the right or option to a license to any patentable
inventions that may result in certain designated areas.&#160; If the sponsored work produces patentable
subject matter, we generally either own the rights, or have the first right to
negotiate for license rights, related to that subject matter.&#160; Any resulting license would be expected to
require us to pay royalties on net sales of licensed products.</font></p>

<p align="left" style="letter-spacing:-.1pt;margin:0in 0in .0001pt;text-align:left;text-indent:.25in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>

<p align="left" style="letter-spacing:-.1pt;margin:0in 0in .0001pt;text-align:left;text-indent:.25in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Our ability to obtain and enforce patents is uncertain and involves
complex legal and factual questions, and we cannot guarantee that any patents
will issue from any pending or future patent applications owned by or licensed
to us. In addition, because patent applications in the United States are
maintained in secrecy for eighteen months after the filing of the applications,
and publication of discoveries in the scientific or patent literature often lag
behind actual discoveries, we cannot be sure that the inventors of subject
matter covered by our patents and patent applications were the first to invent
or the first to file patent applications for these inventions. In the event
that a third party has also filed a patent on a similar invention, we may have to
participate in interference proceedings declared by the U.S. Patent and
Trademark Office, and similar proceedings in foreign jurisdictions, to
determine priority of invention, which could result in a loss of our patent
position. Furthermore, we may not have identified all U.S. and foreign patents
that pose a risk of infringement.</font></p>

<p align="left" style="letter-spacing:-.1pt;margin:0in 0in .0001pt;text-align:left;text-indent:.25in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>

<p align="left" style="letter-spacing:-.1pt;margin:0in 0in .0001pt;text-align:left;text-indent:.25in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">In November 2004, we announced that Roche Diagnostics Corporation,
together with certain of its affiliates, filed a complaint in the United States
District Court, Southern District of Indiana, Indianapolis Division alleging
that Biosite is infringing two patents, U.S. Patent 5,366,609 and U.S. Patent
4,816,224, owned by Roche and/or its affiliates.&#160; We believe these allegations of infringement
are without merit and we intend to vigorously contest these claims.</font></p>

<p align="left" style="letter-spacing:-.1pt;margin:0in 0in .0001pt;text-align:left;text-indent:.25in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>

<p align="left" style="letter-spacing:-.1pt;margin:0in 0in .0001pt;text-align:left;text-indent:.25in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Also, in November 2004, we announced that we have filed a complaint in
the United States District Court, Southern District of California alleging that
Roche Diagnostics Corporation and Roche Diagnostics GmbH are infringing two
patents, U.S. Patent 6,174,686 and U.S. Patent 5,795,725, owned by Biosite. The
patents relate to methods for the measurement of cardiac troponin forms.&#160; We believe that our claims have merit and we
intend to vigorously pursue their prosecution.</font></p>

<p align="left" style="letter-spacing:-.1pt;margin:0in 0in .0001pt;text-align:left;text-indent:.25in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>

<p align="left" style="letter-spacing:-.1pt;margin:0in 0in .0001pt;text-align:left;text-indent:.25in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">All parties in both lawsuits have now been served, however, given the
early stage of both actions, we cannot predict the ultimate outcome of either
of these matters at this time.</font></p>

<p align="center" style="letter-spacing:-.1pt;margin:0in 0in .0001pt;text-align:center;text-indent:0in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>

<p align="center" style="letter-spacing:-.1pt;margin:0in 0in .0001pt;text-align:center;text-indent:0in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">17</font></p>

<div align="left" style="letter-spacing:-.1pt;margin:0in 0in .0001pt;text-align:left;text-indent:0in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">

<hr size="2" width="100%" noshade color="gray" align="left">

</font></div>

</div>
<!-- SEQ.=1,FOLIO='17',FILE='C:\JMS\jboldua\05-1861-2\task332382\1861-2-ba.htm',USER='jboldua',CD='Mar  4 04:20 2005' -->


<br clear="all" style="page-break-before:always;">


<div>

<p align="center" style="letter-spacing:-.1pt;margin:0in 0in .0001pt;text-align:center;text-indent:0in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>

<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Government Regulation</font></p>

<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>

<p align="left" style="letter-spacing:-.1pt;margin:0in 0in .0001pt;text-align:left;text-indent:13.5pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">The
testing, manufacture and sale of our products are subject to regulation by
numerous governmental authorities, principally the FDA and corresponding state
and foreign regulatory agencies. Pursuant to the Federal Food, Drug and
Cosmetic Act, the FDA regulates the pre-clinical and clinical testing,
manufacture, labeling, distribution and promotion of medical devices.&#160; In the United States, we are not able to
commence interstate marketing or commercial sales of new products under
development until we receive clearance or approval from the FDA, which can be a
lengthy, expensive and uncertain process.&#160;
Clearance or approval to commercially distribute new medical devices is
generally received from the FDA through clearance of a 510(k) Premarket
Notification or approval of a Premarket Approval Application.</font></p>

<p style="margin:0in 0in .0001pt;text-indent:13.5pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>

<p style="margin:0in 0in .0001pt;text-indent:13.5pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">The
510(k) Premarket Notification process requires us to demonstrate substantial
equivalence to a medical device first marketed in interstate commerce prior to
May 1976, the enactment date of the Medical Device Amendments.&#160; We must submit data that supports our claim
of substantial equivalence.&#160; For any devices that are cleared through the
510(k) process, modifications or enhancements that could significantly affect
safety or effectiveness, or constitute a major change in the intended use of
the device, will require new 510(k) Premarket Notification submissions.&#160; It generally takes from three to nine months
to obtain 510(k) clearance but can take longer or not at all.</font></p>

<p style="margin:0in 0in .0001pt;text-indent:13.5pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>

<p style="margin:0in 0in .0001pt;text-indent:13.5pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">A
PMA must be filed if a new device is not substantially equivalent to a medical
device first marketed in interstate commerce prior to May 1976.&#160; A PMA application must be supported by valid
scientific evidence to demonstrate the safety and effectiveness of the device,
typically including the results of human clinical investigations, bench tests
and laboratory studies.&#160; The PMA approval
process can be expensive, uncertain and lengthy, and many devices for which FDA
approval of a PMA application have been sought by other companies have never
been approved for marketing.</font></p>

<p style="margin:0in 0in .0001pt;text-indent:13.5pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>

<p style="margin:0in 0in .0001pt;text-indent:13.5pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Both
before and after a product is commercialized, we have ongoing responsibilities
under the regulations of the FDA and other agencies.&#160; Noncompliance with applicable laws and the
requirements of the FDA and other agencies can result in, among other things,
fines, injunctions, civil penalties, recall or seizure of products, total or
partial suspension of production, failure of the government to grant pre-market
clearance or pre-market approval for devices, withdrawal of marketing clearances
or approvals, and criminal prosecution.&#160;
The FDA has the authority to request recall, repair, replacement or
refund of the cost of any device manufactured or distributed by us.&#160; The FDA also administers certain controls
over the export of medical devices from the United States.</font></p>

<p style="margin:0in 0in .0001pt;text-indent:13.5pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>

<p style="margin:0in 0in .0001pt;text-indent:13.5pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">The
use of our products is affected by the Clinical Laboratory Improvement
Amendments of 1988, or CLIA, and related federal and state regulations, which
provide for regulation of laboratory testing.&#160;
The scope of these regulations includes quality control, proficiency
testing, personnel standards and federal inspections.&#160; Under CLIA quality control rules in effect
from 1992 through 2002, laboratories using &#147;unitized&#148; test systems were in
compliance with CLIA if they followed the manufacturers&#146; instructions for daily
quality control, or QC, by relying on the internal controls built into unitized
test systems, including our Triage products.</font></p>

<p style="margin:0in 0in .0001pt;text-indent:13.5pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>

<p style="margin:0in 0in .0001pt;text-indent:13.5pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">On
January 24, 2003, the Centers for Medicare and Medicaid Services, or CMS,
publicly issued a final QC rule under CLIA, which went into effect April 24,
2003.&#160; On January 12, 2004, CMS published
updated Interpretive Guidelines for CLIA-regulated laboratories.&#160; We are working with CMS, FDA and our
customers to evaluate the new Interpretive Guidelines and assist our customers
in complying with any provisions, including QC requirements for &#147;unitized&#148; test
systems that may be new.&#160; CMS has stated
that the first two-year survey cycle of clinical laboratories will be an &#147;educational&#148;
one, especially with respect to new requirements of the new Interpretive
Guidelines.</font></p>

<p style="margin:0in 0in .0001pt;text-indent:13.5pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>

<p style="margin:0in 0in .0001pt;text-indent:13.5pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">While
we believe the weight of scientific data and professional acceptance support
the appropriateness of our internal quality controls, there can be no assurance
that the application of these new Interpretive Guidelines will be favorable to
our products.&#160; Moreover, future
amendments of CLIA, the promulgation of additional regulations or guidelines
impacting laboratory testing, and uncertainties relating to the enforcement of
CLIA may have a material adverse effect on our ability to market our products,
our business and financial condition, our results of operations and our
customers&#146; access to our products.</font></p>

<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>

<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">18</font></p>

<div style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">

<hr size="2" width="100%" noshade color="gray" align="left">

</font></div>

</div>
<!-- SEQ.=1,FOLIO='18',FILE='C:\JMS\jboldua\05-1861-2\task332382\1861-2-ba.htm',USER='jboldua',CD='Mar  4 04:20 2005' -->


<br clear="all" style="page-break-before:always;">


<div>

<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>

<p align="left" style="letter-spacing:-.1pt;margin:0in 0in .0001pt;text-align:left;text-indent:13.5pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">We
are also subject to the regulatory approval and compliance requirements for
each foreign country to which we export our products.&#160; In the European Union, a single quality
system and regulatory approval process has been created, and approval is
represented as ISO certification and CE marking, respectively.</font></p>

<p style="margin:0in -13.5pt .0001pt 0in;text-indent:13.5pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>

<p style="margin:0in 0in .0001pt;text-indent:13.5pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">We may not be able to obtain necessary regulatory
approvals or clearances for our products on a timely basis, if at all.&#160; Delays in receipt of or failure to receive
such approvals or clearances, the loss of previously received approvals or
clearances, limitations on intended use imposed as a condition of such
approvals or clearances, or failure to comply with existing or future
regulatory requirements would have a material adverse effect on us.</font></p>

<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>

<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">19</font></p>

<div style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">

<hr size="2" width="100%" noshade color="gray" align="left">

</font></div>

</div>
<!-- SEQ.=1,FOLIO='19',FILE='C:\JMS\jboldua\05-1861-2\task332382\1861-2-ba.htm',USER='jboldua',CD='Mar  4 04:20 2005' -->



<br clear="all" style="page-break-before:always;">

<div>

<h5 style="font-weight:bold;margin:0in 0in .0001pt;page-break-after:avoid;text-align:center;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;">WHERE YOU CAN FIND MORE
INFORMATION</font></b></h5>

<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>

<p style="margin:0in 0in .0001pt;text-indent:13.5pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Our Internet address is www.biosite.com. We make
available, free of charge, on www.biosite.com our Annual Report on Form 10-K,
Quarterly Reports on Form 10-Q, Current Reports on Form 8-K and amendments to
those reports, as soon as reasonably practicable after we electronically file
such material with, or furnish it to, the SEC.&#160;
We also post copies of our current charters for each committee of our
board of directors, as well as our current Code of Business Conduct and Ethics,
Corporate Governance Guidelines and Whistleblower Policy Statement on our
website.&#160; Currently, our board of
directors maintains an Audit Committee, Compensation Committee, Nominating and
Corporate Governance Committee and Stock Option Committee.&#160; The information found on our website shall
not be deemed incorporated by reference by any general statement incorporating
by reference this report into any filing under the Securities Act of 1933 or
under the Securities Exchange Act of 1934, except to the extent we specifically
incorporate the information found on our website by reference, and shall not
otherwise be deemed filed under such Acts.&#160;
All of the referenced documents are also available free of charge to any
stockholder upon request.&#160; Requests
should be submitted to Investor Relations, Biosite Incorporated, 11030 Roselle
Street, San Diego, California 92121.</font></p>

<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>

<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">20</font></p>

<div style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">

<hr size="2" width="100%" noshade color="gray" align="left">

</font></div>

</div>
<!-- SEQ.=1,FOLIO='20',FILE='C:\JMS\jboldua\05-1861-2\task332547\1861-2-be.htm',USER='jboldua',CD='Mar  4 06:47 2005' -->


<br clear="all" style="page-break-before:always;">


<div style="font-family:Times New Roman;">

<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>

<h5 style="font-weight:bold;margin:0in 0in .0001pt;page-break-after:avoid;text-align:center;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;">RISK FACTORS</font></b></h5>

<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>

<p style="margin:0in 0in .0001pt;text-indent:13.5pt;"><b><i><font size="2" face="Times New Roman" style="font-size:10.0pt;font-style:italic;font-weight:bold;">This Annual Report on Form 10-K includes
forward-looking statements about our business and results of operations that
are subject to risks and uncertainties. See &#147;Forward-Looking Statements&#148;
above.&#160; Factors that could cause or
contribute to such differences include those discussed below.&#160; In addition to the risk factors discussed
below, we are also subject to additional risks and uncertainties not presently
known to us or that we currently deem immaterial.&#160; If any of these known or unknown risks or
uncertainties actually occur, our business could be harmed substantially.</font></i></b></p>

<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>

<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>

<p style="margin:0in 0in .0001pt;"><i><font size="2" face="Times New Roman" style="font-size:10.0pt;font-style:italic;">Our quarterly and annual revenues and operating results may
fluctuate.&#160; We may not maintain
profitability.</font></i></p>

<p style="margin:0in 0in .0001pt;text-indent:13.5pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>

<p align="left" style="letter-spacing:-.1pt;margin:0in 0in .0001pt;text-align:left;text-indent:13.5pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;letter-spacing:0pt;">We have reported consecutive quarterly operating profits
since the third quarter of 1999, after incurring quarterly operating losses
during the prior seven quarters.&#160; Our
operating results may fluctuate on a quarterly or annual basis in the
future.&#160; We may not be able to maintain
profitability in the future.&#160; We believe
that our future operating results may be subject to quarterly and annual
fluctuations due to a variety of factors, including:</font></p>

<p style="margin:0in 0in .0001pt;text-indent:13.5pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>

<p style="margin:0in 0in .0001pt .25in;text-indent:-.25in;"><font size="3" face="Times New Roman" style="font-size:12.0pt;">&#149;</font><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font><font size="2" style="font-size:10.0pt;">competition, including from
products competitive with our Triage BNP Tests and from companies with greater
financial capital and resources;</font></p>

<p style="margin:0in 0in .0001pt .25in;text-indent:-.25in;"><font size="3" face="Times New Roman" style="font-size:12.0pt;">&#149;</font><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font><font size="2" style="font-size:10.0pt;">our ability to market and
sell products in the markets in which we compete, including the hospital
market, the physician office market and international markets;</font></p>

<p style="margin:0in 0in .0001pt .25in;text-indent:-.25in;"><font size="3" face="Times New Roman" style="font-size:12.0pt;">&#149;</font><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font><font size="2" style="font-size:10.0pt;">changes in the mix of
products sold;</font></p>

<p style="margin:0in 0in .0001pt .25in;text-indent:-.25in;"><font size="3" face="Times New Roman" style="font-size:12.0pt;">&#149;</font><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font><font size="2" style="font-size:10.0pt;">seasonal or unanticipated
changes in customer demand or the timing of significant orders;</font></p>

<p style="margin:0in 0in .0001pt .25in;text-indent:-.25in;"><font size="3" face="Times New Roman" style="font-size:12.0pt;">&#149;</font><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font><font size="2" style="font-size:10.0pt;">manufacturing problems,
inefficiencies, capacity constraints, backlog or delays;</font></p>

<p style="margin:0in 0in .0001pt .25in;text-indent:-.25in;"><font size="3" face="Times New Roman" style="font-size:12.0pt;">&#149;</font><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font><font size="2" style="font-size:10.0pt;">prosecution, defense and
resolution of license, patent or other contract disputes;</font></p>

<p style="margin:0in 0in .0001pt .25in;text-indent:-.25in;"><font size="3" face="Times New Roman" style="font-size:12.0pt;">&#149;</font><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font><font size="2" style="font-size:10.0pt;">effectiveness in
transitioning and operating a direct sales distribution model in certain
international countries and expenses associated with these transitions;</font></p>

<p style="margin:0in 0in .0001pt .25in;text-indent:-.25in;"><font size="3" face="Times New Roman" style="font-size:12.0pt;">&#149;</font><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font><font size="2" style="font-size:10.0pt;">competitive pressures on
average selling prices of our products;</font></p>

<p style="margin:0in 0in .0001pt .25in;text-indent:-.25in;"><font size="3" face="Times New Roman" style="font-size:12.0pt;">&#149;</font><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font><font size="2" style="font-size:10.0pt;">regulatory approvals, market
acceptance and sales execution of current or new products;</font></p>

<p style="margin:0in 0in .0001pt .25in;text-indent:-.25in;"><font size="3" face="Times New Roman" style="font-size:12.0pt;">&#149;</font><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font><font size="2" style="font-size:10.0pt;">regulatory changes,
uncertainties or delays;</font></p>

<p style="margin:0in 0in .0001pt .25in;text-indent:-.25in;"><font size="3" face="Times New Roman" style="font-size:12.0pt;">&#149;</font><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font><font size="2" style="font-size:10.0pt;">changes in reimbursement
policies;</font></p>

<p style="margin:0in 0in .0001pt .25in;text-indent:-.25in;"><font size="3" face="Times New Roman" style="font-size:12.0pt;">&#149;</font><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font><font size="2" style="font-size:10.0pt;">costs, timing and
effectiveness of further expansion of our sales force and field support
resources;</font></p>

<p style="margin:0in 0in .0001pt .25in;text-indent:-.25in;"><font size="3" face="Times New Roman" style="font-size:12.0pt;">&#149;</font><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font><font size="2" style="font-size:10.0pt;">whether and when we
successfully develop and introduce new products;</font></p>

<p style="margin:0in 0in .0001pt .25in;text-indent:-.25in;"><font size="3" face="Times New Roman" style="font-size:12.0pt;">&#149;</font><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font><font size="2" style="font-size:10.0pt;">research and development
efforts, including clinical studies and new product scale-up activities;</font></p>

<p style="margin:0in 0in .0001pt .25in;text-indent:-.25in;"><font size="3" face="Times New Roman" style="font-size:12.0pt;">&#149;</font><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font><font size="2" style="font-size:10.0pt;">our ability to execute,
maintain and achieve performance milestones under license and collaborative
agreements;</font></p>

<p style="margin:0in 0in .0001pt .25in;text-indent:-.25in;"><font size="3" face="Times New Roman" style="font-size:12.0pt;">&#149;</font><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font><font size="2" style="font-size:10.0pt;">product recalls;</font></p>

<p style="margin:0in 0in .0001pt .25in;text-indent:-.25in;"><font size="3" face="Times New Roman" style="font-size:12.0pt;">&#149;</font><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font><font size="2" style="font-size:10.0pt;">costs and timing associated
with business development activities, including potential licensing of
technologies or intellectual property rights; and</font></p>

<p style="margin:0in 0in .0001pt .25in;text-indent:-.25in;"><font size="3" face="Times New Roman" style="font-size:12.0pt;">&#149;</font><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font><font size="2" style="font-size:10.0pt;">temporary and permanent
costs and timing associated with the relocation of our personnel, assets and
activities to our new corporate facilities.</font></p>

<p style="margin:0in 0in .0001pt .5in;text-indent:-22.5pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>

<p align="left" style="letter-spacing:-.1pt;margin:0in 0in .0001pt;text-align:left;text-indent:13.5pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;letter-spacing:0pt;">Our operating results would also be adversely affected by a
downturn in the market for our products or a slower than anticipated sales
growth trend for our products.&#160; Because
we continue to increase our operating expenses to support our expanded sales and
marketing activities, manufacturing operations and new product development, our
operating results would be adversely affected if our sales and gross profits
did not correspondingly increase at the same or higher rate or if our product
development efforts are unsuccessful or subject to delays. &#160;Our limited operating history makes accurate
prediction of future operating results difficult or impossible. We may not
achieve revenue growth or sustain profitability on a quarterly or annual basis
and our growth or operating results may not be consistent with predictions made
by us or by securities analysts.</font></p>

<p align="center" style="letter-spacing:-.1pt;margin:0in 0in .0001pt;text-align:center;text-indent:0in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>

<p align="center" style="letter-spacing:-.1pt;margin:0in 0in .0001pt;text-align:center;text-indent:0in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">21</font></p>

<div align="left" style="letter-spacing:-.1pt;margin:0in 0in .0001pt;text-align:left;text-indent:0in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">

<hr size="2" width="100%" noshade color="gray" align="left">

</font></div>

</div>
<!-- SEQ.=1,FOLIO='21',FILE='C:\JMS\jboldua\05-1861-2\task332547\1861-2-be.htm',USER='jboldua',CD='Mar  4 06:47 2005' -->


<br clear="all" style="page-break-before:always;">


<div style="font-family:Times New Roman;">

<p align="center" style="letter-spacing:-.1pt;margin:0in 0in .0001pt;text-align:center;text-indent:0in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>

<p style="margin:0in 0in .0001pt;"><i><font size="2" face="Times New Roman" style="font-size:10.0pt;font-style:italic;">We are dependent on the market acceptance of our existing
products and products under development for revenue growth and profitability.</font></i></p>

<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>

<p align="left" style="letter-spacing:-.1pt;margin:0in 0in .0001pt;text-align:left;text-indent:13.5pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;letter-spacing:0pt;">We believe that our revenue growth and profitability will
substantially depend upon our ability to continue to achieve a growing level of
market acceptance and sales of our newer products, such as the Triage BNP
Tests, Triage Cardiac Panel, Triage Cardio Profiler, Triage Profiler Shortness
of Breath Panel, Triage D-Dimer Test and products currently under development,
such as our Triage Stroke Panel.&#160; Our
revenues will also depend on our effectiveness in transitioning and operating a
direct sales and distribution model in certain international countries, as well
as our ability to appropriately manage our operating expenses and our capital
expenditures to optimize our profitability.&#160;
We have made and continue to make significant additions in headcount,
manufacturing equipment, facilities and infrastructure to address our current
and planned future revenue growth.&#160; We
are also making significant investments in developing and penetrating new
markets in the United States such as the physician office segment.&#160; These investments and commitments are
predicated on assumptions of market acceptance of our products and revenue
growth.</font></p>

<p align="left" style="letter-spacing:-.1pt;margin:0in 0in .0001pt;text-align:left;text-indent:13.5pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>

<p style="margin:0in 0in .0001pt;text-indent:13.5pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">If
we fail to plan, establish and maintain:</font></p>

<p style="margin:0in 0in .0001pt;text-indent:13.5pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>

<p style="margin:0in 0in .0001pt .25in;text-indent:-.25in;"><font size="3" face="Times New Roman" style="font-size:12.0pt;">&#149;</font><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font><font size="2" style="font-size:10.0pt;">reliable, cost-efficient,
high-volume manufacturing capacity;</font></p>

<p style="margin:0in 0in .0001pt .25in;text-indent:-.25in;"><font size="3" face="Times New Roman" style="font-size:12.0pt;">&#149;</font><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font><font size="2" style="font-size:10.0pt;">a cost-effective sales
force, customer education and product support resources and administrative
infrastructure;</font></p>

<p style="margin:0in 0in .0001pt .25in;text-indent:-.25in;"><font size="3" face="Times New Roman" style="font-size:12.0pt;">&#149;</font><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font><font size="2" style="font-size:10.0pt;">effective marketing to
users, especially to those in markets where we have limited experience or
significant competition;</font></p>

<p style="margin:0in 0in .0001pt .25in;text-indent:-.25in;"><font size="3" face="Times New Roman" style="font-size:12.0pt;">&#149;</font><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font><font size="2" style="font-size:10.0pt;">an effective distribution
system for our products; or</font></p>

<p style="margin:0in 0in .0001pt .25in;text-indent:-.25in;"><font size="3" face="Times New Roman" style="font-size:12.0pt;">&#149;</font><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font><font size="2" style="font-size:10.0pt;">appropriate strategies or
tactics to address our competitors,</font></p>

<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>

<p align="left" style="letter-spacing:-.1pt;margin:0in 0in .0001pt;text-align:left;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">sales of our products may
not meet expectations and our profitability may suffer.</font></p>

<p align="left" style="letter-spacing:-.1pt;margin:0in 0in .0001pt;text-align:left;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>

<p style="margin:0in 0in .0001pt;"><i><font size="2" face="Times New Roman" style="font-size:10.0pt;font-style:italic;">If we do not successfully develop new products and new
manufacturing processes as currently planned, we may not recover our
significant investments in those projects.</font></i></p>

<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>

<p align="left" style="letter-spacing:-.1pt;margin:0in 0in .0001pt;text-align:left;text-indent:13.5pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;letter-spacing:0pt;">We are making significant investments in research and
development of potential new products, including the development of diagnostic
products for stroke, ACS, sepsis and abdominal pain, and in expanded uses of
our existing products.&#160; The successful
development of some of our new products will depend on the development of new
technologies.&#160; We are also making
significant investments in processes and equipment to improve our manufacturing
efficiency and capacity in anticipation of new products and revenue growth, as
well as constructing our new corporate complex.&#160;
Our revenue growth and profitability are impacted by all of these
investments.&#160; We are required to
undertake time consuming and costly development activities and seek regulatory
approval for potential new products and for the potential new uses of existing
products.&#160; Products that appear promising
during product development and preclinical studies, including our stroke
diagnostic panel, may not demonstrate acceptable clinical study results, or
other parties have or may have patent or other proprietary rights to our
potential new products, and may not allow us to sell them on reasonable terms,
or at all.&#160; We may experience
difficulties that could delay or prevent the successful development,
introduction or market acceptance of any such new products.&#160; We will be harmed if we are unable, for
technological or other reasons, to:</font></p>

<p align="left" style="letter-spacing:-.1pt;margin:0in 0in .0001pt;text-align:left;text-indent:13.5pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>

<p style="margin:0in 0in .0001pt .25in;text-indent:-.25in;"><font size="3" face="Times New Roman" style="font-size:12.0pt;">&#149;</font><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font><font size="2" style="font-size:10.0pt;">complete new product
development, processes, or capital projects in a timely manner or at all;</font></p>

<p style="margin:0in 0in .0001pt .25in;text-indent:-.25in;"><font size="3" face="Times New Roman" style="font-size:12.0pt;">&#149;</font><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font><font size="2" style="font-size:10.0pt;">complete appropriate
clinical studies to validate the use of potential new products or expanded use
of existing products;</font></p>

<p style="margin:0in 0in .0001pt .25in;text-indent:-.25in;"><font size="3" face="Times New Roman" style="font-size:12.0pt;">&#149;</font><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font><font size="2" style="font-size:10.0pt;">implement or effectively or
efficiently scale-up manufacturing for new products; or</font></p>

<p style="margin:0in 0in .0001pt .25in;text-indent:-.25in;"><font size="3" face="Times New Roman" style="font-size:12.0pt;">&#149;</font><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font><font size="2" style="font-size:10.0pt;">obtain regulatory approval
or clearance for marketing a new product for an intended use or an existing
product for an alternative use.</font></p>

<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>

<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">22</font></p>

<div style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">

<hr size="2" width="100%" noshade color="gray" align="left">

</font></div>

</div>
<!-- SEQ.=1,FOLIO='22',FILE='C:\JMS\jboldua\05-1861-2\task332547\1861-2-be.htm',USER='jboldua',CD='Mar  4 06:47 2005' -->


<br clear="all" style="page-break-before:always;">


<div style="font-family:Times New Roman;">

<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>

<p style="margin:0in 0in .0001pt;"><i><font size="2" face="Times New Roman" style="font-size:10.0pt;font-style:italic;">Our Triage BNP Tests have encountered, and may continue to
encounter, significant competition from products developed and commercialized
by companies with greater financial capital and resources.</font></i></p>

<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>

<p align="left" style="letter-spacing:-.1pt;margin:0in 0in .0001pt;text-align:left;text-indent:13.5pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Product
sales of our Triage BNP Tests represented 67% of our product sales in 2004 and
61% in 2003.&#160; Our Triage BNP Tests are
currently two of several FDA-cleared tests used as an aid in the diagnosis of
CHF.&#160; Bayer, Dade Behring, Roche
Diagnostics and Abbott Laboratories have launched competitive tests at various
times since November 2002.&#160; Shionogi
&amp; Co., Ltd. sells a BNP radioimmunoassay product for research purposes only
in the United States.&#160; Scios, Inc., from
which we licensed the technology and patents related to BNP in 1996, was
acquired by Johnson &amp; Johnson in April 2003.</font></p>

<p align="left" style="letter-spacing:-.1pt;margin:0in 0in .0001pt;text-align:left;text-indent:13.5pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>

<p align="left" style="letter-spacing:-.1pt;margin:0in 0in .0001pt;text-align:left;text-indent:13.5pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">We
have, and continue to, experience competition from these companies and
anticipate competition from others in the future.&#160; Beginning in the third quarter of 2003, we
experienced significant competition, primarily from Bayer, resulting in a loss
of customers who wanted to utilize an automated immunoassay system for BNP
testing.&#160; After initiating sales outside
of the United States in November 2003, Abbott Laboratories began selling a test
in the United States during the first quarter of 2004.&#160; Dade Behring began selling a NT-pro BNP
diagnostic product in September 2004. &#160;These and other competitors may succeed in
developing or marketing products that are more effective or commercially
attractive than the Triage BNP Tests.&#160;
This risk of competition may increase as other potential competitors
gain access to competing technologies, such as NT-pro BNP, which Roche
Diagnostics is offering for license.&#160;
Moreover, we may not have the financial resources, technical expertise
or marketing, distribution or support capabilities to compete successfully with
these and other competitors in the future.&#160;
In addition, as the market for BNP testing matures and more competitive
products become available, our average sales price for our Triage BNP Tests may
decline, which may adversely impact our product sales, gross margins and our
overall financial results.</font></p>

<p align="left" style="letter-spacing:-.1pt;margin:0in 0in .0001pt;text-align:left;text-indent:13.5pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>

<p style="margin:0in 0in .0001pt;"><i><font size="2" face="Times New Roman" style="font-size:10.0pt;font-style:italic;">Competition and technological change in the diagnostic
testing market may make our products less attractive or obsolete.</font></i></p>

<p style="margin:0in 0in .0001pt;text-indent:13.5pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>

<p align="left" style="letter-spacing:-.1pt;margin:0in 0in .0001pt;text-align:left;text-indent:13.5pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">In
addition to the specific competitive risks that we face in the market for our
Triage BNP Tests, we face intense competition for our other products and in the
general market for diagnostic testing.&#160;
Our competitors include:</font></p>

<p style="margin:0in -.25in .0001pt 0in;text-indent:13.5pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>

<p style="margin:0in 0in .0001pt .25in;text-indent:-.25in;"><font size="3" face="Times New Roman" style="font-size:12.0pt;">&#149;</font><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font><font size="2" style="font-size:10.0pt;">companies making
laboratory-based tests and analyzers;</font></p>

<p style="margin:0in 0in .0001pt .25in;text-indent:-.25in;"><font size="3" face="Times New Roman" style="font-size:12.0pt;">&#149;</font><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font><font size="2" style="font-size:10.0pt;">clinical reference
laboratories; and</font></p>

<p style="margin:0in 0in .0001pt .25in;text-indent:-.25in;"><font size="3" face="Times New Roman" style="font-size:12.0pt;">&#149;</font><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font><font size="2" style="font-size:10.0pt;">other rapid diagnostic
product manufacturers.</font></p>

<p style="margin:0in -.25in .0001pt 0in;text-indent:13.5pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>

<p align="left" style="letter-spacing:-.1pt;margin:0in 0in .0001pt;text-align:left;text-indent:13.5pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Currently,
the majority of diagnostic products used by physicians and other healthcare
providers are performed by independent clinical reference laboratories and
hospital-based laboratories using automated testing systems.&#160; Therefore, with the exception of our Triage
BNP Test for Beckman Coulter Immunoassay Systems, in order to achieve market
acceptance for our products we will be required to demonstrate that our
products provide clinical, cost-effective and time saving alternatives to
automated tests traditionally performed by clinical reference laboratories or
hospital-based laboratories.&#160; This may
prove to be even more difficult in the future as CHF testing becomes more
widely available on automated testing systems.</font></p>

<p align="left" style="letter-spacing:-.1pt;margin:0in 0in .0001pt;text-align:left;text-indent:13.5pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>

<p align="left" style="letter-spacing:-.1pt;margin:0in 0in .0001pt;text-align:left;text-indent:13.5pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Our
competitors have developed or are developing diagnostic products and/or testing
systems that do or will compete with our products.&#160; Many of our competitors have substantially
greater financial, technical, research and other resources and larger, more
established marketing, sales, distribution and service organizations than
us.&#160; Moreover, these competitors offer
broader product lines and have greater name recognition than us, and offer
discounts as a competitive tactic.&#160; In
addition, several smaller companies are currently making or developing products
that compete with or will compete with our products. We utilize long-term
contracts with some of our customers as a method of defending against
competition.&#160; Such contracts are of
varying terms and expiration dates.&#160;
Expiring contracts may not be renewed and long-term contracts may not be
acceptable to new customers, which could harm our competitive strategy.</font></p>

<p align="left" style="letter-spacing:-.1pt;margin:0in 0in .0001pt;text-align:left;text-indent:13.5pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>

<p align="left" style="letter-spacing:-.1pt;margin:0in 0in .0001pt;text-align:left;text-indent:13.5pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Our
competitors may succeed in developing or marketing technologies or products
that are more effective or commercially attractive than our products, or that
would render our technologies and products obsolete.&#160; The success of our competitors, many of whom
have made substantial investments in competing technologies, or our failure to
compete successfully, may prevent, limit or interfere with our ability to make,
use or sell our products in either the United States or in international
markets.</font></p>

<p align="center" style="letter-spacing:-.1pt;margin:0in 0in .0001pt;text-align:center;text-indent:0in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>

<p align="center" style="letter-spacing:-.1pt;margin:0in 0in .0001pt;text-align:center;text-indent:0in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">23</font></p>

<div align="left" style="letter-spacing:-.1pt;margin:0in 0in .0001pt;text-align:left;text-indent:0in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">

<hr size="2" width="100%" noshade color="gray" align="left">

</font></div>

</div>
<!-- SEQ.=1,FOLIO='23',FILE='C:\JMS\jboldua\05-1861-2\task332547\1861-2-be.htm',USER='jboldua',CD='Mar  4 06:47 2005' -->


<br clear="all" style="page-break-before:always;">


<div style="font-family:Times New Roman;">

<p align="center" style="letter-spacing:-.1pt;margin:0in 0in .0001pt;text-align:center;text-indent:0in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>

<p align="left" style="letter-spacing:-.1pt;margin:0in 0in .0001pt;text-align:left;text-indent:13.5pt;"><i><font size="2" face="Times New Roman" style="font-size:10.0pt;font-style:italic;">We are subject to manufacturing risks, including our limited
manufacturing experience with newer products and processes, which may lead to
our inability to scale-up manufacturing.&#160;
Additionally, unanticipated acceleration or deceleration of customer
demand may lead to manufacturing inefficiencies.&#160; These manufacturing risks and inefficiencies
may adversely affect our ability to produce products and could reduce our gross
margins and increase our research and development expenses</font></i><font size="2" style="font-size:10.0pt;">.</font></p>

<p align="left" style="letter-spacing:-.1pt;margin:0in 0in .0001pt;text-align:left;text-indent:13.5pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>

<p align="left" style="letter-spacing:-.1pt;margin:0in 0in .0001pt;text-align:left;text-indent:13.5pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">We
must manufacture our products in compliance with regulatory requirements, in
sufficient quantities and on a timely basis, while maintaining acceptable
product quality and manufacturing costs.&#160;
Significant additional resources, implementation of additional automated
and semi-automated manufacturing equipment and changes in our manufacturing
processes and organization have been, and may continue to be, required for the
scaling-up of each new product prior to commercialization or in order to meet
increasing customer demand once commercialization begins, and this work may not
be successfully or efficiently completed.</font></p>

<p align="left" style="letter-spacing:-.1pt;margin:0in 0in .0001pt;text-align:left;text-indent:13.5pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>

<p align="left" style="letter-spacing:-.1pt;margin:0in 0in .0001pt;text-align:left;text-indent:13.5pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">In
addition, although we expect some of our newer products and products under
development to share production attributes with our existing products,
production of these products may require the development of new manufacturing
technologies and expertise.&#160; It may not be
possible for us, or any other party, to manufacture these products at a cost or
in quantities to make these products commercially viable.&#160; If we are unable to develop or contract for
manufacturing capabilities on acceptable terms for our products under development,
our ability to conduct pre-clinical and clinical testing will be adversely
affected, resulting in the delay of submission of products for regulatory
clearance or approval and initiation of other development programs, which would
have a material adverse effect on us.</font></p>

<p align="left" style="letter-spacing:-.1pt;margin:0in 0in .0001pt;text-align:left;text-indent:13.5pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>

<p align="left" style="letter-spacing:-.1pt;margin:0in 0in .0001pt;text-align:left;text-indent:13.5pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Manufacturing
and quality problems have arisen and may continue to arise as we attempt to
scale-up our manufacturing capacity and implement automated and semi-automated
manufacturing methods.&#160; For instance, we
have experienced problems with third-party contractors that work with us in
connection with our development of automated and semi-automated manufacturing
equipment and we continue to rely on third parties for the manufacture of much
of our automated and semi-automated manufacturing equipment.&#160; Consequently, scale-up and implementation of
automated and semi-automated manufacturing methods may not be achieved in a
timely manner or at a commercially reasonable cost, or at all.&#160; In addition, we continue to make significant
investments to improve our manufacturing processes and to purchase
manufacturing equipment that may not yield the improvements that we
expect.&#160; Unanticipated acceleration and
deceleration of customer demand for our products has resulted, and may continue
to result, in inefficiencies or constraints related to our manufacturing, which
has harmed and may in the future harm our gross margins and overall financial
results.&#160; Such inefficiencies or
constraints may also result in delays, lost potential product sales or loss of
current or potential customers due to their dissatisfaction.</font></p>

<p align="left" style="letter-spacing:-.1pt;margin:0in 0in .0001pt;text-align:left;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>

<p style="margin:0in 0in .0001pt;"><i><font size="2" face="Times New Roman" style="font-size:10.0pt;font-style:italic;">We are dependent on key distributors and have limited direct
distribution experience.&nbsp; If any of our distribution relationships are
terminated, or our distributors fail to adequately perform, our product sales
will suffer.</font></i></p>

<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>

<p align="left" style="letter-spacing:-.1pt;margin:0in 0in .0001pt;text-align:left;text-indent:13.5pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">We
primarily rely upon Fisher for distribution of our products in the U.S.
hospital market and may rely upon Fisher or other distributors to distribute
new products or our existing products in other markets.&#160; Fisher accounted for 86% of our product sales
in 2004 and 90% in 2003.&#160; We have a
distribution agreement with Fisher that expires on December 31, 2005, and
automatically renews for an additional one year term unless a notice of non-renewal
is delivered by either party.&#160; We
distribute products in the United States physician office market primarily
through PSS&#160; and Henry Schein.&#160; Internationally, we distribute products
through country-specific and regional distributors, as well as through our
direct sales force in selected countries.&#160;
The loss or termination of one or more of our distributors could have a
material adverse effect on our sales in that market.</font></p>

<p align="left" style="letter-spacing:-.1pt;margin:0in 0in .0001pt;text-align:left;text-indent:13.5pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>

<p align="left" style="letter-spacing:-.1pt;margin:0in 0in .0001pt;text-align:left;text-indent:13.5pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">If
any of our distribution or marketing agreements are terminated and we are
unable to enter into alternative agreements
or if we elect to distribute our products directly, we will have to invest in
additional sales and marketing resources, including additional field account
executives and field support resources, which would significantly increase our
future expenses.&#160; Changes in the
distribution of our products may also result in contract termination fees,
transition related expenses, disruption of our business, increased competition
and lower product sales and operating profits.&#160;
We have limited experience in direct sales, marketing and distribution
of our products, both domestically and internationally.&#160; Our direct sales, marketing and distribution
efforts may not be successful.&#160; Further,
we may not be able to enter into new distribution or marketing agreements on satisfactory
terms, or at all.&#160; A failure to enter
into acceptable distribution agreements or our failure to successfully market
our products would have a material adverse effect on us.</font></p>

<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>

<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">24</font></p>

<div style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">

<hr size="2" width="100%" noshade color="gray" align="left">

</font></div>

</div>
<!-- SEQ.=1,FOLIO='24',FILE='C:\JMS\jboldua\05-1861-2\task332547\1861-2-be.htm',USER='jboldua',CD='Mar  4 06:47 2005' -->


<br clear="all" style="page-break-before:always;">


<div style="font-family:Times New Roman;">

<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>

<p style="margin:0in 0in .0001pt;"><i><font size="2" face="Times New Roman" style="font-size:10.0pt;font-style:italic;">We may be unable to accurately predict future sales through
our distributors, which could harm our ability to efficiently manage our
internal resources to match market demand.</font></i></p>

<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>

<p align="left" style="letter-spacing:-.1pt;margin:0in 0in .0001pt;text-align:left;text-indent:13.5pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">A
significant portion of our product sales is made to Fisher domestically and
other distributors internationally.&#160; As a
result, our financial results, quarterly product sales, trends and comparisons
are affected by seasonal aspects and fluctuations in the buying patterns of
end-user customers, Fisher and our other distributors, and by the changes in inventory
levels of our products held by these distributors.&#160; We also believe that our products may be
subject to some seasonality in their use and fluctuations in the buying
patterns of end-user customers.&#160;&#160; Higher
utilization rates of our Triage BNP Tests may be due to a higher number of ED
visits by patients exhibiting shortness of breath, a symptom of congestive
heart failure and the flu.&nbsp; However, higher utilization may also result
from greater awareness, education and acceptance of the uses of our Triage BNP
Tests, as well as additional users within the hospitals.</font></p>

<p align="left" style="letter-spacing:-.1pt;margin:0in 0in .0001pt;text-align:left;text-indent:13.5pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>

<p align="left" style="letter-spacing:-.1pt;margin:0in 0in .0001pt;text-align:left;text-indent:13.5pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">We
are unable to verify the inventory levels of our international distributors and
only have limited visibility over the inventory levels of our products at
Fisher or our other domestic distributors.&#160;
While we attempt to assist Fisher in maintaining targeted stocking level
of our products, we may not consistently be accurate or successful.&#160; Attempting to assist Fisher in maintaining
targeted stocking levels of our products involves the exercise of judgment and
use of assumptions as to future uncertainties including end-user customer
demand and, as a result, actual results could differ from our estimates.&#160; Inventory levels of our products held by
distributors may exceed or fall below the levels we consider desirable on a
going-forward basis, which may harm our future financial results due to
unexpected buying patterns of our distributors or our inability to efficiently
manage or invest in internal resources, such as manufacturing capacity, to meet
the actual demand for our products.</font></p>

<p align="left" style="letter-spacing:-.1pt;margin:0in 0in .0001pt;text-align:left;text-indent:13.5pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>

<p style="margin:0in 0in .0001pt;"><i><font size="2" face="Times New Roman" style="font-size:10.0pt;font-style:italic;">We are dependent on sole-source suppliers for our
products.&#160; A supply interruption would
harm us.</font></i></p>

<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>

<p align="left" style="letter-spacing:-.1pt;margin:0in 0in .0001pt;text-align:left;text-indent:13.5pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Sole-source
vendors provide some key components and raw materials used in the manufacture
of our products.&#160; Any supply interruption
in a sole-sourced component or raw material would have a material adverse
effect on our ability to manufacture these products until a new source of
supply is qualified or alternative manufacturing processes are implemented and,
as a result, would have a material adverse effect on us.&#160; In addition, an uncorrected impurity or
supplier&#146;s variation in a raw material, either unknown to us or incompatible
with our manufacturing processes of our products, could have a material adverse
effect on our ability to manufacture products.&#160;
We have products under development that, if developed, may require us to
enter into additional supplier arrangements or implement alternative
manufacturing processes.&#160; We may not be
able to enter into additional supplier arrangements on commercially reasonable
terms, or at all.&#160; We also may not be
able to implement alternative manufacturing processes that are effective and
cost efficient, or at all.&#160; Failure to
obtain a supplier on acceptable terms, or at all, or the implementation of
alternative processes for the manufacture of our future products, if any, could
increase our manufacturing costs or limit our production capacity for one or
more of our products, which would have a material adverse effect on us.</font></p>

<p align="left" style="letter-spacing:-.1pt;margin:0in 0in .0001pt;text-align:left;text-indent:13.5pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>

<p align="left" style="letter-spacing:-.1pt;margin:0in 0in .0001pt;text-align:left;text-indent:13.5pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">For
example, we rely upon LRE for production of the fluorometer that is used with
our Triage MeterPlus platform products, which include the rapid Triage BNP
Test, Triage Cardiac Panel, Triage Cardio Profiler, Triage Profiler Shortness
of Breath Panel and Triage TOX Drug Screen and other products currently under
development.&#160; In addition, we rely on
Beckman Coulter to manufacture the Triage BNP Test for Beckman Coulter
Immunoassay Systems for us.&#160; If these or
any other single-source suppliers are unable or unwilling to manufacture
sufficient quantities of the relevant items that meet our quality standards, we
would be required to identify and qualify alternative suppliers.&#160; Although we generally maintain safety stock
inventory levels of these items, which would allow us some time to identify and
qualify alternative suppliers, a delay or inability to identify and qualify
alternative suppliers may materially and adversely affect:</font></p>

<p align="left" style="letter-spacing:-.1pt;margin:0in 0in .0001pt;text-align:left;text-indent:13.5pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>

<p align="left" style="letter-spacing:-.1pt;margin:0in 0in .0001pt;text-align:left;text-indent:13.5pt;"><font size="3" face="Times New Roman" style="font-size:12.0pt;">&#149;</font><font size="2" style="font-size:10.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160; our sales and profit margins;</font></p>

<p align="left" style="letter-spacing:-.1pt;margin:0in 0in .0001pt;text-align:left;text-indent:13.5pt;"><font size="3" face="Times New Roman" style="font-size:12.0pt;">&#149;</font><font size="2" style="font-size:10.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160; our ability to adequately service our
existing customers and market our products to potential new customers;</font></p>

<p align="left" style="letter-spacing:-.1pt;margin:0in 0in .0001pt;text-align:left;text-indent:13.5pt;"><font size="3" face="Times New Roman" style="font-size:12.0pt;">&#149;</font><font size="2" style="font-size:10.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160; our ability to develop and manufacture
products on a timely and competitive basis; or</font></p>

<p align="left" style="letter-spacing:-.1pt;margin:0in 0in .0001pt;text-align:left;text-indent:13.5pt;"><font size="3" face="Times New Roman" style="font-size:12.0pt;">&#149;</font><font size="2" style="font-size:10.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160; the timing of market introductions and
subsequent sales of products.</font></p>

<p align="center" style="letter-spacing:-.1pt;margin:0in 0in .0001pt;text-align:center;text-indent:0in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>

<p align="center" style="letter-spacing:-.1pt;margin:0in 0in .0001pt;text-align:center;text-indent:0in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">25</font></p>

<div align="left" style="letter-spacing:-.1pt;margin:0in 0in .0001pt;text-align:left;text-indent:0in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">

<hr size="2" width="100%" noshade color="gray" align="left">

</font></div>

</div>
<!-- SEQ.=1,FOLIO='25',FILE='C:\JMS\jboldua\05-1861-2\task332547\1861-2-be.htm',USER='jboldua',CD='Mar  4 06:47 2005' -->


<br clear="all" style="page-break-before:always;">


<div>

<p align="center" style="letter-spacing:-.1pt;margin:0in 0in .0001pt;text-align:center;text-indent:0in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>

<p style="margin:0in 0in .0001pt;"><i><font size="2" face="Times New Roman" style="font-size:10.0pt;font-style:italic;">Our patents and proprietary technology may not provide us
with any benefit and the patents of others may prevent us from commercializing
our products.</font></i></p>

<p align="left" style="letter-spacing:-.1pt;margin:0in 0in .0001pt;text-align:left;text-indent:13.5pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>

<p align="left" style="margin:0in 0in .0001pt;text-align:left;text-indent:.25in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Our ability to compete effectively will
depend in part on our ability to develop and maintain proprietary aspects of
our technology, and to operate without infringing the proprietary rights of
others or to obtain licenses to such proprietary rights.&#160; Our patent applications may not result in the
issuance of any patents.&#160; Additionally,
our patent applications may not have priority over others&#146; applications, or, if
issued, our patents may not offer protection against competitors with similar
technology.&#160; Any patents issued to us may
be challenged, invalidated or circumvented in the future and the rights created
thereunder may not provide a competitive advantage.&#160; Any of these circumstances could prevent us
from selling any or all of our products.&#160;
Others may have filed and in the future are likely to file patent
applications that are similar or identical to ours. To determine the priority
of inventions, from time to time, we participate in interference proceedings
declared by the United States Patent and Trademark Office, or USPTO, and
similar proceedings in foreign jurisdictions.&#160;
These proceedings could result in a substantial cost to us.</font></p>

<p align="left" style="letter-spacing:-.1pt;margin:0in 0in .0001pt;text-align:left;text-indent:13.5pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>

<p align="left" style="letter-spacing:-.1pt;margin:0in 0in .0001pt;text-align:left;text-indent:13.5pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Our
products and activities may be covered by technologies that are the subject of
patents issued to, and patent applications filed by, others.&#160; We have obtained licenses, and we may
negotiate to obtain other licenses, for technologies patented by others.&#160; Some of our current licenses are subject to
rights of termination and may be terminated.&#160;
Our licensors may not abide by their contractual obligations and, as a
result, may limit the benefits we currently derive from their licenses.&#160; We may not be able to renegotiate or obtain
licenses for technology patented by others on commercially reasonable terms, or
at all.&#160; We may not be able to develop
alternative approaches if we are unable to obtain licenses and our current and
future licenses may not be adequate for the operation of our business.&#160; The failure to obtain, maintain or enforce
necessary licenses or to identify and implement alternative approaches would
prevent us from operating some or all of our business and would have a material
adverse effect on us.</font></p>

<p align="left" style="letter-spacing:-.1pt;margin:0in 0in .0001pt;text-align:left;text-indent:13.5pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>

<p align="left" style="letter-spacing:-.1pt;margin:0in 0in .0001pt;text-align:left;text-indent:13.5pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">We
rely upon trade secrets, technical know-how and continuing invention to develop
and maintain our competitive position.&#160;
Others may independently develop substantially equivalent proprietary
information and techniques or otherwise gain access to our trade secrets or
disclose such technology.&#160; We may not be
able to meaningfully protect our trade secrets, or be capable of protecting our
rights to our trade secrets.</font></p>

<p align="left" style="letter-spacing:-.1pt;margin:0in 0in .0001pt;text-align:left;text-indent:13.5pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>

<p style="margin:0in 0in .0001pt;"><i><font size="2" face="Times New Roman" style="font-size:10.0pt;font-style:italic;">Legal proceedings to obtain patents and litigation of third-party
claims of intellectual property infringement or relating to existing licenses
could require us to spend substantial amounts of money and could impair our
operations.</font></i></p>

<p align="left" style="letter-spacing:-.1pt;margin:0in 0in .0001pt;text-align:left;text-indent:13.5pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>

<p align="left" style="letter-spacing:-.1pt;margin:0in 0in .0001pt;text-align:left;text-indent:13.5pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Litigation
may be necessary to enforce any patents issued to us, to protect trade secrets
or know-how owned by us, to determine the enforceability, scope and validity of
the proprietary rights of others, or to enforce our rights under license and
other intellectual property-related agreements.&#160;
Litigation related to intellectual property matters has in the past, and
may in the future, result in material expenses to us and be a significant
diversion of effort by our technical and management personnel, regardless of
the outcome.&#160; Litigation, if initiated,
could seek to recover damages as a result of any sales of the products subject
to the litigation and to enjoin further sales of such products.&#160; The outcome of litigation, both pending and
potentially in the future, is inherently uncertain.&#160; An adverse outcome in any litigation or the
failure to obtain a necessary license could subject us to significant liability
and could prevent us from selling any or all of our products, which could have
a material adverse effect on our business, financial condition and results of
operations.</font></p>

<p align="left" style="letter-spacing:-.1pt;margin:0in 0in .0001pt;text-align:left;text-indent:13.5pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>

<p align="left" style="letter-spacing:-.1pt;margin:0in 0in .0001pt;text-align:left;text-indent:13.5pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Our
commercial success also depends in part on us neither infringing patents or
proprietary rights of third parties nor breaching any licenses that may relate
to our technologies and products.&#160; We are
aware of several third-party patents that may relate to our technology.&#160; In addition, we have received and may in the
future receive notices claiming infringement from third parties as well as
invitations to take licenses under third-party patents. There can be no
assurance that we do not or will not infringe these patents, or other patents
or proprietary rights of third parties.&#160;
Any legal action against us or our collaborators claiming damages and
seeking to enjoin commercial activities relating to our products and processes
affected by third-party rights, in addition to subjecting us to potential
liability for damages, may require us or our collaborators to obtain a license
in order to continue to manufacture or market the affected products and
processes.&#160; There can be no assurance
that our collaborators or we would prevail in any such action or that any
license (including licenses proposed by third parties) required under any such
patent would be made available on commercially acceptable terms, if at
all.&#160; There are a significant number of
U.S. and foreign patents and patent applications in our areas of interest, and
we believe that there may be significant litigation in the industry regarding </font></p>

<p align="center" style="letter-spacing:-.1pt;margin:0in 0in .0001pt;text-align:center;text-indent:0in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>

<p align="center" style="letter-spacing:-.1pt;margin:0in 0in .0001pt;text-align:center;text-indent:0in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">26</font></p>

<div align="left" style="letter-spacing:-.1pt;margin:0in 0in .0001pt;text-align:left;text-indent:0in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">

<hr size="2" width="100%" noshade color="gray" align="left">

</font></div>

</div>
<!-- SEQ.=1,FOLIO='26',FILE='C:\JMS\jboldua\05-1861-2\task332547\1861-2-be.htm',USER='jboldua',CD='Mar  4 06:47 2005' -->


<br clear="all" style="page-break-before:always;">


<div style="font-family:Times New Roman;">

<p align="center" style="letter-spacing:-.1pt;margin:0in 0in .0001pt;text-align:center;text-indent:0in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>

<p align="left" style="letter-spacing:-.1pt;margin:0in 0in .0001pt;text-align:left;text-indent:0in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">patent and other intellectual property rights.</font></p>

<p align="left" style="letter-spacing:-.1pt;margin:0in 0in .0001pt;text-align:left;text-indent:13.5pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>

<p align="left" style="letter-spacing:-.1pt;margin:0in 0in .0001pt;text-align:left;text-indent:13.5pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">In
November 2004, we announced that Roche Diagnostics Corporation, together with
several of its affiliates, has filed a complaint in the United States District
Court, Southern District of Indiana, Indianapolis Division alleging that
Biosite is infringing two patents, U.S. Patent 5,366,609 and U.S. Patent
4,816,224, owned by Roche and/or its affiliates.&#160; We believe these allegations of infringement
are without merit and we intend to vigorously contest these claims.&#160; Also, in November 2004, we announced that we
filed a complaint in the United States District Court, Southern District of
California alleging that Roche Diagnostics Corporation and Roche Diagnostics
GmbH are infringing two patents, U.S. Patent 6,174,686 and U.S. Patent
5,795,725, owned by Biosite. These patents relate to methods for the
measurement of cardiac troponin forms.&#160;
We believe that our claims have merit and we intend to vigorously pursue
their prosecution.</font></p>

<p align="left" style="letter-spacing:-.1pt;margin:0in 0in .0001pt;text-align:left;text-indent:13.5pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>

<p style="margin:0in 0in .0001pt;"><i><font size="2" face="Times New Roman" style="font-size:10.0pt;font-style:italic;">We may not be successful in transitioning from the use of
distributors in international markets to directly selling our products in those
markets, which may result in lower product sales and higher expenses.</font></i></p>

<p align="left" style="letter-spacing:-.1pt;margin:0in 0in .0001pt;text-align:left;text-indent:13.5pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>

<p align="left" style="letter-spacing:-.1pt;margin:0in 0in .0001pt;text-align:left;text-indent:13.5pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Until
recently, we sold all of our products internationally through independent
distributors.&#160; We transitioned to a
direct sales and distribution model in France and Germany in 2003 and in
Belgium, Luxembourg, the United Kingdom and Italy in 2004.&#160; Over the next few years, we may transition
the distribution of our products in some additional international countries to a
direct sales and distribution model.&#160; In
any country in which we transition to a direct sales and distribution model, we
will need to make investments in facilities, resources and personnel.&#160; In addition, we will be assuming additional
administrative expenses to manage our operations in those countries.&#160; We may also incur expenses associated with
the termination of our existing distribution arrangements in those
countries.&#160; We have limited experience in
managing operations outside of the United States and in direct sales, marketing
and distribution of our products in international markets.&#160; If we are not successful in implementing
direct sales and distribution in countries where we elect to do so, we may not
achieve our projected sales objectives, and we may also incur additional
expenses, or our operating profits may be lower than anticipated.</font></p>

<p align="left" style="letter-spacing:-.1pt;margin:0in 0in .0001pt;text-align:left;text-indent:13.5pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>

<p style="margin:0in 0in .0001pt;"><i><font size="2" face="Times New Roman" style="font-size:10.0pt;font-style:italic;">Our international sales and operations may be harmed by
political, social or economic changes, or other factors.</font></i></p>

<p align="left" style="letter-spacing:-.1pt;margin:0in 0in .0001pt;text-align:left;text-indent:13.5pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>

<p align="left" style="letter-spacing:-.1pt;margin:0in 0in .0001pt;text-align:left;text-indent:13.5pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Export
sales to international customers amounted to $26.0 million for 2004 and $14.5
million for 2003.&#160; During the last half
of 2003 and in 2004, we have significantly expanded our direct sales and
distribution operations outside of the United States in France, Germany,
Belgium, Luxembourg, the United Kingdom and Italy, and we may expand into additional
countries in the future.&#160; Sales and costs
resulting from our direct sales and distribution operations in Europe are
denominated primarily in local currencies, including the Euro, and are subject
to fluctuations in currency exchange rates.&#160;
Further, we purchase our Triage MeterPlus inventory from LRE and incur
other operating expenses, including clinical trials, which are denominated in
Euros and other local currencies.&#160;
Significant fluctuations in the currency exchange rates may negatively
impact our consolidated sales and earnings.</font></p>

<p align="left" style="letter-spacing:-.1pt;margin:0in 0in .0001pt;text-align:left;text-indent:13.5pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>

<p align="left" style="letter-spacing:-.1pt;margin:0in 0in .0001pt;text-align:left;text-indent:13.5pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">International
sales and operations are also subject to a variety of other risks, including:</font></p>

<p style="margin:0in 0in .0001pt;text-indent:13.5pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>

<p style="margin:0in 0in .0001pt .25in;text-indent:-.25in;"><font size="3" face="Times New Roman" style="font-size:12.0pt;">&#149;</font><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font><font size="2" style="font-size:10.0pt;">difficulty in staffing,
monitoring and managing foreign operations;</font></p>

<p style="margin:0in 0in .0001pt .25in;text-indent:-.25in;"><font size="3" face="Times New Roman" style="font-size:12.0pt;">&#149;</font><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font><font size="2" style="font-size:10.0pt;">understanding of, and
compliance with local employment laws, including reduced flexibility and
increased cost of staffing adjustments;</font></p>

<p style="margin:0in 0in .0001pt .25in;text-indent:-.25in;"><font size="3" face="Times New Roman" style="font-size:12.0pt;">&#149;</font><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font><font size="2" style="font-size:10.0pt;">longer collection cycles;</font></p>

<p style="margin:0in 0in .0001pt .25in;text-indent:-.25in;"><font size="3" face="Times New Roman" style="font-size:12.0pt;">&#149;</font><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font><font size="2" style="font-size:10.0pt;">greater risk of
uncollectible accounts;</font></p>

<p style="margin:0in 0in .0001pt .25in;text-indent:-.25in;"><font size="3" face="Times New Roman" style="font-size:12.0pt;">&#149;</font><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font><font size="2" style="font-size:10.0pt;">unknown or changes in
regulatory practices, including import or export license requirements, trade
barriers, tariffs, employment and tax laws;</font></p>

<p style="margin:0in 0in .0001pt .25in;text-indent:-.25in;"><font size="3" face="Times New Roman" style="font-size:12.0pt;">&#149;</font><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font><font size="2" style="font-size:10.0pt;">adverse tax consequences,
including imposition of withholding or other taxes on payments by subsidiaries;</font></p>

<p style="margin:0in 0in .0001pt .25in;text-indent:-.25in;"><font size="3" face="Times New Roman" style="font-size:12.0pt;">&#149;</font><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font><font size="2" style="font-size:10.0pt;">restrictions on repatriation
of locally-derived revenue;</font></p>

<p style="margin:0in 0in .0001pt .25in;text-indent:-.25in;"><font size="3" face="Times New Roman" style="font-size:12.0pt;">&#149;</font><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font><font size="2" style="font-size:10.0pt;">competition from
locally-produced products with cost advantages or national appeal;</font></p>

<p style="margin:0in 0in .0001pt .25in;text-indent:-.25in;"><font size="3" face="Times New Roman" style="font-size:12.0pt;">&#149;</font><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font><font size="2" style="font-size:10.0pt;">local business practices
that could expose our direct sales and marketing organization to Foreign
Corrupt Practices Act risks;</font></p>

<p style="margin:0in 0in .0001pt .25in;text-indent:-.25in;"><font size="3" face="Times New Roman" style="font-size:12.0pt;">&#149;</font><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font><font size="2" style="font-size:10.0pt;">political, social or
economic conditions and changes in these foreign markets; and</font></p>

<p style="margin:0in 0in .0001pt .25in;text-indent:-.25in;"><font size="3" face="Times New Roman" style="font-size:12.0pt;">&#149;</font><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font><font size="2" style="font-size:10.0pt;">government spending
patterns.</font></p>

<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>

<p align="left" style="letter-spacing:-.1pt;margin:0in 0in .0001pt;text-align:left;text-indent:13.5pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">As
a result, our operating results will fluctuate along with the currencies and
general economic conditions in the </font></p>

<p align="center" style="letter-spacing:-.1pt;margin:0in 0in .0001pt;text-align:center;text-indent:0in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>

<p align="center" style="letter-spacing:-.1pt;margin:0in 0in .0001pt;text-align:center;text-indent:0in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">27</font></p>

<div align="left" style="letter-spacing:-.1pt;margin:0in 0in .0001pt;text-align:left;text-indent:0in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">

<hr size="2" width="100%" noshade color="gray" align="left">

</font></div>

</div>
<!-- SEQ.=1,FOLIO='27',FILE='C:\JMS\jboldua\05-1861-2\task332547\1861-2-be.htm',USER='jboldua',CD='Mar  4 06:47 2005' -->


<br clear="all" style="page-break-before:always;">


<div>

<p align="center" style="letter-spacing:-.1pt;margin:0in 0in .0001pt;text-align:center;text-indent:0in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>

<p align="left" style="letter-spacing:-.1pt;margin:0in 0in .0001pt;text-align:left;text-indent:0in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">countries in which we do business, which could harm our operating
results.</font></p>

<p align="left" style="letter-spacing:-.1pt;margin:0in 0in .0001pt;text-align:left;text-indent:13.5pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>

<p style="margin:0in 0in .0001pt;"><i><font size="2" face="Times New Roman" style="font-size:10.0pt;font-style:italic;">Healthcare reform and restrictions on reimbursement may
adversely affect our results.</font></i></p>

<p style="margin:0in -.25in .0001pt 0in;text-indent:13.5pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>

<p align="left" style="letter-spacing:-.1pt;margin:0in 0in .0001pt;text-align:left;text-indent:13.5pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">In
the United States, healthcare providers that purchase our products and other
diagnostic products generally rely on third-party payors to reimburse all or
part of the cost of the procedure.&#160; In
international markets, reimbursement and healthcare payment systems vary
significantly by country, and include both government sponsored healthcare and
private insurance.&#160; Third-party payors
can affect the pricing or the relative attractiveness of our products by
regulating the maximum amount of reimbursement provided by such payors for
testing services.&#160; Third-party payors are
increasingly scrutinizing and challenging the prices charged for both existing
and new medical products and services.&#160;
Lower than expected or decreases in reimbursement amounts for tests
performed using our products may decrease amounts physicians and other
practitioners are able to charge patients, which in turn may adversely affect
our ability to sell our products to the physicians at prices we target.&#160; Third-party reimbursement and coverage may
not be available or adequate in either U.S. or foreign markets, current
reimbursement amounts may be decreased in the future and future legislation,
regulation or reimbursement policies of third-party payors may adversely affect
the demand for our products or our ability to sell our products on a profitable
basis.</font></p>

<p align="left" style="letter-spacing:-.1pt;margin:0in 0in .0001pt;text-align:left;text-indent:13.5pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>

<p style="margin:0in 0in .0001pt;"><i><font size="2" face="Times New Roman" style="font-size:10.0pt;font-style:italic;">Changes in laboratory regulations for our customers may
adversely affect us.</font></i></p>

<p align="left" style="letter-spacing:-.1pt;margin:0in 0in .0001pt;text-align:left;text-indent:13.5pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>

<p align="left" style="letter-spacing:-.1pt;margin:0in 0in .0001pt;text-align:left;text-indent:13.5pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">The
use of our products is affected by the Clinical Laboratory Improvement
Amendments of 1988, or CLIA, and related federal and state regulations, which
provide for regulation of laboratory testing.&#160;
The scope of these regulations includes quality control, proficiency
testing, personnel standards and federal inspections.</font></p>

<p align="left" style="letter-spacing:-.1pt;margin:0in 0in .0001pt;text-align:left;text-indent:13.5pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>

<p align="left" style="letter-spacing:-.1pt;margin:0in 0in .0001pt;text-align:left;text-indent:13.5pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Under
CLIA quality control rules in effect from 1992 through 2002, laboratories using
&#147;unitized&#148; test systems were in compliance with CLIA if they followed the
manufacturers&#146; instructions for daily quality control, or QC, by relying on the
internal controls built into unitized test systems, including our Triage
products.</font></p>

<p align="left" style="letter-spacing:-.1pt;margin:0in 0in .0001pt;text-align:left;text-indent:13.5pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>

<p align="left" style="letter-spacing:-.1pt;margin:0in 0in .0001pt;text-align:left;text-indent:13.5pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">On
January 24, 2003, the Centers for Medicare and Medicaid Services, or CMS,
publicly issued a final QC rule under CLIA, which went into effect April 24,
2003.&#160; On January 12, 2004, CMS published
updated Interpretive Guidelines for CLIA-regulated laboratories.&#160; We are working with CMS, FDA and our customers
to evaluate the new Interpretive Guidelines and assist our customers in complying
with any provisions, including QC requirements that may be new.&#160; CMS has stated that the first two-year survey
cycle of clinical laboratories will be an &#147;educational&#148; one, especially with
respect to new requirements of the new Interpretive Guidelines.</font></p>

<p align="left" style="letter-spacing:-.1pt;margin:0in 0in .0001pt;text-align:left;text-indent:13.5pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>

<p align="left" style="letter-spacing:-.1pt;margin:0in 0in .0001pt;text-align:left;text-indent:13.5pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">While
we believe the weight of scientific data and professional acceptance support
the appropriateness of our internal quality controls, there can be no assurance
that the application of these new Interpretive Guidelines will be favorable to
our products.&#160; Moreover, future
amendments of CLIA, the promulgation of additional regulations or guidelines
impacting laboratory testing, and uncertainties relating to the enforcement of
CLIA may have a material adverse effect on our ability to market our products,
our business and financial condition, our results of operations and our
customers&#146; access to our products.</font></p>

<p align="left" style="letter-spacing:-.1pt;margin:0in 0in .0001pt;text-align:left;text-indent:13.5pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>

<p style="margin:0in 0in .0001pt;"><i><font size="2" face="Times New Roman" style="font-size:10.0pt;font-style:italic;">Changing facilities costs and other risks relating to our
move to our new corporate complex may negatively impact our operating results.</font></i></p>

<p align="left" style="letter-spacing:-.1pt;margin:0in 0in .0001pt;text-align:left;text-indent:13.5pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>

<p align="left" style="letter-spacing:-.1pt;margin:0in 0in .0001pt;text-align:left;text-indent:13.5pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">In
October 2003, we completed a two-part escrow closing to purchase land for the
construction of our new corporate complex.&#160;
We purchased a total of 26.1 usable acres for approximately $28.2
million.&#160; We expect the new complex to
provide us with up to 800,000 square feet of space, to be constructed in phases
as needed.&#160; The first phase will provide
us with approximately 350,000 square feet of space.&#160; The total cost of the land and construction
costs of the first phase is estimated to be approximately $105 million, of
which we have incurred approximately $75 million through December 31,
2004.&#160; We have funded and currently plan
to continue to finance the construction of the complex using a combination of
available cash balances and debt financing, if necessary.&#160; We may not be able to obtain financing on
commercially reasonable terms or at all.&#160;
We expect the buildings in the first phase of construction to be
completed in the second and third quarters of 2005 and do not anticipate
expanding our operations to the new facility prior to that time.&#160; We expect our occupancy costs to increase
primarily due to increased square footage.</font></p>

<p align="left" style="letter-spacing:-.1pt;margin:0in 0in .0001pt;text-align:left;text-indent:13.5pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>

<p align="left" style="letter-spacing:-.1pt;margin:0in 0in .0001pt;text-align:left;text-indent:13.5pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Should
there be a downturn in our business or the markets in which we compete, we may
not have a need to expand </font></p>

<p align="center" style="letter-spacing:-.1pt;margin:0in 0in .0001pt;text-align:center;text-indent:0in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>

<p align="center" style="letter-spacing:-.1pt;margin:0in 0in .0001pt;text-align:center;text-indent:0in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">28</font></p>

<div align="left" style="letter-spacing:-.1pt;margin:0in 0in .0001pt;text-align:left;text-indent:0in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">

<hr size="2" width="100%" noshade color="gray" align="left">

</font></div>

</div>
<!-- SEQ.=1,FOLIO='28',FILE='C:\JMS\jboldua\05-1861-2\task332547\1861-2-be.htm',USER='jboldua',CD='Mar  4 06:47 2005' -->


<br clear="all" style="page-break-before:always;">


<div style="font-family:Times New Roman;">

<p align="center" style="letter-spacing:-.1pt;margin:0in 0in .0001pt;text-align:center;text-indent:0in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>

<p align="left" style="letter-spacing:-.1pt;margin:0in 0in .0001pt;text-align:left;text-indent:0in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">our facilities as we have planned.&#160;
As a result, we may then seek an alternative use for all or a portion of
the property, or seek to sell the property, which may have a negative impact on
our operating results.&#160; We may also incur
unexpected costs and expenses in connection with our move from our existing
facilities to our new corporate complex, or we may experience unanticipated
decreases in productivity and other losses due to inefficiencies relating to
this transition or delays in obtaining any required approvals or clearances
from regulatory agencies related to the validation of the manufacturing
facilities.&#160; For instance, the scale-up
of manufacturing at our new corporate complex could result in lower than
expected manufacturing output and higher than expected product costs.&#160; In addition, we expect to incur some
duplicate facilities expenses, such as rent, during the period in which we
transfer our operations to the new corporate complex as we will transfer our
operations in stages.</font></p>

<p align="left" style="letter-spacing:-.1pt;margin:0in 0in .0001pt;text-align:left;text-indent:13.5pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>

<p align="left" style="letter-spacing:-.1pt;margin:0in 0in .0001pt;text-align:left;text-indent:13.5pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">All
of our existing office and laboratory leases in the United States will expire
during 2005.&#160; In the event of any delays
in the construction or completion of our new corporate complex, we may not be
able to extend our existing property leases on acceptable terms or at all and
we may not be able to find acceptable alternative facilities.&#160; This and other consequences of any delay in
the construction or completion of our new corporate complex may significantly
disrupt our business, increase our operating expenses and reduce our
productivity, which could harm our financial results.</font></p>

<p align="left" style="letter-spacing:-.1pt;margin:0in 0in .0001pt;text-align:left;text-indent:13.5pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>

<p align="left" style="letter-spacing:-.1pt;margin:0in 0in .0001pt;text-align:left;text-indent:13.5pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Additionally,
in order to meet the increase in customer demand for our products, we have
made, and continue to make, short-term investments in additional facility space
and related leasehold improvements have been, and continue to be, made in order
to increase our manufacturing capacity prior to our relocation to the new
corporate complex.&#160; Because of their
short-term nature, these investments in additional facility space and related
leasehold improvements may not be done as efficiently or cost effectively as
longer-term investments or improvements, which may harm our financial results.</font></p>

<p align="left" style="letter-spacing:-.1pt;margin:0in 0in .0001pt;text-align:left;text-indent:13.5pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>

<p style="margin:0in 0in .0001pt;"><i><font size="2" face="Times New Roman" style="font-size:10.0pt;font-style:italic;">Delays in the conduct or completion of our clinical studies
or the analysis of the data from our clinical studies may result in delays in
our planned filings for regulatory approvals, and may adversely affect our
ability to commercialize our products.</font></i></p>

<p align="left" style="letter-spacing:-.1pt;margin:0in 0in .0001pt;text-align:left;text-indent:13.5pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>

<p align="left" style="letter-spacing:-.1pt;margin:0in 0in .0001pt;text-align:left;text-indent:13.5pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">We
cannot predict whether we will encounter problems with any of our completed,
ongoing or planned clinical studies that would cause us or regulatory
authorities to delay or suspend our ongoing or planned clinical studies, or
delay the analysis of data from our completed or ongoing clinical studies.</font></p>

<p align="left" style="letter-spacing:-.1pt;margin:0in 0in .0001pt;text-align:left;text-indent:13.5pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>

<p align="left" style="letter-spacing:-.1pt;margin:0in 0in .0001pt;text-align:left;text-indent:13.5pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Any
of the following could delay the completion of our ongoing and planned clinical
studies:</font></p>

<p align="left" style="letter-spacing:-.1pt;margin:0in 0in .0001pt;text-align:left;text-indent:13.5pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>

<p style="margin:0in 0in .0001pt .25in;text-indent:-.25in;"><font size="3" face="Times New Roman" style="font-size:12.0pt;">&#149;</font><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font><font size="2" style="font-size:10.0pt;">ongoing discussions with the
FDA or comparable foreign authorities regarding the scope or design of our
clinical studies;</font></p>

<p style="margin:0in 0in .0001pt .25in;text-indent:-.25in;"><font size="3" face="Times New Roman" style="font-size:12.0pt;">&#149;</font><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font><font size="2" style="font-size:10.0pt;">delays in enrolling
patients;</font></p>

<p style="margin:0in 0in .0001pt .25in;text-indent:-.25in;"><font size="3" face="Times New Roman" style="font-size:12.0pt;">&#149;</font><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font><font size="2" style="font-size:10.0pt;">lower than anticipated
retention rate of patients in a clinical study;</font></p>

<p style="margin:0in 0in .0001pt .25in;text-indent:-.25in;"><font size="3" face="Times New Roman" style="font-size:12.0pt;">&#149;</font><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font><font size="2" style="font-size:10.0pt;">unexpected results or
adverse events of clinical studies;</font></p>

<p style="margin:0in 0in .0001pt .25in;text-indent:-.25in;"><font size="3" face="Times New Roman" style="font-size:12.0pt;">&#149;</font><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font><font size="2" style="font-size:10.0pt;">insufficient supply or
deficient quality of materials necessary for the performance of clinical
studies; or</font></p>

<p style="margin:0in 0in .0001pt .25in;text-indent:-.25in;"><font size="3" face="Times New Roman" style="font-size:12.0pt;">&#149;</font><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font><font size="2" style="font-size:10.0pt;">difficulties in coordinating
clinical study activities with third party clinical study sites.</font></p>

<p align="left" style="letter-spacing:-.1pt;margin:0in 0in .0001pt;text-align:left;text-indent:13.5pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>

<p align="left" style="letter-spacing:-.1pt;margin:0in 0in .0001pt;text-align:left;text-indent:13.5pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">If
the results of our ongoing or planned clinical studies for our potential
products are not available when we expect or if we encounter any delay in the
analysis of data from our clinical studies, we may not be able to commence marketing
or commercial sales of products when we expect.</font></p>

<p align="left" style="letter-spacing:-.1pt;margin:0in 0in .0001pt;text-align:left;text-indent:13.5pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>

<p style="margin:0in 0in .0001pt;"><i><font size="2" face="Times New Roman" style="font-size:10.0pt;font-style:italic;">The regulatory approval and compliance process is expensive,
time consuming and uncertain.&#160; As a
result, we may not obtain required approvals or previously acquired approvals
for the commercialization of our products may be rescinded.</font></i></p>

<p align="left" style="letter-spacing:-.1pt;margin:0in 0in .0001pt;text-align:left;text-indent:13.5pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>

<p align="left" style="letter-spacing:-.1pt;margin:0in 0in .0001pt;text-align:left;text-indent:13.5pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">The
testing, manufacture and sale of our products are subject to regulation by
numerous governmental authorities worldwide, principally the FDA in the United
States. and corresponding state and foreign regulatory agencies.&#160; Our future performance depends on, among
other matters, our estimates as to when and at what cost we will receive
regulatory approval for new products.&#160;
Regulatory approval can be a lengthy, expensive and uncertain process,
making the timing and cost of obtaining approvals difficult to predict.</font></p>

<p align="center" style="letter-spacing:-.1pt;margin:0in 0in .0001pt;text-align:center;text-indent:0in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>

<p align="center" style="letter-spacing:-.1pt;margin:0in 0in .0001pt;text-align:center;text-indent:0in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">29</font></p>

<div align="left" style="letter-spacing:-.1pt;margin:0in 0in .0001pt;text-align:left;text-indent:0in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">

<hr size="2" width="100%" noshade color="gray" align="left">

</font></div>

</div>
<!-- SEQ.=1,FOLIO='29',FILE='C:\JMS\jboldua\05-1861-2\task332547\1861-2-be.htm',USER='jboldua',CD='Mar  4 06:47 2005' -->


<br clear="all" style="page-break-before:always;">


<div>

<p align="center" style="letter-spacing:-.1pt;margin:0in 0in .0001pt;text-align:center;text-indent:0in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>

<p align="left" style="letter-spacing:-.1pt;margin:0in 0in .0001pt;text-align:left;text-indent:13.5pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">In
the United States, clearance or approval to commercially distribute new medical
devices is received from the FDA through clearance of a 510(k) Premarket Notification
or approval of a PMA.&#160; The 510(k)
clearance process requires us to demonstrate that our new product is
substantially equivalent to a medical device first marketed in interstate
commerce prior to May 1976, the enactment date of the Medical Device
Amendments.&#160; It generally takes from
three to nine months from submission to obtain 510(k) clearance but may take
longer or may not be obtained at all. The FDA may determine that a new proposed
device is not substantially equivalent to a device first marketed in interstate
commerce prior to May 1976 or that additional information is needed before a
substantial equivalence determination can be made.&#160; A &#147;not substantially equivalent&#148;
determination, or a request for additional information, could prevent or delay
the market introduction of new products that fall into this category.</font></p>

<p align="left" style="letter-spacing:-.1pt;margin:0in 0in .0001pt;text-align:left;text-indent:13.5pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>

<p align="left" style="letter-spacing:-.1pt;margin:0in 0in .0001pt;text-align:left;text-indent:13.5pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">In
October 2004, we filed a 510(k) with the FDA seeking clearances for the Triage
Profiler CP Panel.&#160; The Triage Profiler
CP Panel incorporates a proprietary MultiMarker Index<sup>&#153;</sup> algorithm
which analyzes information from all four markers and presents a single
composite index result.&#160; Given the
proprietary MultiMarker Index algorithm used in the calculation of the
composite result, the FDA has determined that the device is not substantially
equivalent to devices marketed in interstate commerce prior to May 28, 1976 and
therefore classified the device by statute into class III (Premarket
Approval).&#160; We believe that the FDA&#146;s
decision to request that we file a PMA in no way reflects on the quality of the
data we previously submitted, or the perceived diagnostic utility of the
MultiMarker Index algorithm.&#160; Rather, we
believe that the FDA&#146;s decision was based on the fact that the Triage Profiler
CP Panel has new technological characteristics that may not be generally used
in medical practice today.&#160; We are
working with the FDA to build on the clinical data we previously submitted and
to determine the appropriate regulatory pathway for this potential product.</font></p>

<p align="left" style="letter-spacing:-.1pt;margin:0in 0in .0001pt;text-align:left;text-indent:13.5pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>

<p align="left" style="letter-spacing:-.1pt;margin:0in 0in .0001pt;text-align:left;text-indent:13.5pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">For
any devices that are cleared through the 510(k) Premarket Notification process,
modifications or enhancements that could significantly affect safety or
effectiveness, or constitute a major change in the intended use of the device,
will require new 510(k) submissions.&#160; We
have made modifications to our products since receipt of initial 510(k)
clearance. With respect to several of these modifications, we filed new
510(k)s&#160; describing the modifications and
have received FDA 510(k) clearance. We made other modifications to some of our
products that we believe do not require the submission of new 510(k)s. There
can be no assurance, however, that the FDA would agree with any of our
determinations not to submit, or would not require us to submit, a new 510(k)
for any of these modifications made to our products.&#160; If the FDA requires us to submit a new 510(k)
for any device modification, we may be prohibited from marketing the modified
products until the 510(k) is cleared by the FDA.</font></p>

<p align="left" style="letter-spacing:-.1pt;margin:0in 0in .0001pt;text-align:left;text-indent:13.5pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>

<p align="left" style="letter-spacing:-.1pt;margin:0in 0in .0001pt;text-align:left;text-indent:13.5pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">We
submitted a PMA application for our Triage Stroke Panel in December 2004.&#160; The PMA approval process can be expensive,
uncertain and lengthy, and a number of devices for which FDA approval of a PMA
application has been sought by other companies have never been approved for
marketing.&#160; It generally takes from six
to eighteen months from submission to obtain PMA approval, but it may take
longer or may not be approved at all.</font></p>

<p align="left" style="letter-spacing:-.1pt;margin:0in 0in .0001pt;text-align:left;text-indent:13.5pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>

<p align="left" style="letter-spacing:-.1pt;margin:0in 0in .0001pt;text-align:left;text-indent:13.5pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">We
are also subject to the regulatory approval and compliance requirements for
each foreign country to which we export our products.&#160; In the European Union, a single quality
system and regulatory approval process has been created, and approval is
represented as ISO certification and CE marking, respectively.</font></p>

<p align="left" style="letter-spacing:-.1pt;margin:0in 0in .0001pt;text-align:left;text-indent:13.5pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>

<p align="left" style="letter-spacing:-.1pt;margin:0in 0in .0001pt;text-align:left;text-indent:13.5pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Both
before and after a product is commercialized, we have ongoing responsibilities under
the regulations of the FDA and other agencies.&#160;
Our manufacturing facilities and those of our contract manufacturers
are, or can be, subject to periodic regulatory inspections by the FDA and other
federal, state and other regulatory agencies.&#160;
Noncompliance with applicable laws and requirements can result in, among
other things, fines, injunctions, civil penalties, recall or seizure of
products, total or partial suspension of production, failure of the government
to grant pre-market clearance or pre-market approval for devices, withdrawal of
marketing clearances or approvals, and criminal prosecution. The FDA has the
authority to request recall, repair, replacement or refund of the cost of any
device manufactured or distributed by us.&#160;
The FDA also administers certain controls over the export of medical
devices from the United States.&#160; We are
also subject to routine inspection by the FDA and certain state agencies for
compliance with Quality System Requirement and Medical Device Reporting
requirements in the United States and other applicable regulations worldwide,
including but not limited to ISO regulations.&#160;
Changes in existing requirements or adoption of new laws or requirements
could have a material adverse effect on our business, financial condition and
results of operation. We may incur significant costs to comply with laws and
regulations.</font></p>

<p align="left" style="letter-spacing:-.1pt;margin:0in 0in .0001pt;text-align:left;text-indent:13.5pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>

<p align="left" style="letter-spacing:-.1pt;margin:0in 0in .0001pt;text-align:left;text-indent:13.5pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">We
are also subject to numerous federal, state and local laws relating to such
matters as safe working conditions, </font></p>

<p align="center" style="letter-spacing:-.1pt;margin:0in 0in .0001pt;text-align:center;text-indent:0in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>

<p align="center" style="letter-spacing:-.1pt;margin:0in 0in .0001pt;text-align:center;text-indent:0in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">30</font></p>

<div align="left" style="letter-spacing:-.1pt;margin:0in 0in .0001pt;text-align:left;text-indent:0in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">

<hr size="2" width="100%" noshade color="gray" align="left">

</font></div>

</div>
<!-- SEQ.=1,FOLIO='30',FILE='C:\JMS\jboldua\05-1861-2\task332547\1861-2-be.htm',USER='jboldua',CD='Mar  4 06:47 2005' -->


<br clear="all" style="page-break-before:always;">


<div style="font-family:Times New Roman;">

<p align="center" style="letter-spacing:-.1pt;margin:0in 0in .0001pt;text-align:center;text-indent:0in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>

<p align="left" style="letter-spacing:-.1pt;margin:0in 0in .0001pt;text-align:left;text-indent:0in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">manufacturing practices, environmental protection, fire hazard control
and disposal of hazardous or potentially hazardous substances. We may incur
significant costs to comply with laws and regulations, or such laws or
regulations in the future may have a material adverse effect upon our business,
financial condition and results of operations.</font></p>

<p align="left" style="letter-spacing:-.1pt;margin:0in 0in .0001pt;text-align:left;text-indent:13.5pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>

<p align="left" style="letter-spacing:-.1pt;margin:0in 0in .0001pt;text-align:left;text-indent:13.5pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Regulatory
agencies have made, and continue to make, changes in their approval and
compliance requirements and processes.&#160;
We cannot predict what, how or when these changes will occur or what
effect the changes will have on the regulation of our products.&#160; Any new legislation may impose additional
costs or lengthen review times of our products.&#160;
We may not be able to obtain necessary worldwide regulatory approvals or
clearances for our products on a timely basis, if at all.&#160; Delays in receipt of or failure to receive
such approvals or clearances, the loss of previously received approvals or
clearances, limitations on intended use imposed as a condition of such
approvals or clearances, or failure to comply with existing or future
regulatory requirements would have a material adverse effect on our business,
financial condition and results of operations.</font></p>

<p align="left" style="letter-spacing:-.1pt;margin:0in 0in .0001pt;text-align:left;text-indent:13.5pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>

<p style="margin:0in 0in .0001pt;"><i><font size="2" face="Times New Roman" style="font-size:10.0pt;font-style:italic;">Long-lived and intangible assets may become impaired and result
in an impairment charge.</font></i></p>

<p align="left" style="letter-spacing:-.1pt;margin:0in 0in .0001pt;text-align:left;text-indent:13.5pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>

<p align="left" style="letter-spacing:-.1pt;margin:0in 0in .0001pt;text-align:left;text-indent:13.5pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">At
December 31, 2004, we had approximately $122.6 million of long-lived assets,
including $30.0 million of land, $45.2 million of building
construction-in-progress, $2.4 million of leasehold improvements, $33.5 million
of equipment, furniture and fixtures, $3.7 million of deferred taxes and $7.8
million of capitalized license rights and other assets.&#160; Leasehold improvements, equipment, intangible
assets and certain other long-lived assets are amortized or depreciated over
the lesser of their useful lives or the remaining lease term.&#160; In San Diego, we lease 10 buildings with
leases that expire between March 2005 and December 2005.&#160; The carrying amounts of long-lived and
intangible assets are affected whenever events or changes in circumstances
indicate that the carrying amount of an asset may not be recoverable. Such
events or changes might include a significant decline in market share, a
significant decline in profits, rapid changes in technology, significant
litigation or other matters. Additionally, we may determine that certain
equipment, furniture and fixtures will not be used at the new corporate
complex.&#160; Adverse events or changes in
circumstances may affect the estimated undiscounted future operating cash flows
expected to be derived from long-lived and intangible assets. In the event
impairment exists, an impairment charge would be determined by comparing the
carrying amount of the asset to the applicable estimated future cash flows,
discounted at a risk-adjusted interest rate. An impairment charge may result in
a material adverse effect on our operating results.&#160; In addition, the remaining amortization
period for the impaired asset would be reassessed and revised if necessary.</font></p>

<p align="left" style="letter-spacing:-.1pt;margin:0in 0in .0001pt;text-align:left;text-indent:13.5pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>

<p align="left" style="letter-spacing:-.1pt;margin:0in 0in .0001pt;text-align:left;text-indent:13.5pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">As
of December 31, 2004, we had approximately $11.1 million of short-term and
long-term deferred tax assets, consisting primarily of temporary differences
between book and tax treatment of certain items such as depreciation.&#160; No valuation allowance has been recorded to
offset the deferred tax assets as we have determined that it is more likely
than not that these assets will be realized.&#160;
We will continue to assess the likelihood of realization of such assets;
however, if future events occur which do not make the realization of such
assets more likely than not, we will record a valuation allowance against all
or a portion of the net deferred tax assets.&#160;
Examples of future events that may occur which would make the
realization of such assets unlikely would be a lack of taxable income resulting
from poor operating results or rising tax deductions generated from
disqualifying dispositions of stock issued under our stock plans.</font></p>

<p align="left" style="letter-spacing:-.1pt;margin:0in 0in .0001pt;text-align:left;text-indent:13.5pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>

<p style="margin:0in 0in .0001pt;"><i><font size="2" face="Times New Roman" style="font-size:10.0pt;font-style:italic;">We may need additional capital.&#160; If additional capital is not available, we
may have to curtail or cease operations.</font></i></p>

<p align="left" style="letter-spacing:-.1pt;margin:0in 0in .0001pt;text-align:left;text-indent:13.5pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>

<p align="left" style="letter-spacing:-.1pt;margin:0in 0in .0001pt;text-align:left;text-indent:13.5pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">If
cash generated from operations is insufficient to satisfy our working capital
and capital expenditure requirements, we may be required to sell additional
equity or debt securities or obtain additional credit facilities.&#160; Additional capital, if needed, may not be available
on satisfactory terms, or at all.&#160;
Furthermore, any additional equity financing may be dilutive to
stockholders, and debt financing, if available, may include restrictive
covenants.&#160; Our future liquidity and
capital funding requirements will depend on numerous factors, including:</font></p>

<p align="left" style="letter-spacing:-.1pt;margin:0in 0in .0001pt;text-align:left;text-indent:13.5pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>

<p style="margin:0in 0in .0001pt .25in;text-indent:-.25in;"><font size="3" face="Times New Roman" style="font-size:12.0pt;">&#149;</font><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font><font size="2" style="font-size:10.0pt;">the costs, timing and
effectiveness of further expansion of sales, marketing and manufacturing
activities and resources;</font></p>

<p style="margin:0in 0in .0001pt .25in;text-indent:-.25in;"><font size="3" face="Times New Roman" style="font-size:12.0pt;">&#149;</font><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font><font size="2" style="font-size:10.0pt;">expansion of our
manufacturing capacity and our facilities expansion needs, including the construction
of our new corporate complex;</font></p>

<p style="margin:0in 0in .0001pt .25in;text-indent:-.25in;"><font size="3" face="Times New Roman" style="font-size:12.0pt;">&#149;</font><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font><font size="2" style="font-size:10.0pt;">the effects of competition,
including products competitive with our Triage BNP Tests, from companies with
greater financial capital and resources;</font></p>

<p style="margin:0in 0in .0001pt .25in;text-indent:-.25in;"><font size="3" face="Times New Roman" style="font-size:12.0pt;">&#149;</font><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font><font size="2" style="font-size:10.0pt;">the impact of the
prosecution, defense and resolution of ongoing and potential future license and
patent disputes;</font></p>

<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>

<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">31</font></p>

<div style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">

<hr size="2" width="100%" noshade color="gray" align="left">

</font></div>

</div>
<!-- SEQ.=1,FOLIO='31',FILE='C:\JMS\jboldua\05-1861-2\task332547\1861-2-be.htm',USER='jboldua',CD='Mar  4 06:47 2005' -->


<br clear="all" style="page-break-before:always;">


<div style="font-family:Times New Roman;">

<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>

<p style="margin:0in 0in .0001pt .25in;text-indent:-.25in;"><font size="3" face="Times New Roman" style="font-size:12.0pt;">&#149;</font><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font><font size="2" style="font-size:10.0pt;">the extent to which our new
products and products under development are successfully developed, gain
regulatory approval and market acceptance and become and remain competitive;</font></p>

<p style="margin:0in 0in .0001pt .25in;text-indent:-.25in;"><font size="3" face="Times New Roman" style="font-size:12.0pt;">&#149;</font><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font><font size="2" style="font-size:10.0pt;">seasonal or unanticipated
changes in customer demand;</font></p>

<p style="margin:0in 0in .0001pt .25in;text-indent:-.25in;"><font size="3" face="Times New Roman" style="font-size:12.0pt;">&#149;</font><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font><font size="2" style="font-size:10.0pt;">regulatory changes,
uncertainties or delays;</font></p>

<p style="margin:0in 0in .0001pt .25in;text-indent:-.25in;"><font size="3" face="Times New Roman" style="font-size:12.0pt;">&#149;</font><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font><font size="2" style="font-size:10.0pt;">the scope, timing and
results of research and development efforts, including clinical studies and
regulatory actions regarding our potential products;</font></p>

<p style="margin:0in 0in .0001pt .25in;text-indent:-.25in;"><font size="3" face="Times New Roman" style="font-size:12.0pt;">&#149;</font><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font><font size="2" style="font-size:10.0pt;">changes in third-party
reimbursement policies;</font></p>

<p style="margin:0in 0in .0001pt .25in;text-indent:-.25in;"><font size="3" face="Times New Roman" style="font-size:12.0pt;">&#149;</font><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font><font size="2" style="font-size:10.0pt;">the ability to execute,
enforce and maintain license and collaborative agreements and attain the
milestones under these agreements necessary to earn contract revenues; and</font></p>

<p style="margin:0in 0in .0001pt .25in;text-indent:-.25in;"><font size="3" face="Times New Roman" style="font-size:12.0pt;">&#149;</font><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font><font size="2" style="font-size:10.0pt;">the costs and timing
associated with business development activities, including potential licensing
of technologies patented by others.</font></p>

<p style="margin:0in 0in .0001pt .25in;text-indent:-.25in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>

<p align="left" style="letter-spacing:-.1pt;margin:0in 0in .0001pt;text-align:left;text-indent:13.5pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">If
we require additional capital, and if we are not able to raise capital on
acceptable terms when needed, we would have to scale back our operations,
reduce our work force and license or sell to others products we would otherwise
seek to develop or commercialize ourselves.</font></p>

<p align="left" style="letter-spacing:-.1pt;margin:0in 0in .0001pt;text-align:left;text-indent:0in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>

<p style="margin:0in 0in .0001pt;"><i><font size="2" face="Times New Roman" style="font-size:10.0pt;font-style:italic;">We are dependent on others for the development of
products.&#160; The failure of our
collaborations to successfully develop products would harm our business.</font></i></p>

<p align="left" style="letter-spacing:-.1pt;margin:0in 0in .0001pt;text-align:left;text-indent:13.5pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>

<p align="left" style="letter-spacing:-.1pt;margin:0in 0in .0001pt;text-align:left;text-indent:13.5pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Our
business strategy includes entering into agreements with clinical and
commercial collaborators and other third parties for the development, clinical
evaluation and marketing of existing products and products under development.
Many of the agreements are subject to rights of termination and may be
terminated without our consent.&#160; These
parties also may not abide by their contractual obligations to us and may
discontinue or sell their current lines of business.&#160; Research performed under a collaboration for
which we receive or provide funding may not lead to the development of products
in the timeframe expected, or at all.&#160; If
these agreements are terminated earlier than expected, or if third parties do
not perform their obligations to us properly and on a timely basis, we may not
be able to successfully develop new products as planned, or at all.</font></p>

<p align="left" style="letter-spacing:-.1pt;margin:0in 0in .0001pt;text-align:left;text-indent:13.5pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>

<p style="margin:0in 0in .0001pt;"><i><font size="2" face="Times New Roman" style="font-size:10.0pt;font-style:italic;">We may not be able to manage our growth.</font></i></p>

<p align="left" style="letter-spacing:-.1pt;margin:0in 0in .0001pt;text-align:left;text-indent:13.5pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>

<p align="left" style="letter-spacing:-.1pt;margin:0in 0in .0001pt;text-align:left;text-indent:13.5pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">We
have experienced growth and anticipate continued growth in the number of our
employees, the scope of our operating and financial systems and the geographic
area of our operations if market acceptance of our products increases and
potential new products are developed and commercialized.&#160; This growth will result in an increase in
responsibilities for both existing and new management personnel. Our ability to
manage growth effectively will require us to continue to implement and improve
our operational, financial and management information systems and internal
control, and to train, motivate and manage our employees.&#160; We may not be able to manage our expansion,
and a failure to do so could have a material adverse effect on us.</font></p>

<p align="left" style="letter-spacing:-.1pt;margin:0in 0in .0001pt;text-align:left;text-indent:13.5pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>

<p align="left" style="letter-spacing:-.1pt;margin:0in 0in .0001pt;text-align:left;text-indent:13.5pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Unanticipated
acceleration and deceleration of customer demand for our products has and may
continue to result in constraints or inefficiencies related to our
manufacturing, sales force, implementation resources and administrative
infrastructure.&#160; Such constraints or
inefficiencies may adversely affect us as a result of delays, lost potential
product sales or loss of current or potential customers due to their
dissatisfaction.&#160; Similarly,
over-expansion or investments in anticipation of growth that does not
materialize could harm our financial results and result in overcapacity.&#160; For instance, we have made non-cancelable
purchase commitments for certain inventory and product components.&#160; Any such inventory or components that are not
used when planned is subject to loss because of spoilage or obsolescence.</font></p>

<p align="center" style="letter-spacing:-.1pt;margin:0in 0in .0001pt;text-align:center;text-indent:0in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>

<p align="center" style="letter-spacing:-.1pt;margin:0in 0in .0001pt;text-align:center;text-indent:0in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">32</font></p>

<div align="left" style="letter-spacing:-.1pt;margin:0in 0in .0001pt;text-align:left;text-indent:0in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">

<hr size="2" width="100%" noshade color="gray" align="left">

</font></div>

</div>
<!-- SEQ.=1,FOLIO='32',FILE='C:\JMS\jboldua\05-1861-2\task332547\1861-2-be.htm',USER='jboldua',CD='Mar  4 06:47 2005' -->


<br clear="all" style="page-break-before:always;">


<div>

<p align="center" style="letter-spacing:-.1pt;margin:0in 0in .0001pt;text-align:center;text-indent:0in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>

<p style="margin:0in 0in .0001pt;"><i><font size="2" face="Times New Roman" style="font-size:10.0pt;font-style:italic;">If we lose our key personnel or are unable to attract and
retain additional personnel, we may not be able to pursue collaborations or
develop our own products.</font></i></p>

<p align="left" style="letter-spacing:-.1pt;margin:0in 0in .0001pt;text-align:left;text-indent:13.5pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>

<p align="left" style="letter-spacing:-.1pt;margin:0in 0in .0001pt;text-align:left;text-indent:13.5pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Our
future success depends in part on the continued service of our key technical,
sales, marketing and executive personnel, and our ability to identify, hire and
retain qualified personnel.&#160; Competition
for such personnel is intense and involves factors such as compensation, equity
incentives, work culture, organization and direction.&#160; We may not be able to retain existing
personnel or identify or hire additional personnel.&#160; If we are unable to retain existing personnel
or identify or hire additional personnel, we may not be able to research,
develop, commercialize or market our products, and as a result, our business
may be harmed.</font></p>

<p align="left" style="letter-spacing:-.1pt;margin:0in 0in .0001pt;text-align:left;text-indent:13.5pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>

<p style="margin:0in 0in .0001pt;"><i><font size="2" face="Times New Roman" style="font-size:10.0pt;font-style:italic;">We may have significant clinical and product liability
exposure.</font></i></p>

<p align="left" style="letter-spacing:-.1pt;margin:0in 0in .0001pt;text-align:left;text-indent:13.5pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>

<p align="left" style="letter-spacing:-.1pt;margin:0in 0in .0001pt;text-align:left;text-indent:13.5pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">The
testing, manufacturing and marketing of medical diagnostic products entails an
inherent risk of clinical and product liability claims.&#160; Our launch of new products to assist in the
diagnosis of other indications, such as stroke, may further increase our risk
of these claims.&#160; Potential clinical and
product liability claims may exceed the amount of our insurance coverage or may
be excluded from coverage under the terms of the policy.&#160; In the future, our existing insurance may not
be renewed at a cost and level of coverage comparable to that presently in
effect, or at all.&#160; In the event that we
are held liable for a claim against which we are not indemnified or for damages
exceeding the limits of our insurance coverage, our liabilities could exceed
our total assets.</font></p>

<p align="left" style="letter-spacing:-.1pt;margin:0in 0in .0001pt;text-align:left;text-indent:13.5pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>

<p style="margin:0in 0in .0001pt;"><i><font size="2" face="Times New Roman" style="font-size:10.0pt;font-style:italic;">Future changes in financial accounting standards or
practices or existing taxation rules or practices may cause adverse unexpected
revenue fluctuations and affect our reported results of operations.</font></i></p>

<p align="left" style="letter-spacing:-.1pt;margin:0in 0in .0001pt;text-align:left;text-indent:13.5pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>

<p align="left" style="letter-spacing:-.1pt;margin:0in 0in .0001pt;text-align:left;text-indent:13.5pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">A
change in accounting standards or practices or a change in existing taxation
rules or practices can have a significant effect on our reported results and
may even affect our reporting of transactions completed before the change is
effective.&#160; New accounting pronouncements
and taxation rules and varying interpretations of accounting pronouncements and
taxation practice have occurred and may occur in the future.&#160; Changes to existing rules or the questioning
of current practices may adversely affect our reported financial results or the
way we conduct our business.&#160; For
example, changes have been approved by the Financial Accounting Standards
Board, or FASB, that require that we record compensation expense in our
statements of income for equity compensation instruments, including employee
stock options, using the fair value method.&#160;
Although there will be no change in our total cash flows, our reported
financial results beginning in the third quarter of 2005 will be negatively and
materially impacted by this accounting change.&#160;
Other potential changes in existing taxation rules related to stock
options and other forms of equity compensation could also have a significant
negative effect on our reported results.</font></p>

<p style="margin:0in 0in .0001pt;text-indent:13.5pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>

<p style="margin:0in 0in .0001pt;"><i><font size="2" face="Times New Roman" style="font-size:10.0pt;font-style:italic;">Evolving regulation of corporate governance and public
disclosure may result in additional expenses and continuing uncertainty.</font></i></p>

<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>

<p align="left" style="letter-spacing:-.1pt;margin:0in 0in .0001pt;text-align:left;text-indent:13.5pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Changing
laws, regulations and standards relating to corporate governance and public
disclosure, including the Sarbanes-Oxley Act of 2002, new Securities and
Exchange Commission, or SEC, regulations and Nasdaq National Market rules are
creating uncertainty for companies such as ours. These new or changed laws,
regulations and standards are subject to varying interpretations, in many cases
due to their lack of specificity, and as a result, their application in
practice may evolve over time as new guidance is provided by regulatory and
governing bodies. This could result in continuing uncertainty regarding
compliance matters and higher costs necessitated by ongoing revisions to
disclosure and governance practices. We are committed to maintaining high
standards of corporate governance and public disclosure. As a result, we intend
to invest resources to comply with evolving laws, regulations and standards,
and this investment may result in increased general and administrative expenses
and a diversion of management time and attention from revenue-generating
activities to compliance activities. If our efforts to comply with new or changed
laws, regulations and standards differ from the activities intended by
regulatory or governing bodies due to ambiguities related to practice,
regulatory authorities may initiate legal proceedings against us and we may be
harmed.</font></p>

<p align="center" style="letter-spacing:-.1pt;margin:0in 0in .0001pt;text-align:center;text-indent:0in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>

<p align="center" style="letter-spacing:-.1pt;margin:0in 0in .0001pt;text-align:center;text-indent:0in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">33</font></p>

<div align="left" style="letter-spacing:-.1pt;margin:0in 0in .0001pt;text-align:left;text-indent:0in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">

<hr size="2" width="100%" noshade color="gray" align="left">

</font></div>

</div>
<!-- SEQ.=1,FOLIO='33',FILE='C:\JMS\jboldua\05-1861-2\task332547\1861-2-be.htm',USER='jboldua',CD='Mar  4 06:47 2005' -->


<br clear="all" style="page-break-before:always;">


<div>

<p align="center" style="letter-spacing:-.1pt;margin:0in 0in .0001pt;text-align:center;text-indent:0in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>

<p style="margin:0in 0in .0001pt;"><i><font size="2" face="Times New Roman" style="font-size:10.0pt;font-style:italic;">Investor confidence and share value may be adversely
impacted if our independent auditors are unable to provide us with the
attestation of the adequacy of our internal controls over financial reporting,
as required by Section 404 of the Sarbanes-Oxley Act of 2002.</font></i></p>

<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>

<p align="left" style="letter-spacing:-.1pt;margin:0in 0in .0001pt;text-align:left;text-indent:13.5pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">As
directed by Section 404 of the Sarbanes-Oxley Act of 2002, the Securities and
Exchange Commission adopted rules requiring public companies to include a
report of management on our internal controls over financial reporting in our
annual reports on Form 10-K that contains an assessment by management of the
effectiveness of our internal controls over financial reporting.&#160; In addition, our independent auditors must
attest to and report on management&#146;s assessment of the effectiveness of our
internal controls over financial reporting.&#160;
This requirement first applies to this Annual Report on Form 10-K.&#160; How companies are implementing these new
requirements including internal control reforms, if any, to comply with Section
404&#146;s requirements, and how independent auditors are applying these new
requirements and testing companies&#146; internal controls, remain subject to
uncertainty.&#160; The requirements of Section
404 of the Sarbanes-Oxley Act of 2002 are ongoing and also apply to future
years.&#160; We expect that our internal
controls will continue to evolve as our business activities change.&#160; Although we will continue to diligently and
vigorously review our internal controls over financial reporting in order to
ensure compliance with the Section 404 requirements, any control system,
regardless of how well designed, operated and evaluated, can provide only
reasonable, not absolute, assurance that its objectives will be met.&#160; If, during any year, our independent auditors
are not satisfied with our internal controls over financial reporting or the
level at which these controls are documented, designed, operated, tested or
assessed, or if the independent auditors interpret the requirements, rules or
regulations differently than we do, then they may decline to attest to
management&#146;s assessment or may issue a report that is qualified.&#160; This could result in an adverse reaction in
the financial marketplace due to a loss of investor confidence in the
reliability of our financial statements, which ultimately could negatively
impact the market price of our shares.</font></p>

<p align="center" style="letter-spacing:-.1pt;margin:0in 0in .0001pt;text-align:center;text-indent:0in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>

<p align="center" style="letter-spacing:-.1pt;margin:0in 0in .0001pt;text-align:center;text-indent:0in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">34</font></p>

<div align="left" style="letter-spacing:-.1pt;margin:0in 0in .0001pt;text-align:left;text-indent:0in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">

<hr size="2" width="100%" noshade color="gray" align="left">

</font></div>

</div>
<!-- SEQ.=1,FOLIO='34',FILE='C:\JMS\jboldua\05-1861-2\task332547\1861-2-be.htm',USER='jboldua',CD='Mar  4 06:47 2005' -->


<br clear="all" style="page-break-before:always;">


<div style="font-family:Times New Roman;">

<p align="center" style="letter-spacing:-.1pt;margin:0in 0in .0001pt;text-align:center;text-indent:0in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>

<h1 style="font-weight:bold;margin:0in 0in .0001pt;text-align:center;text-transform:uppercase;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;text-transform:none;">PART IV</font></b></h1>

<p style="margin:0in 0in .0001pt;page-break-after:avoid;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>

<h2 align="left" style="font-weight:bold;margin:0in 0in .0001pt;text-align:left;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;">Item 15.&#160; &#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; Exhibits,
Financial Statement Schedules</font></b></h2>

<p style="margin:0in 0in .0001pt;page-break-after:avoid;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>

<p style="margin:0in 0in .0001pt;page-break-after:avoid;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;letter-spacing:-.15pt;">(a) &#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; (1)&nbsp;&nbsp;Financial Statements</font></b></p>

<p style="margin:0in 0in .0001pt;page-break-after:avoid;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>

<p style="margin:0in 0in .0001pt;text-indent:13.5pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Refer to the Index on page F-l hereto.</font></p>

<p style="margin:0in 0in .0001pt;text-indent:13.5pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>

<p style="margin:0in 0in .0001pt;page-break-after:avoid;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;letter-spacing:-.15pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; (2)&nbsp;&nbsp;Financial
Statement Schedules</font></b></p>

<p style="margin:0in 0in .0001pt;page-break-after:avoid;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>

<p style="margin:0in 0in .0001pt;text-indent:13.5pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Refer to Schedule II, Valuation and Qualifying Accounts,
hereto.</font></p>

<p style="margin:0in 0in .0001pt;text-indent:13.5pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>

<p style="margin:0in 0in .0001pt;text-indent:13.5pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">The other financial statement schedules required by this
item have been omitted since they are either not required, not applicable or
the information is otherwise included herein.</font></p>

<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>

<p style="margin:0in 0in .0001pt .75in;page-break-after:avoid;text-indent:-.25in;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;letter-spacing:-.15pt;">(3)</font></b><b><font size="1" style="font-size:3.0pt;font-weight:bold;letter-spacing:-.15pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font></b><b><font size="2" style="font-size:10.0pt;font-weight:bold;letter-spacing:-.15pt;">Exhibits</font></b></p>

<p style="margin:0in 0in .0001pt;page-break-after:avoid;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>

<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>

<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>

<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>

<table border="0" cellspacing="0" cellpadding="0" width="100%" style="border-collapse:collapse;width:100.0%;">
 <tr>
  <td width="17%" valign="top" style="padding:0in .7pt 0in .7pt;width:17.66%;">
  <p style="margin:0in 0in .0001pt;"><b><font size="1" face="Times New Roman" style="font-size:8.0pt;font-weight:bold;">EXHIBIT</font></b></p>
  </td>
  <td width="3%" valign="bottom" style="padding:0in .7pt 0in .7pt;width:3.82%;">
  <p style="margin:0in 0in .0001pt;"><b><font size="1" face="Times New Roman" style="font-size:1.0pt;font-weight:bold;">&nbsp;</font></b></p>
  </td>
  <td width="78%" valign="top" style="padding:0in .7pt 0in .7pt;width:78.52%;">
  <p style="margin:0in 0in .0001pt;"><b><font size="1" face="Times New Roman" style="font-size:1.0pt;font-weight:bold;">&nbsp;</font></b></p>
  </td>
 </tr>
 <tr>
  <td width="17%" valign="top" style="border:none;border-bottom:solid windowtext 1.0pt;padding:0in .7pt 0in .7pt;width:17.66%;">
  <p style="margin:0in 0in .0001pt;"><b><font size="1" face="Times New Roman" style="font-size:8.0pt;font-weight:bold;">NUMBER</font></b></p>
  </td>
  <td width="3%" valign="bottom" style="padding:0in .7pt 0in .7pt;width:3.82%;">
  <p style="margin:0in 0in .0001pt;"><b><font size="1" face="Times New Roman" style="font-size:1.0pt;font-weight:bold;">&nbsp;</font></b></p>
  </td>
  <td width="78%" valign="top" style="border:none;border-bottom:solid windowtext 1.0pt;padding:0in .7pt 0in .7pt;width:78.52%;">
  <p align="center" style="margin:0in 0in .0001pt;text-align:center;"><b><font size="1" face="Times New Roman" style="font-size:8.0pt;font-weight:bold;">DESCRIPTION
  OF DOCUMENT</font></b></p>
  </td>
 </tr>
 <tr>
  <td width="17%" valign="top" style="border:none;padding:0in .7pt 0in .7pt;width:17.66%;">
  <p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
  </td>
  <td width="3%" valign="bottom" style="padding:0in .7pt 0in .7pt;width:3.82%;">
  <p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
  </td>
  <td width="78%" valign="top" style="border:none;padding:0in .7pt 0in .7pt;width:78.52%;">
  <p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
  </td>
 </tr>
 <tr>
  <td width="17%" valign="top" style="padding:0in .7pt 0in .7pt;width:17.66%;">
  <p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">3.(i)(9)</font></p>
  </td>
  <td width="3%" valign="bottom" style="padding:0in .7pt 0in .7pt;width:3.82%;">
  <p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>
  </td>
  <td width="78%" valign="top" style="padding:0in .7pt 0in .7pt;width:78.52%;">
  <p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Restated
  Certificate of Incorporation.</font></p>
  </td>
 </tr>
 <tr>
  <td width="17%" valign="top" style="padding:0in .7pt 0in .7pt;width:17.66%;">
  <p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
  </td>
  <td width="3%" valign="bottom" style="padding:0in .7pt 0in .7pt;width:3.82%;">
  <p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
  </td>
  <td width="78%" valign="top" style="padding:0in .7pt 0in .7pt;width:78.52%;">
  <p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
  </td>
 </tr>
 <tr>
  <td width="17%" valign="top" style="padding:0in .7pt 0in .7pt;width:17.66%;">
  <p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">3.(i)(9)</font></p>
  </td>
  <td width="3%" valign="bottom" style="padding:0in .7pt 0in .7pt;width:3.82%;">
  <p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>
  </td>
  <td width="78%" valign="top" style="padding:0in .7pt 0in .7pt;width:78.52%;">
  <p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Certificate
  of Amendment to the Restated Certificate of Incorporation.</font></p>
  </td>
 </tr>
 <tr>
  <td width="17%" valign="top" style="padding:0in .7pt 0in .7pt;width:17.66%;">
  <p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
  </td>
  <td width="3%" valign="bottom" style="padding:0in .7pt 0in .7pt;width:3.82%;">
  <p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
  </td>
  <td width="78%" valign="top" style="padding:0in .7pt 0in .7pt;width:78.52%;">
  <p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
  </td>
 </tr>
 <tr>
  <td width="17%" valign="top" style="padding:0in .7pt 0in .7pt;width:17.66%;">
  <p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">3.(i)(9)</font></p>
  </td>
  <td width="3%" valign="bottom" style="padding:0in .7pt 0in .7pt;width:3.82%;">
  <p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>
  </td>
  <td width="78%" valign="top" style="padding:0in .7pt 0in .7pt;width:78.52%;">
  <p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Certificate
  of Designation, Rights and Preferences of Series A Participating Preferred
  Stock.</font></p>
  </td>
 </tr>
 <tr>
  <td width="17%" valign="top" style="padding:0in .7pt 0in .7pt;width:17.66%;">
  <p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
  </td>
  <td width="3%" valign="bottom" style="padding:0in .7pt 0in .7pt;width:3.82%;">
  <p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
  </td>
  <td width="78%" valign="top" style="padding:0in .7pt 0in .7pt;width:78.52%;">
  <p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
  </td>
 </tr>
 <tr>
  <td width="17%" valign="top" style="padding:0in .7pt 0in .7pt;width:17.66%;">
  <p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">3.(ii)(14)</font></p>
  </td>
  <td width="3%" valign="bottom" style="padding:0in .7pt 0in .7pt;width:3.82%;">
  <p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>
  </td>
  <td width="78%" valign="top" style="padding:0in .7pt 0in .7pt;width:78.52%;">
  <p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Certificate
  of Amendment to the Restated Certificate of Incorporation</font><font size="2" style="font-size:10.0pt;">.</font></p>
  </td>
 </tr>
 <tr>
  <td width="17%" valign="top" style="padding:0in .7pt 0in .7pt;width:17.66%;">
  <p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
  </td>
  <td width="3%" valign="bottom" style="padding:0in .7pt 0in .7pt;width:3.82%;">
  <p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
  </td>
  <td width="78%" valign="top" style="padding:0in .7pt 0in .7pt;width:78.52%;">
  <p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
  </td>
 </tr>
 <tr>
  <td width="17%" valign="top" style="padding:0in .7pt 0in .7pt;width:17.66%;">
  <p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">3.(iii)(2)</font></p>
  </td>
  <td width="3%" valign="bottom" style="padding:0in .7pt 0in .7pt;width:3.82%;">
  <p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>
  </td>
  <td width="78%" valign="top" style="padding:0in .7pt 0in .7pt;width:78.52%;">
  <p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Amended
  and Restated Bylaws</font><font size="2" style="font-size:10.0pt;">.</font></p>
  </td>
 </tr>
 <tr>
  <td width="17%" valign="top" style="padding:0in .7pt 0in .7pt;width:17.66%;">
  <p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
  </td>
  <td width="3%" valign="bottom" style="padding:0in .7pt 0in .7pt;width:3.82%;">
  <p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
  </td>
  <td width="78%" valign="top" style="padding:0in .7pt 0in .7pt;width:78.52%;">
  <p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
  </td>
 </tr>
 <tr>
  <td width="17%" valign="top" style="padding:0in .7pt 0in .7pt;width:17.66%;">
  <p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">4.1(13)</font></p>
  </td>
  <td width="3%" valign="bottom" style="padding:0in .7pt 0in .7pt;width:3.82%;">
  <p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>
  </td>
  <td width="78%" valign="top" style="padding:0in .7pt 0in .7pt;width:78.52%;">
  <p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Form of Common Stock
  Certificate with rights legend.</font></p>
  </td>
 </tr>
 <tr>
  <td width="17%" valign="top" style="padding:0in .7pt 0in .7pt;width:17.66%;">
  <p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
  </td>
  <td width="3%" valign="bottom" style="padding:0in .7pt 0in .7pt;width:3.82%;">
  <p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
  </td>
  <td width="78%" valign="top" style="padding:0in .7pt 0in .7pt;width:78.52%;">
  <p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
  </td>
 </tr>
 <tr>
  <td width="17%" valign="top" style="padding:0in .7pt 0in .7pt;width:17.66%;">
  <p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">10.1(1)(A)</font></p>
  </td>
  <td width="3%" valign="bottom" style="padding:0in .7pt 0in .7pt;width:3.82%;">
  <p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>
  </td>
  <td width="78%" valign="top" style="padding:0in .7pt 0in .7pt;width:78.52%;">
  <p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Amended and Restated 1989
  Stock Plan of Biosite Incorporated.</font></p>
  </td>
 </tr>
 <tr>
  <td width="17%" valign="top" style="padding:0in .7pt 0in .7pt;width:17.66%;">
  <p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
  </td>
  <td width="3%" valign="bottom" style="padding:0in .7pt 0in .7pt;width:3.82%;">
  <p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
  </td>
  <td width="78%" valign="top" style="padding:0in .7pt 0in .7pt;width:78.52%;">
  <p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
  </td>
 </tr>
 <tr>
  <td width="17%" valign="top" style="padding:0in .7pt 0in .7pt;width:17.66%;">
  <p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">10.2(4)(A)</font></p>
  </td>
  <td width="3%" valign="bottom" style="padding:0in .7pt 0in .7pt;width:3.82%;">
  <p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>
  </td>
  <td width="78%" valign="top" style="padding:0in .7pt 0in .7pt;width:78.52%;">
  <p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Amended and Restated 1996
  Stock Incentive Plan of Biosite Incorporated (&#147;1996 Stock Plan&#148;).</font></p>
  </td>
 </tr>
 <tr>
  <td width="17%" valign="top" style="padding:0in .7pt 0in .7pt;width:17.66%;">
  <p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
  </td>
  <td width="3%" valign="bottom" style="padding:0in .7pt 0in .7pt;width:3.82%;">
  <p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
  </td>
  <td width="78%" valign="top" style="padding:0in .7pt 0in .7pt;width:78.52%;">
  <p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
  </td>
 </tr>
 <tr>
  <td width="17%" valign="top" style="padding:0in .7pt 0in .7pt;width:17.66%;">
  <p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">10.3(1)(A)</font></p>
  </td>
  <td width="3%" valign="bottom" style="padding:0in .7pt 0in .7pt;width:3.82%;">
  <p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>
  </td>
  <td width="78%" valign="top" style="padding:0in .7pt 0in .7pt;width:78.52%;">
  <p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Form of Incentive Stock Option
  Agreement under the 1996 Stock Plan.</font></p>
  </td>
 </tr>
 <tr>
  <td width="17%" valign="top" style="padding:0in .7pt 0in .7pt;width:17.66%;">
  <p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
  </td>
  <td width="3%" valign="bottom" style="padding:0in .7pt 0in .7pt;width:3.82%;">
  <p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
  </td>
  <td width="78%" valign="top" style="padding:0in .7pt 0in .7pt;width:78.52%;">
  <p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
  </td>
 </tr>
 <tr>
  <td width="17%" valign="top" style="padding:0in .7pt 0in .7pt;width:17.66%;">
  <p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">10.4(1)(A)</font></p>
  </td>
  <td width="3%" valign="bottom" style="padding:0in .7pt 0in .7pt;width:3.82%;">
  <p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>
  </td>
  <td width="78%" valign="top" style="padding:0in .7pt 0in .7pt;width:78.52%;">
  <p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Form of Nonstatutory Stock
  Option Agreement under the 1996 Stock Plan.</font></p>
  </td>
 </tr>
 <tr>
  <td width="17%" valign="top" style="padding:0in .7pt 0in .7pt;width:17.66%;">
  <p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
  </td>
  <td width="3%" valign="bottom" style="padding:0in .7pt 0in .7pt;width:3.82%;">
  <p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
  </td>
  <td width="78%" valign="top" style="padding:0in .7pt 0in .7pt;width:78.52%;">
  <p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
  </td>
 </tr>
 <tr>
  <td width="17%" valign="top" style="padding:0in .7pt 0in .7pt;width:17.66%;">
  <p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">10.5(5)(A)</font></p>
  </td>
  <td width="3%" valign="bottom" style="padding:0in .7pt 0in .7pt;width:3.82%;">
  <p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>
  </td>
  <td width="78%" valign="top" style="padding:0in .7pt 0in .7pt;width:78.52%;">
  <p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Biosite Incorporated
  Amended and Restated Employee Stock Purchase Plan.</font></p>
  </td>
 </tr>
 <tr>
  <td width="17%" valign="top" style="padding:0in .7pt 0in .7pt;width:17.66%;">
  <p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
  </td>
  <td width="3%" valign="bottom" style="padding:0in .7pt 0in .7pt;width:3.82%;">
  <p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
  </td>
  <td width="78%" valign="top" style="padding:0in .7pt 0in .7pt;width:78.52%;">
  <p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
  </td>
 </tr>
 <tr>
  <td width="17%" valign="top" style="padding:0in .7pt 0in .7pt;width:17.66%;">
  <p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">10.6(20)(A)</font></p>
  </td>
  <td width="3%" valign="bottom" style="padding:0in .7pt 0in .7pt;width:3.82%;">
  <p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>
  </td>
  <td width="78%" valign="top" style="padding:0in .7pt 0in .7pt;width:78.52%;">
  <p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Form of Indemnity Agreement
  between the Company and its officers and directors.</font></p>
  </td>
 </tr>
 <tr>
  <td width="17%" valign="top" style="padding:0in .7pt 0in .7pt;width:17.66%;">
  <p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
  </td>
  <td width="3%" valign="bottom" style="padding:0in .7pt 0in .7pt;width:3.82%;">
  <p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
  </td>
  <td width="78%" valign="top" style="padding:0in .7pt 0in .7pt;width:78.52%;">
  <p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
  </td>
 </tr>
 <tr>
  <td width="17%" valign="top" style="padding:0in .7pt 0in .7pt;width:17.66%;">
  <p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">10.7(1)</font></p>
  </td>
  <td width="3%" valign="bottom" style="padding:0in .7pt 0in .7pt;width:3.82%;">
  <p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>
  </td>
  <td width="78%" valign="top" style="padding:0in .7pt 0in .7pt;width:78.52%;">
  <p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Sublease Agreement between
  Biosite and General Atomics, dated February 17, 1992, as amended on August
  10, 1992, January 21, 1993, October&nbsp;29, 1993, March 1, 1995 and October
  1, 1996.</font></p>
  </td>
 </tr>
 <tr>
  <td width="17%" valign="top" style="padding:0in .7pt 0in .7pt;width:17.66%;">
  <p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
  </td>
  <td width="3%" valign="bottom" style="padding:0in .7pt 0in .7pt;width:3.82%;">
  <p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
  </td>
  <td width="78%" valign="top" style="padding:0in .7pt 0in .7pt;width:78.52%;">
  <p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
  </td>
 </tr>
 <tr>
  <td width="17%" valign="top" style="padding:0in .7pt 0in .7pt;width:17.66%;">
  <p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">10.8(1)(+)</font></p>
  </td>
  <td width="3%" valign="bottom" style="padding:0in .7pt 0in .7pt;width:3.82%;">
  <p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>
  </td>
  <td width="78%" valign="top" style="padding:0in .7pt 0in .7pt;width:78.52%;">
  <p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Antibody License Agreement
  between Biosite and Sandoz Pharma Ltd. (currently known as Novartis Pharma
  AG), dated September 22, 1995, as amended on July&nbsp;26, 1996.</font></p>
  </td>
 </tr>
</table>

<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>

<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">35</font></p>

<div style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">

<hr size="2" width="100%" noshade color="gray" align="left">

</font></div>

</div>
<!-- SEQ.=1,FOLIO='35',FILE='C:\JMS\jboldua\05-1861-2\task332547\1861-2-be.htm',USER='jboldua',CD='Mar  4 06:47 2005' -->


<br clear="all" style="page-break-before:always;">


<div>

<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>

<table border="0" cellspacing="0" cellpadding="0" width="100%" style="border-collapse:collapse;width:100.0%;">
 <tr>
  <td width="17%" valign="top" style="padding:0in .7pt 0in .7pt;width:17.66%;">
  <p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">10.9(1)(+)</font></p>
  </td>
  <td width="3%" valign="bottom" style="padding:0in .7pt 0in .7pt;width:3.82%;">
  <p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>
  </td>
  <td width="78%" valign="top" style="padding:0in .7pt 0in .7pt;width:78.52%;">
  <p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Easy Assay License
  Agreement between Biosite and Sandoz Pharma Ltd. (currently known as Novartis
  Pharma AG), dated September 22, 1995.</font></p>
  </td>
 </tr>
 <tr>
  <td width="17%" valign="top" style="padding:0in .7pt 0in .7pt;width:17.66%;">
  <p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
  </td>
  <td width="3%" valign="bottom" style="padding:0in .7pt 0in .7pt;width:3.82%;">
  <p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
  </td>
  <td width="78%" valign="top" style="padding:0in .7pt 0in .7pt;width:78.52%;">
  <p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
  </td>
 </tr>
 <tr>
  <td width="17%" valign="top" style="padding:0in .7pt 0in .7pt;width:17.66%;">
  <p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">10.11(1)(+)</font></p>
  </td>
  <td width="3%" valign="bottom" style="padding:0in .7pt 0in .7pt;width:3.82%;">
  <p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>
  </td>
  <td width="78%" valign="top" style="padding:0in .7pt 0in .7pt;width:78.52%;">
  <p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Development, Supply and
  Distribution Agreement between Biosite and Kyoto Dai-Ichi Kagaku Co.,
  Ltd., dated as of February 14, 1995.</font></p>
  </td>
 </tr>
 <tr>
  <td width="17%" valign="top" style="padding:0in .7pt 0in .7pt;width:17.66%;">
  <p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
  </td>
  <td width="3%" valign="bottom" style="padding:0in .7pt 0in .7pt;width:3.82%;">
  <p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
  </td>
  <td width="78%" valign="top" style="padding:0in .7pt 0in .7pt;width:78.52%;">
  <p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
  </td>
 </tr>
 <tr>
  <td width="17%" valign="top" style="padding:0in .7pt 0in .7pt;width:17.66%;">
  <p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">10.19(1)</font></p>
  </td>
  <td width="3%" valign="bottom" style="padding:0in .7pt 0in .7pt;width:3.82%;">
  <p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>
  </td>
  <td width="78%" valign="top" style="padding:0in .7pt 0in .7pt;width:78.52%;">
  <p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Debenture Purchase
  Agreement between Biosite and Sandoz Pharma Ltd. (currently known as Novartis
  Pharma AG), dated as of September 22, 1995.</font></p>
  </td>
 </tr>
 <tr>
  <td width="17%" valign="top" style="padding:0in .7pt 0in .7pt;width:17.66%;">
  <p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
  </td>
  <td width="3%" valign="bottom" style="padding:0in .7pt 0in .7pt;width:3.82%;">
  <p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
  </td>
  <td width="78%" valign="top" style="padding:0in .7pt 0in .7pt;width:78.52%;">
  <p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
  </td>
 </tr>
 <tr>
  <td width="17%" valign="top" style="padding:0in .7pt 0in .7pt;width:17.66%;">
  <p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">10.20(1)(+)</font></p>
  </td>
  <td width="3%" valign="bottom" style="padding:0in .7pt 0in .7pt;width:3.82%;">
  <p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>
  </td>
  <td width="78%" valign="top" style="padding:0in .7pt 0in .7pt;width:78.52%;">
  <p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Settlement and License
  Agreement &amp; Agreement of Dismissal with Prejudice, between Biosite and
  Abbott Laboratories, dated as of September 6, 1996.</font></p>
  </td>
 </tr>
 <tr>
  <td width="17%" valign="top" style="padding:0in .7pt 0in .7pt;width:17.66%;">
  <p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
  </td>
  <td width="3%" valign="bottom" style="padding:0in .7pt 0in .7pt;width:3.82%;">
  <p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
  </td>
  <td width="78%" valign="top" style="padding:0in .7pt 0in .7pt;width:78.52%;">
  <p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
  </td>
 </tr>
 <tr>
  <td width="17%" valign="top" style="padding:0in .7pt 0in .7pt;width:17.66%;">
  <p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">10.21(1)</font></p>
  </td>
  <td width="3%" valign="bottom" style="padding:0in .7pt 0in .7pt;width:3.82%;">
  <p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>
  </td>
  <td width="78%" valign="top" style="padding:0in .7pt 0in .7pt;width:78.52%;">
  <p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Lease Agreement between
  Biosite and TCEP II Properties Limited Partnership dated July 26, 1996.</font></p>
  </td>
 </tr>
 <tr>
  <td width="17%" valign="top" style="padding:0in .7pt 0in .7pt;width:17.66%;">
  <p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
  </td>
  <td width="3%" valign="bottom" style="padding:0in .7pt 0in .7pt;width:3.82%;">
  <p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
  </td>
  <td width="78%" valign="top" style="padding:0in .7pt 0in .7pt;width:78.52%;">
  <p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
  </td>
 </tr>
 <tr>
  <td width="17%" valign="top" style="padding:0in .7pt 0in .7pt;width:17.66%;">
  <p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">10.22(1)</font></p>
  </td>
  <td width="3%" valign="bottom" style="padding:0in .7pt 0in .7pt;width:3.82%;">
  <p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>
  </td>
  <td width="78%" valign="top" style="padding:0in .7pt 0in .7pt;width:78.52%;">
  <p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Lease Agreement between
  Biosite and Sorrento West Limited dated September 21, 1994.</font></p>
  </td>
 </tr>
 <tr>
  <td width="17%" valign="top" style="padding:0in .7pt 0in .7pt;width:17.66%;">
  <p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
  </td>
  <td width="3%" valign="bottom" style="padding:0in .7pt 0in .7pt;width:3.82%;">
  <p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
  </td>
  <td width="78%" valign="top" style="padding:0in .7pt 0in .7pt;width:78.52%;">
  <p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
  </td>
 </tr>
 <tr>
  <td width="17%" valign="top" style="padding:0in .7pt 0in .7pt;width:17.66%;">
  <p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">10.23(3)</font></p>
  </td>
  <td width="3%" valign="bottom" style="padding:0in .7pt 0in .7pt;width:3.82%;">
  <p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>
  </td>
  <td width="78%" valign="top" style="padding:0in .7pt 0in .7pt;width:78.52%;">
  <p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Rights Agreement dated as
  of October 22, 1997 between Biosite (formerly Biosite Diagnostics
  Incorporated) and Fleet National Bank (f/k/a BankBoston, N.A.) as Rights
  Agent.</font></p>
  </td>
 </tr>
 <tr>
  <td width="17%" valign="top" style="padding:0in .7pt 0in .7pt;width:17.66%;">
  <p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
  </td>
  <td width="3%" valign="bottom" style="padding:0in .7pt 0in .7pt;width:3.82%;">
  <p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
  </td>
  <td width="78%" valign="top" style="padding:0in .7pt 0in .7pt;width:78.52%;">
  <p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
  </td>
 </tr>
 <tr>
  <td width="17%" valign="top" style="padding:0in .7pt 0in .7pt;width:17.66%;">
  <p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">10.24(7)</font></p>
  </td>
  <td width="3%" valign="bottom" style="padding:0in .7pt 0in .7pt;width:3.82%;">
  <p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>
  </td>
  <td width="78%" valign="top" style="padding:0in .7pt 0in .7pt;width:78.52%;">
  <p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Amendment No. 1 to Rights
  Agreement dated as of December 9, 1999 between Biosite Incorporated (formerly
  Biosite Diagnostics Incorporated) and Fleet National Bank
  (f/k/a&nbsp;BankBoston, N.A.) as Rights Agent.</font></p>
  </td>
 </tr>
 <tr>
  <td width="17%" valign="top" style="padding:0in .7pt 0in .7pt;width:17.66%;">
  <p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
  </td>
  <td width="3%" valign="bottom" style="padding:0in .7pt 0in .7pt;width:3.82%;">
  <p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
  </td>
  <td width="78%" valign="top" style="padding:0in .7pt 0in .7pt;width:78.52%;">
  <p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
  </td>
 </tr>
 <tr>
  <td width="17%" valign="top" style="padding:0in .7pt 0in .7pt;width:17.66%;">
  <p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">10.25(8)</font></p>
  </td>
  <td width="3%" valign="bottom" style="padding:0in .7pt 0in .7pt;width:3.82%;">
  <p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>
  </td>
  <td width="78%" valign="top" style="padding:0in .7pt 0in .7pt;width:78.52%;">
  <p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Amendment No. 2 to Rights
  Agreement dated as of July 18, 2001 between Biosite Incorporated (formally
  Biosite Diagnostics Incorporated) and Fleet National Bank (f/k/a BankBoston,
  N.A.) and American Stock Transfer and Trust as successor Rights Agent.</font></p>
  </td>
 </tr>
 <tr>
  <td width="17%" valign="top" style="padding:0in .7pt 0in .7pt;width:17.66%;">
  <p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
  </td>
  <td width="3%" valign="bottom" style="padding:0in .7pt 0in .7pt;width:3.82%;">
  <p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
  </td>
  <td width="78%" valign="top" style="padding:0in .7pt 0in .7pt;width:78.52%;">
  <p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
  </td>
 </tr>
 <tr>
  <td width="17%" valign="top" style="padding:0in .7pt 0in .7pt;width:17.66%;">
  <p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">10.28(6)(+)</font></p>
  </td>
  <td width="3%" valign="bottom" style="padding:0in .7pt 0in .7pt;width:3.82%;">
  <p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>
  </td>
  <td width="78%" valign="top" style="padding:0in .7pt 0in .7pt;width:78.52%;">
  <p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Distribution Agreement
  between Biosite and Fisher Scientific Company L.L.C. dated January&nbsp;1,
  2001.</font></p>
  </td>
 </tr>
 <tr>
  <td width="17%" valign="top" style="padding:0in .7pt 0in .7pt;width:17.66%;">
  <p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
  </td>
  <td width="3%" valign="bottom" style="padding:0in .7pt 0in .7pt;width:3.82%;">
  <p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
  </td>
  <td width="78%" valign="top" style="padding:0in .7pt 0in .7pt;width:78.52%;">
  <p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
  </td>
 </tr>
 <tr>
  <td width="17%" valign="top" style="padding:0in .7pt 0in .7pt;width:17.66%;">
  <p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">10.29(12)(*)</font></p>
  </td>
  <td width="3%" valign="bottom" style="padding:0in .7pt 0in .7pt;width:3.82%;">
  <p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>
  </td>
  <td width="78%" valign="top" style="padding:0in .7pt 0in .7pt;width:78.52%;">
  <p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Distribution Agreement
  between Biosite and Fisher Scientific Company L.L.C. effective
  January&nbsp;1, 2004.</font></p>
  </td>
 </tr>
 <tr>
  <td width="17%" valign="top" style="padding:0in .7pt 0in .7pt;width:17.66%;">
  <p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
  </td>
  <td width="3%" valign="bottom" style="padding:0in .7pt 0in .7pt;width:3.82%;">
  <p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
  </td>
  <td width="78%" valign="top" style="padding:0in .7pt 0in .7pt;width:78.52%;">
  <p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
  </td>
 </tr>
 <tr>
  <td width="17%" valign="top" style="padding:0in .7pt 0in .7pt;width:17.66%;">
  <p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">10.30(13)</font></p>
  </td>
  <td width="3%" valign="bottom" style="padding:0in .7pt 0in .7pt;width:3.82%;">
  <p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>
  </td>
  <td width="78%" valign="top" style="padding:0in .7pt 0in .7pt;width:78.52%;">
  <p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Purchase Agreement and
  Escrow Instructions between Biosite and H.G. Fenton Company dated December 7,
  2001.</font></p>
  </td>
 </tr>
 <tr>
  <td width="17%" valign="top" style="padding:0in .7pt 0in .7pt;width:17.66%;">
  <p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
  </td>
  <td width="3%" valign="bottom" style="padding:0in .7pt 0in .7pt;width:3.82%;">
  <p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
  </td>
  <td width="78%" valign="top" style="padding:0in .7pt 0in .7pt;width:78.52%;">
  <p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
  </td>
 </tr>
 <tr>
  <td width="17%" valign="top" style="padding:0in .7pt 0in .7pt;width:17.66%;">
  <p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">10.31(13)</font></p>
  </td>
  <td width="3%" valign="bottom" style="padding:0in .7pt 0in .7pt;width:3.82%;">
  <p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>
  </td>
  <td width="78%" valign="top" style="padding:0in .7pt 0in .7pt;width:78.52%;">
  <p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">First Amendment to
  Purchase Agreement and Escrow Instructions between Biosite and H.G. Fenton
  Company dated February 12, 2002.</font></p>
  </td>
 </tr>
 <tr>
  <td width="17%" valign="top" style="padding:0in .7pt 0in .7pt;width:17.66%;">
  <p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
  </td>
  <td width="3%" valign="bottom" style="padding:0in .7pt 0in .7pt;width:3.82%;">
  <p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
  </td>
  <td width="78%" valign="top" style="padding:0in .7pt 0in .7pt;width:78.52%;">
  <p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
  </td>
 </tr>
 <tr>
  <td width="17%" valign="top" style="padding:0in .7pt 0in .7pt;width:17.66%;">
  <p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">10.32(13)</font></p>
  </td>
  <td width="3%" valign="bottom" style="padding:0in .7pt 0in .7pt;width:3.82%;">
  <p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>
  </td>
  <td width="78%" valign="top" style="padding:0in .7pt 0in .7pt;width:78.52%;">
  <p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Second Amendment to
  Purchase Agreement and Escrow Instructions between Biosite and H.G. Fenton
  Company dated February 14, 2002.</font></p>
  </td>
 </tr>
 <tr>
  <td width="17%" valign="top" style="padding:0in .7pt 0in .7pt;width:17.66%;">
  <p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
  </td>
  <td width="3%" valign="bottom" style="padding:0in .7pt 0in .7pt;width:3.82%;">
  <p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
  </td>
  <td width="78%" valign="top" style="padding:0in .7pt 0in .7pt;width:78.52%;">
  <p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
  </td>
 </tr>
 <tr>
  <td width="17%" valign="top" style="padding:0in .7pt 0in .7pt;width:17.66%;">
  <p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">10.34(14)</font></p>
  </td>
  <td width="3%" valign="bottom" style="padding:0in .7pt 0in .7pt;width:3.82%;">
  <p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>
  </td>
  <td width="78%" valign="top" style="padding:0in .7pt 0in .7pt;width:78.52%;">
  <p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Third
  Amendment to Purchase Agreement and Escrow Instructions between Biosite and
  H.G. Fenton Company dated June 10, 2002.</font></p>
  </td>
 </tr>
 <tr>
  <td width="17%" valign="top" style="padding:0in .7pt 0in .7pt;width:17.66%;">
  <p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
  </td>
  <td width="3%" valign="bottom" style="padding:0in .7pt 0in .7pt;width:3.82%;">
  <p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
  </td>
  <td width="78%" valign="top" style="padding:0in .7pt 0in .7pt;width:78.52%;">
  <p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
  </td>
 </tr>
 <tr>
  <td width="17%" valign="top" style="padding:0in .7pt 0in .7pt;width:17.66%;">
  <p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">10.35(14)</font></p>
  </td>
  <td width="3%" valign="bottom" style="padding:0in .7pt 0in .7pt;width:3.82%;">
  <p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>
  </td>
  <td width="78%" valign="top" style="padding:0in .7pt 0in .7pt;width:78.52%;">
  <p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Fourth
  Amendment to Purchase Agreement and Escrow Instructions between Biosite and
  H.G. Fenton Company dated January 24, 2003.</font></p>
  </td>
 </tr>
 <tr>
  <td width="17%" valign="top" style="padding:0in .7pt 0in .7pt;width:17.66%;">
  <p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
  </td>
  <td width="3%" valign="bottom" style="padding:0in .7pt 0in .7pt;width:3.82%;">
  <p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
  </td>
  <td width="78%" valign="top" style="padding:0in .7pt 0in .7pt;width:78.52%;">
  <p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
  </td>
 </tr>
 <tr>
  <td width="17%" valign="top" style="padding:0in .7pt 0in .7pt;width:17.66%;">
  <p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">10.36(14)</font></p>
  </td>
  <td width="3%" valign="bottom" style="padding:0in .7pt 0in .7pt;width:3.82%;">
  <p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>
  </td>
  <td width="78%" valign="top" style="padding:0in .7pt 0in .7pt;width:78.52%;">
  <p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Fifth
  Amendment to Purchase Agreement and Escrow Instructions between Biosite and
  H.G. Fenton Company dated April 25, 2003.</font></p>
  </td>
 </tr>
 <tr>
  <td width="17%" valign="top" style="padding:0in .7pt 0in .7pt;width:17.66%;">
  <p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
  </td>
  <td width="3%" valign="bottom" style="padding:0in .7pt 0in .7pt;width:3.82%;">
  <p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
  </td>
  <td width="78%" valign="top" style="padding:0in .7pt 0in .7pt;width:78.52%;">
  <p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
  </td>
 </tr>
 <tr>
  <td width="17%" valign="top" style="padding:0in .7pt 0in .7pt;width:17.66%;">
  <p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">10.37(14)</font></p>
  </td>
  <td width="3%" valign="bottom" style="padding:0in .7pt 0in .7pt;width:3.82%;">
  <p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>
  </td>
  <td width="78%" valign="top" style="padding:0in .7pt 0in .7pt;width:78.52%;">
  <p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Sixth
  Amendment to Purchase Agreement and Escrow Instructions between Biosite and
  H.G. Fenton Company dated May 27, 2003.</font></p>
  </td>
 </tr>
</table>

<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>

<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">36</font></p>

<div style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">

<hr size="2" width="100%" noshade color="gray" align="left">

</font></div>

</div>
<!-- SEQ.=1,FOLIO='36',FILE='C:\JMS\jboldua\05-1861-2\task332547\1861-2-be.htm',USER='jboldua',CD='Mar  4 06:47 2005' -->


<br clear="all" style="page-break-before:always;">


<div style="font-family:Times New Roman;">

<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>

<table border="0" cellspacing="0" cellpadding="0" width="100%" style="border-collapse:collapse;width:100.0%;">
 <tr>
  <td width="17%" valign="top" style="padding:0in .7pt 0in .7pt;width:17.66%;">
  <p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">10.38(14)</font></p>
  </td>
  <td width="3%" valign="bottom" style="padding:0in .7pt 0in .7pt;width:3.82%;">
  <p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>
  </td>
  <td width="78%" valign="top" style="padding:0in .7pt 0in .7pt;width:78.52%;">
  <p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Seventh
  Amendment to Purchase Agreement and Escrow Instructions between Biosite and
  H.G. Fenton Company dated June 16, 2003.</font></p>
  </td>
 </tr>
 <tr>
  <td width="17%" valign="top" style="padding:0in .7pt 0in .7pt;width:17.66%;">
  <p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
  </td>
  <td width="3%" valign="bottom" style="padding:0in .7pt 0in .7pt;width:3.82%;">
  <p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
  </td>
  <td width="78%" valign="top" style="padding:0in .7pt 0in .7pt;width:78.52%;">
  <p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
  </td>
 </tr>
 <tr>
  <td width="17%" valign="top" style="padding:0in .7pt 0in .7pt;width:17.66%;">
  <p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">10.39(15)</font></p>
  </td>
  <td width="3%" valign="bottom" style="padding:0in .7pt 0in .7pt;width:3.82%;">
  <p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>
  </td>
  <td width="78%" valign="top" style="padding:0in .7pt 0in .7pt;width:78.52%;">
  <p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Eighth
  Amendment to Purchase Agreement and Escrow Instructions between Biosite and
  H.G. Fenton Company dated September 15, 2003.</font></p>
  </td>
 </tr>
 <tr>
  <td width="17%" valign="top" style="padding:0in .7pt 0in .7pt;width:17.66%;">
  <p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
  </td>
  <td width="3%" valign="bottom" style="padding:0in .7pt 0in .7pt;width:3.82%;">
  <p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
  </td>
  <td width="78%" valign="top" style="padding:0in .7pt 0in .7pt;width:78.52%;">
  <p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
  </td>
 </tr>
 <tr>
  <td width="17%" valign="top" style="padding:0in .7pt 0in .7pt;width:17.66%;">
  <p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">10.40(16)</font></p>
  </td>
  <td width="3%" valign="bottom" style="padding:0in .7pt 0in .7pt;width:3.82%;">
  <p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>
  </td>
  <td width="78%" valign="top" style="padding:0in .7pt 0in .7pt;width:78.52%;">
  <p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Ninth
  Amendment to Purchase Agreement and Escrow Instructions between Biosite and
  H.G. Fenton Company dated October 9, 2003.</font></p>
  </td>
 </tr>
 <tr>
  <td width="17%" valign="top" style="padding:0in .7pt 0in .7pt;width:17.66%;">
  <p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
  </td>
  <td width="3%" valign="bottom" style="padding:0in .7pt 0in .7pt;width:3.82%;">
  <p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
  </td>
  <td width="78%" valign="top" style="padding:0in .7pt 0in .7pt;width:78.52%;">
  <p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
  </td>
 </tr>
 <tr>
  <td width="17%" valign="top" style="padding:0in .7pt 0in .7pt;width:17.66%;">
  <p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">10.41(17)(+)</font></p>
  </td>
  <td width="3%" valign="bottom" style="padding:0in .7pt 0in .7pt;width:3.82%;">
  <p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>
  </td>
  <td width="78%" valign="top" style="padding:0in .7pt 0in .7pt;width:78.52%;">
  <p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Distribution
  Agreement between Biosite and </font><font size="2" style="font-size:10.0pt;">PSS World Medical, Inc.
  dated May 13, 2003.</font></p>
  </td>
 </tr>
 <tr>
  <td width="17%" valign="top" style="padding:0in .7pt 0in .7pt;width:17.66%;">
  <p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
  </td>
  <td width="3%" valign="bottom" style="padding:0in .7pt 0in .7pt;width:3.82%;">
  <p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
  </td>
  <td width="78%" valign="top" style="padding:0in .7pt 0in .7pt;width:78.52%;">
  <p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
  </td>
 </tr>
 <tr>
  <td width="17%" valign="top" style="padding:0in .7pt 0in .7pt;width:17.66%;">
  <p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">10.42(11)(A)</font></p>
  </td>
  <td width="3%" valign="bottom" style="padding:0in .7pt 0in .7pt;width:3.82%;">
  <p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>
  </td>
  <td width="78%" valign="top" style="padding:0in .7pt 0in .7pt;width:78.52%;">
  <p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Biosite
  Incorporated 2002 Nonqualified Stock Incentive Plan.</font></p>
  </td>
 </tr>
 <tr>
  <td width="17%" valign="top" style="padding:0in .7pt 0in .7pt;width:17.66%;">
  <p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
  </td>
  <td width="3%" valign="bottom" style="padding:0in .7pt 0in .7pt;width:3.82%;">
  <p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
  </td>
  <td width="78%" valign="top" style="padding:0in .7pt 0in .7pt;width:78.52%;">
  <p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
  </td>
 </tr>
 <tr>
  <td width="17%" valign="top" style="padding:0in .7pt 0in .7pt;width:17.66%;">
  <p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">10.43(18)(A)</font></p>
  </td>
  <td width="3%" valign="bottom" style="padding:0in .7pt 0in .7pt;width:3.82%;">
  <p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>
  </td>
  <td width="78%" valign="top" style="padding:0in .7pt 0in .7pt;width:78.52%;">
  <p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Biosite
  Incorporated Executive Bonus Plan.</font></p>
  </td>
 </tr>
 <tr>
  <td width="17%" valign="top" style="padding:0in .7pt 0in .7pt;width:17.66%;">
  <p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
  </td>
  <td width="3%" valign="bottom" style="padding:0in .7pt 0in .7pt;width:3.82%;">
  <p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
  </td>
  <td width="78%" valign="top" style="padding:0in .7pt 0in .7pt;width:78.52%;">
  <p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
  </td>
 </tr>
 <tr>
  <td width="17%" valign="top" style="padding:0in .7pt 0in .7pt;width:17.66%;">
  <p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">10.44(19)(A)</font></p>
  </td>
  <td width="3%" valign="bottom" style="padding:0in .7pt 0in .7pt;width:3.82%;">
  <p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>
  </td>
  <td width="78%" valign="top" style="padding:0in .7pt 0in .7pt;width:78.52%;">
  <p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Biosite
  Incorporated Nonqualified Deferred Compensation Plan effective June 1, 2002.</font></p>
  </td>
 </tr>
 <tr>
  <td width="17%" valign="top" style="padding:0in .7pt 0in .7pt;width:17.66%;">
  <p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
  </td>
  <td width="3%" valign="bottom" style="padding:0in .7pt 0in .7pt;width:3.82%;">
  <p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
  </td>
  <td width="78%" valign="top" style="padding:0in .7pt 0in .7pt;width:78.52%;">
  <p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
  </td>
 </tr>
 <tr>
  <td width="17%" valign="top" style="padding:0in .7pt 0in .7pt;width:17.66%;">
  <p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">10.45(21)(A)</font></p>
  </td>
  <td width="3%" valign="bottom" style="padding:0in .7pt 0in .7pt;width:3.82%;">
  <p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>
  </td>
  <td width="78%" valign="top" style="padding:0in .7pt 0in .7pt;width:78.52%;">
  <p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Biosite
  Incorporated Change in Control Severance Benefit Plan.</font></p>
  </td>
 </tr>
 <tr>
  <td width="17%" valign="top" style="padding:0in .7pt 0in .7pt;width:17.66%;">
  <p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
  </td>
  <td width="3%" valign="bottom" style="padding:0in .7pt 0in .7pt;width:3.82%;">
  <p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
  </td>
  <td width="78%" valign="top" style="padding:0in .7pt 0in .7pt;width:78.52%;">
  <p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
  </td>
 </tr>
 <tr>
  <td width="17%" valign="top" style="padding:0in .7pt 0in .7pt;width:17.66%;">
  <p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">10.46(21)(A)</font></p>
  </td>
  <td width="3%" valign="bottom" style="padding:0in .7pt 0in .7pt;width:3.82%;">
  <p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>
  </td>
  <td width="78%" valign="top" style="padding:0in .7pt 0in .7pt;width:78.52%;">
  <p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Form
  of Director Fee Deferral Program under the 1996 Stock Plan.</font></p>
  </td>
 </tr>
 <tr>
  <td width="17%" valign="top" style="padding:0in .7pt 0in .7pt;width:17.66%;">
  <p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
  </td>
  <td width="3%" valign="bottom" style="padding:0in .7pt 0in .7pt;width:3.82%;">
  <p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
  </td>
  <td width="78%" valign="top" style="padding:0in .7pt 0in .7pt;width:78.52%;">
  <p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
  </td>
 </tr>
 <tr>
  <td width="17%" valign="top" style="padding:0in .7pt 0in .7pt;width:17.66%;">
  <p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">21.1(21)</font></p>
  </td>
  <td width="3%" valign="bottom" style="padding:0in .7pt 0in .7pt;width:3.82%;">
  <p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>
  </td>
  <td width="78%" valign="top" style="padding:0in .7pt 0in .7pt;width:78.52%;">
  <p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Subsidiaries of the
  Company.</font></p>
  </td>
 </tr>
 <tr>
  <td width="17%" valign="top" style="padding:0in .7pt 0in .7pt;width:17.66%;">
  <p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
  </td>
  <td width="3%" valign="bottom" style="padding:0in .7pt 0in .7pt;width:3.82%;">
  <p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
  </td>
  <td width="78%" valign="top" style="padding:0in .7pt 0in .7pt;width:78.52%;">
  <p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
  </td>
 </tr>
 <tr>
  <td width="17%" valign="top" style="padding:0in .7pt 0in .7pt;width:17.66%;">
  <p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">23.1(21)</font></p>
  </td>
  <td width="3%" valign="bottom" style="padding:0in .7pt 0in .7pt;width:3.82%;">
  <p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>
  </td>
  <td width="78%" valign="top" style="padding:0in .7pt 0in .7pt;width:78.52%;">
  <p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Consent of Ernst &amp;
  Young LLP, Independent Registered Public Accounting Firm.</font></p>
  </td>
 </tr>
 <tr>
  <td width="17%" valign="top" style="padding:0in .7pt 0in .7pt;width:17.66%;">
  <p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
  </td>
  <td width="3%" valign="bottom" style="padding:0in .7pt 0in .7pt;width:3.82%;">
  <p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
  </td>
  <td width="78%" valign="top" style="padding:0in .7pt 0in .7pt;width:78.52%;">
  <p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
  </td>
 </tr>
 <tr>
  <td width="17%" valign="top" style="padding:0in .7pt 0in .7pt;width:17.66%;">
  <p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">31.1(21)</font></p>
  </td>
  <td width="3%" valign="bottom" style="padding:0in .7pt 0in .7pt;width:3.82%;">
  <p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>
  </td>
  <td width="78%" valign="top" style="padding:0in .7pt 0in .7pt;width:78.52%;">
  <p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Section
  302 Certification of Kim D. Blickenstaff, Chief Executive Officer</font></p>
  </td>
 </tr>
 <tr>
  <td width="17%" valign="top" style="padding:0in .7pt 0in .7pt;width:17.66%;">
  <p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
  </td>
  <td width="3%" valign="bottom" style="padding:0in .7pt 0in .7pt;width:3.82%;">
  <p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
  </td>
  <td width="78%" valign="top" style="padding:0in .7pt 0in .7pt;width:78.52%;">
  <p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
  </td>
 </tr>
 <tr>
  <td width="17%" valign="top" style="padding:0in .7pt 0in .7pt;width:17.66%;">
  <p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">31.2(21)</font></p>
  </td>
  <td width="3%" valign="bottom" style="padding:0in .7pt 0in .7pt;width:3.82%;">
  <p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>
  </td>
  <td width="78%" valign="top" style="padding:0in .7pt 0in .7pt;width:78.52%;">
  <p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Section
  302 Certification of Christopher J. Twomey, Chief Financial Officer</font></p>
  </td>
 </tr>
 <tr>
  <td width="17%" valign="top" style="padding:0in .7pt 0in .7pt;width:17.66%;">
  <p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
  </td>
  <td width="3%" valign="bottom" style="padding:0in .7pt 0in .7pt;width:3.82%;">
  <p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
  </td>
  <td width="78%" valign="top" style="padding:0in .7pt 0in .7pt;width:78.52%;">
  <p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
  </td>
 </tr>
 <tr>
  <td width="17%" valign="top" style="padding:0in .7pt 0in .7pt;width:17.66%;">
  <p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">31.3</font></p>
  </td>
  <td width="3%" valign="bottom" style="padding:0in .7pt 0in .7pt;width:3.82%;">
  <p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>
  </td>
  <td width="78%" valign="top" style="padding:0in .7pt 0in .7pt;width:78.52%;">
  <p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Section
  302 Certification of Kim D. Blickenstaff, Chief Executive Officer</font></p>
  </td>
 </tr>
 <tr>
  <td width="17%" valign="top" style="padding:0in .7pt 0in .7pt;width:17.66%;">
  <p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
  </td>
  <td width="3%" valign="bottom" style="padding:0in .7pt 0in .7pt;width:3.82%;">
  <p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
  </td>
  <td width="78%" valign="top" style="padding:0in .7pt 0in .7pt;width:78.52%;">
  <p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
  </td>
 </tr>
 <tr>
  <td width="17%" valign="top" style="padding:0in .7pt 0in .7pt;width:17.66%;">
  <p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">31.4</font></p>
  </td>
  <td width="3%" valign="bottom" style="padding:0in .7pt 0in .7pt;width:3.82%;">
  <p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>
  </td>
  <td width="78%" valign="top" style="padding:0in .7pt 0in .7pt;width:78.52%;">
  <p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Section
  302 Certification of Christopher J. Twomey, Chief Financial Officer</font></p>
  </td>
 </tr>
 <tr>
  <td width="17%" valign="top" style="padding:0in .7pt 0in .7pt;width:17.66%;">
  <p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
  </td>
  <td width="3%" valign="bottom" style="padding:0in .7pt 0in .7pt;width:3.82%;">
  <p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
  </td>
  <td width="78%" valign="top" style="padding:0in .7pt 0in .7pt;width:78.52%;">
  <p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
  </td>
 </tr>
 <tr>
  <td width="17%" valign="top" style="padding:0in .7pt 0in .7pt;width:17.66%;">
  <p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">32.1(21)</font></p>
  </td>
  <td width="3%" valign="bottom" style="padding:0in .7pt 0in .7pt;width:3.82%;">
  <p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>
  </td>
  <td width="78%" valign="top" style="padding:0in .7pt 0in .7pt;width:78.52%;">
  <p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Section
  906 Certification of Kim D. Blickenstaff, Chief Executive Officer</font></p>
  </td>
 </tr>
 <tr>
  <td width="17%" valign="top" style="padding:0in .7pt 0in .7pt;width:17.66%;">
  <p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
  </td>
  <td width="3%" valign="bottom" style="padding:0in .7pt 0in .7pt;width:3.82%;">
  <p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
  </td>
  <td width="78%" valign="top" style="padding:0in .7pt 0in .7pt;width:78.52%;">
  <p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
  </td>
 </tr>
 <tr>
  <td width="17%" valign="top" style="padding:0in .7pt 0in .7pt;width:17.66%;">
  <p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">32.2(21)</font></p>
  </td>
  <td width="3%" valign="bottom" style="padding:0in .7pt 0in .7pt;width:3.82%;">
  <p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>
  </td>
  <td width="78%" valign="top" style="padding:0in .7pt 0in .7pt;width:78.52%;">
  <p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Section
  906 Certification of Christopher J. Twomey, Chief Financial Officer</font></p>
  </td>
 </tr>
 <tr>
  <td width="17%" valign="top" style="padding:0in .7pt 0in .7pt;width:17.66%;">
  <p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
  </td>
  <td width="3%" valign="bottom" style="padding:0in .7pt 0in .7pt;width:3.82%;">
  <p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
  </td>
  <td width="78%" valign="top" style="padding:0in .7pt 0in .7pt;width:78.52%;">
  <p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
  </td>
 </tr>
 <tr>
  <td width="17%" valign="top" style="padding:0in .7pt 0in .7pt;width:17.66%;">
  <p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">32.3</font></p>
  </td>
  <td width="3%" valign="bottom" style="padding:0in .7pt 0in .7pt;width:3.82%;">
  <p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>
  </td>
  <td width="78%" valign="top" style="padding:0in .7pt 0in .7pt;width:78.52%;">
  <p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Section
  906 Certification of Kim D. Blickenstaff, Chief Executive Officer</font></p>
  </td>
 </tr>
 <tr>
  <td width="17%" valign="top" style="padding:0in .7pt 0in .7pt;width:17.66%;">
  <p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
  </td>
  <td width="3%" valign="bottom" style="padding:0in .7pt 0in .7pt;width:3.82%;">
  <p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
  </td>
  <td width="78%" valign="top" style="padding:0in .7pt 0in .7pt;width:78.52%;">
  <p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
  </td>
 </tr>
 <tr>
  <td width="17%" valign="top" style="padding:0in .7pt 0in .7pt;width:17.66%;">
  <p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">32.4</font></p>
  </td>
  <td width="3%" valign="bottom" style="padding:0in .7pt 0in .7pt;width:3.82%;">
  <p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>
  </td>
  <td width="78%" valign="top" style="padding:0in .7pt 0in .7pt;width:78.52%;">
  <p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Section
  906 Certification of Christopher J. Twomey, Chief Financial Officer</font></p>
  </td>
 </tr>
</table>

<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>

<div style="margin:0in 0in 6.0pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">

<hr size="1" width="25%" noshade color="black" align="left">

</font></div>

<p style="margin:0in 0in 6.0pt .5in;text-indent:-.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">(1)</font><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font><font size="2" style="font-size:10.0pt;">Incorporated by
reference to the exhibits of the same number to Biosite&#146;s Registration
Statement on Form S-1, No. 333-17657.</font></p>

<p style="margin:0in 0in 6.0pt .5in;text-indent:-.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">(2)</font><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font><font size="2" style="font-size:10.0pt;">Incorporated by
reference to Exhibit 3.(ii) to Biosite&#146;s Quarterly Report on Form 10-Q for the
quarter ended March 31, 2003.</font></p>

<p style="margin:0in 0in 6.0pt .5in;text-indent:-.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">(3)</font><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font><font size="2" style="font-size:10.0pt;">Incorporated by
reference to Exhibit 4.1 to Biosite&#146;s Registration Statement on Form 8-A, filed
on October 28, 1997.</font></p>

<p style="margin:0in 0in 6.0pt .5in;text-indent:-.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">(4)</font><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font><font size="2" style="font-size:10.0pt;">Incorporated by
reference to Exhibit A to Biosite&#146;s Definitive Proxy Statement dated April 27,
2004 and filed with the Securities and Exchange Commission.</font></p>

<p style="margin:0in 0in 6.0pt .5in;text-indent:-.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">(5)</font><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font><font size="2" style="font-size:10.0pt;">Incorporated by
reference to Exhibit B to Biosite&#146;s Definitive Proxy Statement dated April 27,
2004 and filed with the Securities and Exchange Commission.</font></p>

<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>

<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">37</font></p>

<div style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">

<hr size="2" width="100%" noshade color="gray" align="left">

</font></div>

</div>
<!-- SEQ.=1,FOLIO='37',FILE='C:\JMS\jboldua\05-1861-2\task332547\1861-2-be.htm',USER='jboldua',CD='Mar  4 06:47 2005' -->


<br clear="all" style="page-break-before:always;">


<div style="font-family:Times New Roman;">

<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>

<p style="margin:0in 0in 6.0pt .5in;text-indent:-.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">(6)</font><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font><font size="2" style="font-size:10.0pt;">Incorporated by
reference to Exhibit 10.29 to Biosite&#146;s Annual Report on Form 10-K for the year
ended December 31, 2000.</font></p>

<p style="margin:0in 0in 6.0pt .5in;text-indent:-.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">(7)</font><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font><font size="2" style="font-size:10.0pt;">Incorporated by
reference to Exhibit 4.2 to Amendment No. 1 to Biosite&#146;s Registration Statement
on Form 8-A, filed on July 18, 2001.</font></p>

<p style="margin:0in 0in 6.0pt .5in;text-indent:-.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">(8)</font><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font><font size="2" style="font-size:10.0pt;">Incorporated by
reference to Exhibit 4.3 to Amendment No. 1 to Biosite&#146;s Registration Statement
on Form 8-A, filed on July 18, 2001.</font></p>

<p style="margin:0in 0in 6.0pt .5in;text-indent:-.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">(9)</font><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font><font size="2" style="font-size:10.0pt;">Incorporated by
reference to Exhibit 3(i) to Biosite&#146;s Quarterly Report on Form 10-Q for the
quarter ended June 30, 2001.</font></p>

<p style="margin:0in 0in 6.0pt .5in;text-indent:-.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">(10)</font><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font><font size="2" style="font-size:10.0pt;">Incorporated by
reference to exhibits of the same number to Biosite&#146;s Annual Report on Form
10-K for the year ended December 31, 2001.</font></p>

<p style="margin:0in 0in 6.0pt .5in;text-indent:-.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">(11)</font><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font><font size="2" style="font-size:10.0pt;">Incorporated by
reference to Exhibit 10.33 to Biosite&#146;s Registration Statement on Form S-8 (No.
333-111075), filed on December 11, 2003.</font></p>

<p style="margin:0in 0in 6.0pt .5in;text-indent:-.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">(12)</font><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font><font size="2" style="font-size:10.0pt;">Incorporated by
reference to Exhibit 10.43 to Biosite&#146;s Quarterly Report on Form 10-Q for the
quarter ended September 30, 2003.</font></p>

<p style="margin:0in 0in 6.0pt .5in;text-indent:-.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">(13)</font><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font><font size="2" style="font-size:10.0pt;">Incorporated by
reference to exhibits of the same number to Biosite&#146;s Annual Report on Form
10-K for the year ended December 31, 2001.</font></p>

<p style="margin:0in 0in 6.0pt .5in;text-indent:-.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">(14)</font><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font><font size="2" style="font-size:10.0pt;">Incorporated by
reference to exhibits of the same number to Biosite&#146;s Quarterly Report on Form
10-Q for the quarter ended June 30, 2003.</font></p>

<p style="margin:0in 0in 6.0pt .5in;text-indent:-.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">(15)</font><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font><font size="2" style="font-size:10.0pt;">Incorporated by
reference to Exhibit 10.40 to Biosite&#146;s Quarterly Report on Form 10-Q for the
quarter ended September 30, 2003.</font></p>

<p style="margin:0in 0in 6.0pt .5in;text-indent:-.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">(16)</font><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font><font size="2" style="font-size:10.0pt;">Incorporated by
reference to Exhibit 10.41 to Biosite&#146;s Quarterly Report on Form 10-Q for the
quarter ended September 30, 2003.</font></p>

<p style="margin:0in 0in 6.0pt .5in;text-indent:-.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">(17)</font><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font><font size="2" style="font-size:10.0pt;">Incorporated by
reference to Exhibit 10.39 to Biosite&#146;s Quarterly Report on Form 10-Q for the
quarter ended June 30, 2003.</font></p>

<p style="margin:0in 0in 6.0pt .5in;text-indent:-.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">(18)</font><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font><font size="2" style="font-size:10.0pt;">Incorporated by
reference to Exhibit 10.34 to Biosite&#146;s Quarterly Report on Form 10-Q for the
quarter ended March 31, 2003.</font></p>

<p style="margin:0in 0in 6.0pt .5in;text-indent:-.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">(19)</font><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font><font size="2" style="font-size:10.0pt;">Incorporated by
reference to Exhibit 10.42 to Biosite&#146;s Quarterly Report on Form 10-Q for the
quarter ended September 30, 2003.</font></p>

<p style="margin:0in 0in 6.0pt .5in;text-indent:-.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">(20)</font><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font><font size="2" style="font-size:10.0pt;">Incorporated by
reference to the exhibit of the same number to Biosite&#146;s Current Report on Form
8-K, filed on January 19, 2005.</font></p>

<p style="margin:0in 0in 6.0pt .5in;text-indent:-.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">(21)</font><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font><font size="2" style="font-size:10.0pt;">Incorporated by
reference to the exhibit of the same number to Biosite&#146;s Annual Report on Form
10-K for the year ended December 31, 2004.</font></p>

<p style="margin:0in 0in 6.0pt .25in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>

<p align="left" style="letter-spacing:-.1pt;margin:0in 0in 6.0pt;text-align:left;"><font size="2" face="Times New Roman" style="font-size:10.0pt;letter-spacing:0pt;">(A)&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; Indicates
management contract or compensatory plan or arrangement.</font></p>

<p style="margin:0in 0in 6.0pt .5in;text-indent:-.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">(+)</font><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font><font size="2" style="font-size:10.0pt;">Confidential
treatment has been granted for certain portions of these exhibits, which have
been omitted and filed separately with the Securities and Exchange Commission
pursuant to Rule 24b-2 under the Securities Exchange Act of 1934.</font></p>

<p style="margin:0in 0in 6.0pt .5in;text-indent:-.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">(*)</font><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font><font size="2" style="font-size:10.0pt;">Confidential
treatment has been requested for certain portions of this exhibit, which have
been omitted and filed separately with the Securities and Exchange Commission
pursuant to Rule 24b-2 under the Securities Exchange Act of 1934.</font></p>

<p style="margin:0in 0in 6.0pt .5in;text-indent:-.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>

<p style="margin:0in 0in 6.0pt;page-break-after:avoid;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;letter-spacing:-.15pt;">b)&nbsp;&nbsp;Exhibits</font></b></p>

<p align="left" style="letter-spacing:-.1pt;margin:0in 0in 6.0pt;text-align:left;text-indent:13.5pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Refer to Item 15(a)(3) above.</font></p>

<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>

<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">38</font></p>

<div style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">

<hr size="2" width="100%" noshade color="gray" align="left">

</font></div>

</div>
<!-- SEQ.=1,FOLIO='38',FILE='C:\JMS\jboldua\05-1861-2\task332547\1861-2-be.htm',USER='jboldua',CD='Mar  4 06:47 2005' -->


<br clear="all" style="page-break-before:always;">


<div>

<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>

<p style="margin:0in 0in 6.0pt;page-break-after:avoid;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;letter-spacing:-.15pt;">c)&nbsp;&nbsp;Financial
Statement Schedules</font></b></p>

<p align="left" style="letter-spacing:-.1pt;margin:0in 0in 6.0pt;text-align:left;text-indent:13.5pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Refer to Item 15(a)(2) above.</font></p>

<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>

<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">39</font></p>

<div style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">

<hr size="2" width="100%" noshade color="gray" align="left">

</font></div>

</div>
<!-- SEQ.=1,FOLIO='39',FILE='C:\JMS\jboldua\05-1861-2\task332547\1861-2-be.htm',USER='jboldua',CD='Mar  4 06:47 2005' -->


<br clear="all" style="page-break-before:always;">


<div>

<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>

<h1 style="font-weight:bold;margin:0in 0in .0001pt;text-align:center;text-transform:uppercase;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;text-transform:none;">SIGNATURES</font></b></h1>

<p style="margin:0in 0in 6.0pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>

<p style="margin:0in 0in 6.0pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Pursuant to the requirements of Section 13 or 15(d) of the Securities
Exchange Act of 1934, the registrant has duly caused this report to be signed
on its behalf by the undersigned, thereunto duly authorized.</font></p>

<p style="margin:0in 0in 6.0pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>

<p style="margin:0in 0in 6.0pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">BIOSITE INCORPORATED</font></p>

<p style="margin:0in 0in 6.0pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>

<table border="0" cellspacing="0" cellpadding="0" width="100%" style="border-collapse:collapse;width:100.0%;">
 <tr>
  <td width="36%" valign="top" style="border:none;border-bottom:solid windowtext 1.0pt;padding:0in .7pt 0in .7pt;width:36.88%;">
  <p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">/s/ KIM D. BLICKENSTAFF</font></p>
  </td>
  <td width="63%" valign="top" style="padding:0in .7pt 0in .7pt;width:63.12%;">
  <p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Date:
  March 3, 2005</font></p>
  </td>
 </tr>
 <tr>
  <td width="36%" valign="top" style="border:none;padding:0in .7pt 0in .7pt;width:36.88%;">
  <p style="margin:0in 0in .0001pt 60.0pt;text-indent:-10.0pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Kim D. Blickenstaff</font></p>
  </td>
  <td width="63%" valign="top" style="padding:0in .7pt 0in .7pt;width:63.12%;">
  <p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>
  </td>
 </tr>
 <tr>
  <td width="36%" valign="top" style="padding:0in .7pt 0in .7pt;width:36.88%;">
  <p style="margin:0in 0in .0001pt 20.0pt;text-indent:-10.0pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Chairman and Chief Executive Officer</font></p>
  </td>
  <td width="63%" valign="top" style="padding:0in .7pt 0in .7pt;width:63.12%;">
  <p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>
  </td>
 </tr>
</table>

<p style="margin:0in 0in 6.0pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>

<p style="margin:0in 0in 6.0pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>

<p style="margin:0in 0in 6.0pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; Pursuant to the requirements of the
Securities Exchange Act of 1934, this report has been signed below by the
following persons on behalf of the registrant and in the capacities and on the
dates indicated.</font></p>

<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>

<table border="0" cellspacing="0" cellpadding="0" width="99%" style="border-collapse:collapse;width:99.96%;">
 <tr>
  <td width="36%" valign="top" style="border:none;border-bottom:solid windowtext 1.0pt;padding:0in .7pt 0in .7pt;width:36.9%;">
  <p align="center" style="margin:0in 0in .0001pt;text-align:center;"><b><font size="1" face="Times New Roman" style="font-size:8.0pt;font-weight:bold;">Name</font></b></p>
  </td>
  <td width="2%" valign="top" style="padding:0in .7pt 0in .7pt;width:2.16%;">
  <p align="center" style="margin:0in 0in .0001pt;text-align:center;"><b><font size="1" face="Times New Roman" style="font-size:1.0pt;font-weight:bold;">&nbsp;</font></b></p>
  </td>
  <td width="43%" valign="top" style="border:none;border-bottom:solid windowtext 1.0pt;padding:0in .7pt 0in .7pt;width:43.2%;">
  <p align="center" style="margin:0in 0in .0001pt;text-align:center;"><b><font size="1" face="Times New Roman" style="font-size:8.0pt;font-weight:bold;">Title</font></b></p>
  </td>
  <td width="1%" valign="top" style="padding:0in .7pt 0in .7pt;width:1.94%;">
  <p align="center" style="margin:0in 0in .0001pt;text-align:center;"><b><font size="1" face="Times New Roman" style="font-size:1.0pt;font-weight:bold;">&nbsp;</font></b></p>
  </td>
  <td width="15%" valign="top" style="border:none;border-bottom:solid windowtext 1.0pt;padding:0in .7pt 0in .7pt;width:15.82%;">
  <p align="center" style="margin:0in 0in .0001pt;text-align:center;"><b><font size="1" face="Times New Roman" style="font-size:8.0pt;font-weight:bold;">Date</font></b></p>
  </td>
 </tr>
 <tr>
  <td width="36%" valign="top" style="border:none;padding:0in .7pt 0in .7pt;width:36.9%;">
  <p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
  </td>
  <td width="2%" valign="top" style="padding:0in .7pt 0in .7pt;width:2.16%;">
  <p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
  </td>
  <td width="43%" valign="top" style="border:none;padding:0in .7pt 0in .7pt;width:43.2%;">
  <p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
  </td>
  <td width="1%" valign="top" style="padding:0in .7pt 0in .7pt;width:1.94%;">
  <p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
  </td>
  <td width="15%" valign="top" style="border:none;padding:0in .7pt 0in .7pt;width:15.82%;">
  <p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
  </td>
 </tr>
 <tr>
  <td width="36%" valign="top" style="border:none;border-bottom:solid windowtext 1.0pt;padding:0in .7pt 0in .7pt;width:36.9%;">
  <p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">/s/
  KIM D. BLICKENSTAFF</font></p>
  </td>
  <td width="2%" valign="top" style="padding:0in .7pt 0in .7pt;width:2.16%;">
  <p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>
  </td>
  <td width="43%" rowspan="2" valign="top" style="padding:0in .7pt 0in .7pt;width:43.2%;">
  <p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Chairman of the Board and
  Chief Executive Officer (Principal Executive Officer)</font></p>
  </td>
  <td width="1%" valign="top" style="padding:0in .7pt 0in .7pt;width:1.94%;">
  <p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>
  </td>
  <td width="15%" valign="top" style="padding:0in .7pt 0in .7pt;width:15.82%;">
  <p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">March
  3, 2005</font></p>
  </td>
 </tr>
 <tr>
  <td width="36%" valign="top" style="border:none;padding:0in .7pt 0in .7pt;width:36.9%;">
  <p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Kim
  D. Blickenstaff</font></p>
  </td>
  <td width="2%" valign="top" style="padding:0in .7pt 0in .7pt;width:2.16%;">
  <p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>
  </td>
  <td width="1%" valign="top" style="padding:0in .7pt 0in .7pt;width:1.94%;">
  <p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>
  </td>
  <td width="15%" valign="top" style="padding:0in .7pt 0in .7pt;width:15.82%;">
  <p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>
  </td>
 </tr>
 <tr>
  <td width="36%" valign="top" style="padding:0in .7pt 0in .7pt;width:36.9%;">
  <p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
  </td>
  <td width="2%" valign="top" style="padding:0in .7pt 0in .7pt;width:2.16%;">
  <p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
  </td>
  <td width="43%" valign="top" style="padding:0in .7pt 0in .7pt;width:43.2%;">
  <p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
  </td>
  <td width="1%" valign="top" style="padding:0in .7pt 0in .7pt;width:1.94%;">
  <p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
  </td>
  <td width="15%" valign="top" style="padding:0in .7pt 0in .7pt;width:15.82%;">
  <p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
  </td>
 </tr>
 <tr>
  <td width="36%" valign="top" style="padding:0in .7pt 0in .7pt;width:36.9%;">
  <p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
  </td>
  <td width="2%" valign="top" style="padding:0in .7pt 0in .7pt;width:2.16%;">
  <p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
  </td>
  <td width="43%" valign="top" style="padding:0in .7pt 0in .7pt;width:43.2%;">
  <p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
  </td>
  <td width="1%" valign="top" style="padding:0in .7pt 0in .7pt;width:1.94%;">
  <p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
  </td>
  <td width="15%" valign="top" style="padding:0in .7pt 0in .7pt;width:15.82%;">
  <p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
  </td>
 </tr>
 <tr>
  <td width="36%" valign="bottom" style="border:none;border-bottom:solid windowtext 1.0pt;padding:0in .7pt 0in .7pt;width:36.9%;">
  <p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">/s/
  CHRISTOPHER J. TWOMEY</font></p>
  </td>
  <td width="2%" valign="top" style="padding:0in .7pt 0in .7pt;width:2.16%;">
  <p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>
  </td>
  <td width="43%" rowspan="2" valign="top" style="padding:0in .7pt 0in .7pt;width:43.2%;">
  <p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Senior Vice President,
  Finance, Chief Financial Officer and Secretary (Principal Financial Officer
  and Accounting Officer)</font></p>
  </td>
  <td width="1%" valign="top" style="padding:0in .7pt 0in .7pt;width:1.94%;">
  <p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>
  </td>
  <td width="15%" valign="top" style="padding:0in .7pt 0in .7pt;width:15.82%;">
  <p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">March
  3, 2005</font></p>
  </td>
 </tr>
 <tr>
  <td width="36%" valign="top" style="border:none;padding:0in .7pt 0in .7pt;width:36.9%;">
  <p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Christopher
  J. Twomey</font></p>
  </td>
  <td width="2%" valign="top" style="padding:0in .7pt 0in .7pt;width:2.16%;">
  <p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>
  </td>
  <td width="1%" valign="top" style="padding:0in .7pt 0in .7pt;width:1.94%;">
  <p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>
  </td>
  <td width="15%" valign="top" style="padding:0in .7pt 0in .7pt;width:15.82%;">
  <p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>
  </td>
 </tr>
 <tr>
  <td width="36%" valign="top" style="padding:0in .7pt 0in .7pt;width:36.9%;">
  <p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
  </td>
  <td width="2%" valign="top" style="padding:0in .7pt 0in .7pt;width:2.16%;">
  <p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
  </td>
  <td width="43%" valign="top" style="padding:0in .7pt 0in .7pt;width:43.2%;">
  <p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
  </td>
  <td width="1%" valign="top" style="padding:0in .7pt 0in .7pt;width:1.94%;">
  <p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
  </td>
  <td width="15%" valign="top" style="padding:0in .7pt 0in .7pt;width:15.82%;">
  <p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
  </td>
 </tr>
 <tr>
  <td width="36%" valign="top" style="padding:0in .7pt 0in .7pt;width:36.9%;">
  <p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
  </td>
  <td width="2%" valign="top" style="padding:0in .7pt 0in .7pt;width:2.16%;">
  <p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
  </td>
  <td width="43%" valign="top" style="padding:0in .7pt 0in .7pt;width:43.2%;">
  <p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
  </td>
  <td width="1%" valign="top" style="padding:0in .7pt 0in .7pt;width:1.94%;">
  <p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
  </td>
  <td width="15%" valign="top" style="padding:0in .7pt 0in .7pt;width:15.82%;">
  <p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
  </td>
 </tr>
 <tr>
  <td width="36%" valign="top" style="border:none;border-bottom:solid windowtext 1.0pt;padding:0in .7pt 0in .7pt;width:36.9%;">
  <p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">/s/
  TIMOTHY J. WOLLAEGER</font></p>
  </td>
  <td width="2%" valign="top" style="padding:0in .7pt 0in .7pt;width:2.16%;">
  <p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>
  </td>
  <td width="43%" rowspan="2" valign="top" style="padding:0in .7pt 0in .7pt;width:43.2%;">
  <p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Director</font></p>
  </td>
  <td width="1%" valign="top" style="padding:0in .7pt 0in .7pt;width:1.94%;">
  <p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>
  </td>
  <td width="15%" valign="top" style="padding:0in .7pt 0in .7pt;width:15.82%;">
  <p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">March
  3, 2005</font></p>
  </td>
 </tr>
 <tr>
  <td width="36%" valign="top" style="border:none;padding:0in .7pt 0in .7pt;width:36.9%;">
  <p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Timothy
  J. Wollaeger</font></p>
  </td>
  <td width="2%" valign="top" style="padding:0in .7pt 0in .7pt;width:2.16%;">
  <p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>
  </td>
  <td width="1%" valign="top" style="padding:0in .7pt 0in .7pt;width:1.94%;">
  <p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>
  </td>
  <td width="15%" valign="top" style="padding:0in .7pt 0in .7pt;width:15.82%;">
  <p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>
  </td>
 </tr>
 <tr>
  <td width="36%" valign="top" style="padding:0in .7pt 0in .7pt;width:36.9%;">
  <p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
  </td>
  <td width="2%" valign="top" style="padding:0in .7pt 0in .7pt;width:2.16%;">
  <p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
  </td>
  <td width="43%" valign="top" style="padding:0in .7pt 0in .7pt;width:43.2%;">
  <p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
  </td>
  <td width="1%" valign="top" style="padding:0in .7pt 0in .7pt;width:1.94%;">
  <p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
  </td>
  <td width="15%" valign="top" style="padding:0in .7pt 0in .7pt;width:15.82%;">
  <p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
  </td>
 </tr>
 <tr>
  <td width="36%" valign="top" style="padding:0in .7pt 0in .7pt;width:36.9%;">
  <p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
  </td>
  <td width="2%" valign="top" style="padding:0in .7pt 0in .7pt;width:2.16%;">
  <p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
  </td>
  <td width="43%" valign="top" style="padding:0in .7pt 0in .7pt;width:43.2%;">
  <p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
  </td>
  <td width="1%" valign="top" style="padding:0in .7pt 0in .7pt;width:1.94%;">
  <p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
  </td>
  <td width="15%" valign="top" style="padding:0in .7pt 0in .7pt;width:15.82%;">
  <p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
  </td>
 </tr>
 <tr>
  <td width="36%" valign="top" style="border:none;border-bottom:solid windowtext 1.0pt;padding:0in .7pt 0in .7pt;width:36.9%;">
  <p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">/S/
  KENNETH F. BUECHLER, PH.D.</font></p>
  </td>
  <td width="2%" valign="top" style="padding:0in .7pt 0in .7pt;width:2.16%;">
  <p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>
  </td>
  <td width="43%" rowspan="2" valign="top" style="padding:0in .7pt 0in .7pt;width:43.2%;">
  <p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Director, President and
  Chief Scientific Officer</font></p>
  </td>
  <td width="1%" valign="top" style="padding:0in .7pt 0in .7pt;width:1.94%;">
  <p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>
  </td>
  <td width="15%" valign="top" style="padding:0in .7pt 0in .7pt;width:15.82%;">
  <p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">March
  3, 2005</font></p>
  </td>
 </tr>
 <tr>
  <td width="36%" valign="top" style="border:none;padding:0in .7pt 0in .7pt;width:36.9%;">
  <p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Kenneth
  F. Buechler, Ph.D.</font></p>
  </td>
  <td width="2%" valign="top" style="padding:0in .7pt 0in .7pt;width:2.16%;">
  <p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>
  </td>
  <td width="1%" valign="top" style="padding:0in .7pt 0in .7pt;width:1.94%;">
  <p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>
  </td>
  <td width="15%" valign="top" style="padding:0in .7pt 0in .7pt;width:15.82%;">
  <p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>
  </td>
 </tr>
 <tr>
  <td width="36%" valign="top" style="padding:0in .7pt 0in .7pt;width:36.9%;">
  <p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
  </td>
  <td width="2%" valign="top" style="padding:0in .7pt 0in .7pt;width:2.16%;">
  <p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
  </td>
  <td width="43%" valign="top" style="padding:0in .7pt 0in .7pt;width:43.2%;">
  <p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
  </td>
  <td width="1%" valign="top" style="padding:0in .7pt 0in .7pt;width:1.94%;">
  <p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
  </td>
  <td width="15%" valign="top" style="padding:0in .7pt 0in .7pt;width:15.82%;">
  <p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
  </td>
 </tr>
 <tr>
  <td width="36%" valign="top" style="padding:0in .7pt 0in .7pt;width:36.9%;">
  <p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
  </td>
  <td width="2%" valign="top" style="padding:0in .7pt 0in .7pt;width:2.16%;">
  <p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
  </td>
  <td width="43%" valign="top" style="padding:0in .7pt 0in .7pt;width:43.2%;">
  <p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
  </td>
  <td width="1%" valign="top" style="padding:0in .7pt 0in .7pt;width:1.94%;">
  <p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
  </td>
  <td width="15%" valign="top" style="padding:0in .7pt 0in .7pt;width:15.82%;">
  <p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
  </td>
 </tr>
 <tr>
  <td width="36%" valign="top" style="border:none;border-bottom:solid windowtext 1.0pt;padding:0in .7pt 0in .7pt;width:36.9%;">
  <p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">/s/
  ANTHONY DEMARIA, M.D.</font></p>
  </td>
  <td width="2%" valign="top" style="padding:0in .7pt 0in .7pt;width:2.16%;">
  <p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>
  </td>
  <td width="43%" rowspan="2" valign="top" style="padding:0in .7pt 0in .7pt;width:43.2%;">
  <p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Director</font></p>
  </td>
  <td width="1%" valign="top" style="padding:0in .7pt 0in .7pt;width:1.94%;">
  <p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>
  </td>
  <td width="15%" valign="top" style="padding:0in .7pt 0in .7pt;width:15.82%;">
  <p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">March
  3, 2005</font></p>
  </td>
 </tr>
 <tr>
  <td width="36%" valign="top" style="border:none;padding:0in .7pt 0in .7pt;width:36.9%;">
  <p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Anthony
  DeMaria, M.D.</font></p>
  </td>
  <td width="2%" valign="top" style="padding:0in .7pt 0in .7pt;width:2.16%;">
  <p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>
  </td>
  <td width="1%" valign="top" style="padding:0in .7pt 0in .7pt;width:1.94%;">
  <p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>
  </td>
  <td width="15%" valign="top" style="padding:0in .7pt 0in .7pt;width:15.82%;">
  <p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>
  </td>
 </tr>
 <tr>
  <td width="36%" valign="top" style="padding:0in .7pt 0in .7pt;width:36.9%;">
  <p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
  </td>
  <td width="2%" valign="top" style="padding:0in .7pt 0in .7pt;width:2.16%;">
  <p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
  </td>
  <td width="43%" valign="top" style="padding:0in .7pt 0in .7pt;width:43.2%;">
  <p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
  </td>
  <td width="1%" valign="top" style="padding:0in .7pt 0in .7pt;width:1.94%;">
  <p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
  </td>
  <td width="15%" valign="top" style="padding:0in .7pt 0in .7pt;width:15.82%;">
  <p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
  </td>
 </tr>
 <tr>
  <td width="36%" valign="top" style="padding:0in .7pt 0in .7pt;width:36.9%;">
  <p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
  </td>
  <td width="2%" valign="top" style="padding:0in .7pt 0in .7pt;width:2.16%;">
  <p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
  </td>
  <td width="43%" valign="top" style="padding:0in .7pt 0in .7pt;width:43.2%;">
  <p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
  </td>
  <td width="1%" valign="top" style="padding:0in .7pt 0in .7pt;width:1.94%;">
  <p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
  </td>
  <td width="15%" valign="top" style="padding:0in .7pt 0in .7pt;width:15.82%;">
  <p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
  </td>
 </tr>
 <tr>
  <td width="36%" valign="top" style="border:none;border-bottom:solid windowtext 1.0pt;padding:0in .7pt 0in .7pt;width:36.9%;">
  <p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">/s/
  HOWARD E. GREENE, JR.</font></p>
  </td>
  <td width="2%" valign="top" style="padding:0in .7pt 0in .7pt;width:2.16%;">
  <p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>
  </td>
  <td width="43%" rowspan="2" valign="top" style="padding:0in .7pt 0in .7pt;width:43.2%;">
  <p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Director</font></p>
  </td>
  <td width="1%" valign="top" style="padding:0in .7pt 0in .7pt;width:1.94%;">
  <p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>
  </td>
  <td width="15%" valign="top" style="padding:0in .7pt 0in .7pt;width:15.82%;">
  <p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">March
  3, 2005</font></p>
  </td>
 </tr>
 <tr>
  <td width="36%" valign="top" style="border:none;padding:0in .7pt 0in .7pt;width:36.9%;">
  <p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Howard
  E. Greene, Jr.</font></p>
  </td>
  <td width="2%" valign="top" style="padding:0in .7pt 0in .7pt;width:2.16%;">
  <p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>
  </td>
  <td width="1%" valign="top" style="padding:0in .7pt 0in .7pt;width:1.94%;">
  <p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>
  </td>
  <td width="15%" valign="top" style="padding:0in .7pt 0in .7pt;width:15.82%;">
  <p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>
  </td>
 </tr>
 <tr>
  <td width="36%" valign="top" style="padding:0in .7pt 0in .7pt;width:36.9%;">
  <p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
  </td>
  <td width="2%" valign="top" style="padding:0in .7pt 0in .7pt;width:2.16%;">
  <p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
  </td>
  <td width="43%" valign="top" style="padding:0in .7pt 0in .7pt;width:43.2%;">
  <p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
  </td>
  <td width="1%" valign="top" style="padding:0in .7pt 0in .7pt;width:1.94%;">
  <p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
  </td>
  <td width="15%" valign="top" style="padding:0in .7pt 0in .7pt;width:15.82%;">
  <p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
  </td>
 </tr>
 <tr>
  <td width="36%" valign="top" style="padding:0in .7pt 0in .7pt;width:36.9%;">
  <p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
  </td>
  <td width="2%" valign="top" style="padding:0in .7pt 0in .7pt;width:2.16%;">
  <p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
  </td>
  <td width="43%" valign="top" style="padding:0in .7pt 0in .7pt;width:43.2%;">
  <p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
  </td>
  <td width="1%" valign="top" style="padding:0in .7pt 0in .7pt;width:1.94%;">
  <p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
  </td>
  <td width="15%" valign="top" style="padding:0in .7pt 0in .7pt;width:15.82%;">
  <p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
  </td>
 </tr>
 <tr>
  <td width="36%" valign="top" style="border:none;border-bottom:solid windowtext 1.0pt;padding:0in .7pt 0in .7pt;width:36.9%;">
  <p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">/s/
  LONNIE M. SMITH</font></p>
  </td>
  <td width="2%" valign="top" style="padding:0in .7pt 0in .7pt;width:2.16%;">
  <p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>
  </td>
  <td width="43%" rowspan="2" valign="top" style="padding:0in .7pt 0in .7pt;width:43.2%;">
  <p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Director</font></p>
  </td>
  <td width="1%" valign="top" style="padding:0in .7pt 0in .7pt;width:1.94%;">
  <p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>
  </td>
  <td width="15%" valign="top" style="padding:0in .7pt 0in .7pt;width:15.82%;">
  <p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">March
  3, 2005</font></p>
  </td>
 </tr>
 <tr>
  <td width="36%" valign="top" style="border:none;padding:0in .7pt 0in .7pt;width:36.9%;">
  <p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Lonnie
  M. Smith</font></p>
  </td>
  <td width="2%" valign="top" style="padding:0in .7pt 0in .7pt;width:2.16%;">
  <p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>
  </td>
  <td width="1%" valign="top" style="padding:0in .7pt 0in .7pt;width:1.94%;">
  <p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>
  </td>
  <td width="15%" valign="top" style="padding:0in .7pt 0in .7pt;width:15.82%;">
  <p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>
  </td>
 </tr>
</table>

<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>

<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">40</font></p>

<div style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">

<hr size="2" width="100%" noshade color="gray" align="left">

</font></div>

</div>
<!-- SEQ.=1,FOLIO='40',FILE='C:\JMS\jboldua\05-1861-2\task332547\1861-2-be.htm',USER='jboldua',CD='Mar  4 06:47 2005' -->


</body>

</html>
</TEXT>
</DOCUMENT>
